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ABSTRACT 
Diabetes is an increasingly prevalent and costly cause of morbidity and mortality, representing 
not only a major clinical care concern but an immense public health challenge.  In 2010, diabetes 
affected 25.8 million Americans – 8.3% of the US population and 26.9% of those aged 65 years 
or older.  People with diabetes are disproportionately affected by eye and renal disease, non-
traumatic amputations, and cardiovascular disease, which result in significant health-care costs 
of $245 billion in the US in 2012.  Although many interventions can reduce health burden of 
diabetes, health care resources are limited.  Hence, evidence is needed to inform health care 
practitioners and policymakers of these interventions’ costs and benefits to practices, payers, and 
patients, and thus aid them in prioritizing the interventions for diabetes prevention and control. 
Through a decision-analytic approach using computational modeling, this dissertation 
proposed the cost-effectiveness analysis on implementing the Chronic Care Model (CCM) for 
diabetes control in the community and military settings and on implementing an Online 
adaptation of the Diabetes Prevention Program lifestyle intervention (ODPP) for weight 
management in an overweight/obese primary care population with high cardiovascular risk.  Our 
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analyses showed that from a health care system and a societal perspective, the CCM compared 
with usual care cost $42,179-$45,495 and $42,051-$113,280 per quality-adjusted life-year 
(QALY) gained; the CCM compared with provider continuing medical education (PROV) cost 
$17,186 and $50,718 per QALY gained; and the ODPP compared with usual care cost $7,777-
$14,351 and $18,263-$29,331 per QALY gained.  Generally, these results were robust in 
sensitivity analyses.  This dissertation provided supporting evidence that compared with usual 
care or PROV, the CCM for secondary and tertiary diabetes prevention in the community and 
military settings as well as the ODPP for primary diabetes prevention in the primary care setting 
appear to be economically reasonable interventions for diabetes management.  These findings are 
of public health significance as the economic evaluation conducted in this dissertation is an 
important component of evidence-based clinical and public health practices, which is a decision 
making aid to help assess the relative value of alternative interventions that can enhance clinical 
care and public health. 
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1.0 INTRODUCTION 
 
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects 
in insulin secretion, insulin action, or both.  The chronic hyperglycemia of diabetes is associated 
with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, 
nerves, heart, and blood vessels (1).  Diabetes is a chronic illness that can lead to serious 
complications and premature death (2) and requires continuing medical care and ongoing patient 
self-management education and support to prevent acute complications and to reduce the risk of 
long-term complications (3).  Individuals with impaired fasting glucose (IFG) and/or impaired 
glucose tolerance (IGT) are currently considered to have “pre-diabetes” as they are at a relatively 
high risk of progressing overt diabetes.  IFG and IGT should not be regarded as clinical entities 
in their own right but rather as risk factors for diabetes and/or future cardiovascular disease 
(CVD) as well as premature mortality (3-5).  As is the case for individuals found to have IFG 
and IGT, individuals with a glycated hemoglobin (A1C) of 5.7-6.4% should also be informed of 
their increased risk for diabetes as well as CVD and counseled about effective strategies to lower 
their risks (3).  Pre-diabetes is associated with obesity, dyslipidemia with high triglycerides 
and/or low high-density lipoprotein cholesterol (HDLc), and hypertension.  Structured lifestyle 
intervention, aimed at increasing physical activity and producing 5-10% loss of body weight, and 
several pharmacological agents can prevent or delay the development of diabetes in people with 
pre-diabetes (3). 
 Diabetes is an increasingly prevalent and costly cause of morbidity and mortality, 
resulting in one of the globally major public health threats (6-9).  The estimated prevalence of 
diabetes among adults (≥20 years of age) worldwide is 2.8% (or 171 million people) and 6.4% 
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(or 285 million people) in 2000 and 2010 respectively.  The prevalence is expected to increase to 
7.7%, affecting 439 million people by 2030 (6,7).  Adults with diabetes have an annual mortality 
of about 5.4% (double the rate for non-diabetic adults), and their life expectancy may be 
shortened by as much as 15 years, with up to 75% dying of macrovascular complications, e.g. 
coronary heart disease and stroke (10,11).  The total number of excess deaths attributable to 
diabetes worldwide in 2010 is estimated to be almost 4 million in the age group 20-79 years, 
6.8% of global (all ages) all-cause mortality.  Specifically, diabetes may account for 6% of all-
cause deaths in adults in the African Region and up to 15.7% in the North American Region (8).  
Diabetes is common, disabling, and deadly; however, diabetes is preventable and controllable, 
based on a large body of existing evidence that support a range of interventions to improve 
diabetes outcomes by controlling risk factors (3,12).  Recent research shows that improvements 
in risk factor control in the US would collectively increase life expectancy by 1.0 year for people 
newly diagnosed with diabetes in 2005 compared to those diagnosed with diabetes 11 years 
earlier (13). 
    Diabetes is costly to the health care system and society.  Globally, the health 
expenditure on diabetes is expected to total at least US$376 billion in 2010; 12% of the world’s 
total health expenditure with US$1,330 per person spent on diabetes.  The projected health 
expenditure for diabetes will expectedly increase to total at least US$490 billion in 2030 
worldwide (9).  In the US, the total estimated annual cost of diabetes in 2007 is US$174 billion, 
including US$116 billion in excess medical expenditures and US$58 billion in reduced national 
productivity (14).  This is an increase of US$42 billion since 2002 (15).  This 32% increase 
translates to more than US$8 billion per year.  The annual cost in 2002 US$ of diabetes could 
rise to an estimated US$156 billion by 2010 and to US$192 billion by 2020 (15) if current trends 
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continue.  The high economic burden of diabetes is one of the most pressing health policy issues 
in the US today (16) and highlights the urgency of better understanding about new interventions 
for diabetes prevention and control and whether they may or may not help reduce costs.  
 Considering the evolving disease burden of diabetes in the US, efforts exploring new 
interventions to prevent or delay the complications of diabetes, or, better yet, to prevent or delay 
the development of diabetes itself are urgently needed (17).  However, facing increasing demand 
for limited resources from the growing number of new interventions available, policy makers and 
health care providers need to seek guidance on how to prioritize health care resources wisely and 
efficiently (18).  Economic analysis of efficiency can help the decision maker determine how to 
allocate resources across a defined number of competing needs to maximize health outcomes 
from a limited budget (19,20).  Efficiency can be estimated using cost-benefit, cost-effectiveness 
or cost-utility analysis.  Only the latter two are used in health care since the monetary valuation 
of health benefits is not acceptable on ethical and on practical grounds (21).  The use of 
economic analysis to inform decision making has increased rapidly in the last two to three 
decades.  Currently, economic analysis plays a limited role in decision making, but may increase 
in importance as health care costs continue to rise (21,22). 
 Applying the economic framework to inform and guide policy decisions about resource 
allocation in diabetes prevention and control is important for at least three reasons (18).  First, 
diabetes is costly.  Second, resources that can be devoted to diabetes prevention and control are 
limited because of the “opportunity cost” of doing so.  Opportunity costs are the value that is 
forgone by using resources for one activity instead of another.  Third, the need for resources will 
continue to increase because of the increasing prevalence of diabetes and demand for 
comprehensive care and new interventions. 
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 The objective of this dissertation is to apply computational simulation modeling for 
evaluating long-term cost-effectiveness of implementing the diabetes control and prevention 
interventions in the community and military settings.  The overall summary measure from the 
cost-effectiveness evaluation is the incremental cost-effectiveness ratio (ICER), representing the 
incremental cost required to achieve one additional unit of health benefits if an intervention is 
used instead of another.  The ICER is expressed as US$ per quality-adjusted life-expectancy 
gained.  First, data from a cluster-design, randomized controlled trial will be used to estimate 
cost-effectiveness of implementing the Chronic Care Model for diabetes control in an 
underserved urban area of Pittsburgh, PA.  Second, data from a military population will be used 
to estimate cost-effectiveness of implementing the Chronic Care Model for diabetes control in a 
military-based medical center in San Antonio, TX.  Finally, data from a clinical trial conducted 
in an academic general internal medicine practice will be used to estimate cost-effectiveness of 
implementing an Internet-based lifestyle intervention to reduce risk of type 2 diabetes and 
cardiovascular disease in the primary care setting in Pittsburgh, PA. 
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2.0 DIABETES 
 
Classification of Diabetes 
First written reference to diabetes by ancient Egyptian physicians appears since at least 1500 BC 
(23).  Diabetes is a complex and heterogeneous disorder with diverse etiologic mechanisms; 
hence, any given classification is arbitrary.  Currently, the classification of diabetes includes four 
clinical categories (i.e., type 1 diabetes (T1D), type 2 diabetes (T2D), other specific types of 
diabetes due to other causes, and gestational diabetes mellitus), and the first two categories are 
the most common forms of diabetes (1,24).  The Expert Committee also identifies an 
intermediate group of individuals whose glucose levels do not meet criteria for diabetes but are 
too high to be considered normal.  These individuals have IFG and/or IGT.  “Pre-diabetes” is 
used for these entities as progression to diabetes is common, particularly when interventions such 
as lifestyle change or medications are not provided (1,4). 
 
Prevalence, Incidence, Morbidity, and Mortality of Diabetes 
Approximately 23.6 million people in the US had diagnosed and undiagnosed diabetes, 
indicating that the prevalence of diabetes among the whole US population has increased by 24% 
in 5 years from 6.3% in 2002 to 7.8% in 2007.  Specifically, the prevalence of diagnosed and 
undiagnosed diabetes among US people aged 20 years or older in 2007 was 10.7% (or 23.5 
million people), while that of diagnosed diabetes in those younger than 20 years of age in 2007 
was 0.2% (or 186,300 people).  If the 57 million American adults with IFG were added, about a 
third of the adult US population had abnormal glucose metabolism in 2007 (2,17).  Also, the 
projected number of people with diagnosed diabetes in the US will increase by 198% from 16.2 
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million in 2005 to 48.3 million in 2050, with the largest increases occurring in older and minority 
subpopulations (25). 
The incidence of diagnosed diabetes in 2003 was 6.9 per 1,000 adults, or 1,330,000 
adults in the US.  This was a rapid increase of 41% from 1997 when the incidence was 4.9 per 
1,000 adults.  Incidence varied by age, race/ethnicity, weight status, and education levels.  
Obesity was a major factor for the increase of newly diagnosed diabetes; diabetes incidence 
increased sharply with weight status, ranging from 1.9 per 1,000 among normal-weight people to 
17.8 per 1,000 among the obese (26).  Recent estimates in the US indicate about 1.6 million new 
cases of diagnosed diabetes in people aged 20 years or older in 2007 (2).  Also, another recent 
study shows that the average, annual and age-adjusted incidence of diagnosed diabetes among 
adults aged 18 years or older increased from 4.8 per 1,000 people in 1995-1997 to 9.1 in 2005-
2007; that is, the rate of new cases of diagnosed diabetes soared by about 90 percent in the US 
over the past decade (27). 
Diabetes is the leading cause of new cases of blindness among adults aged 20-74 years, 
and diabetic retinopathy causes 12,000 to 24,000 new cases of blindness each year.  Diabetes is 
also the leading cause of end-stage renal disease, accounting for 44% of new cases in 2005.  
Also, severe forms of diabetic nerve disease are a major contributing cause of lower-extremity 
amputations; more than 60% of non-traumatic lower-limb amputations occur in people with 
diabetes.  People with diabetes aged 60 years or older are 2-3 times more likely to report an 
inability to walk one-quarter of a mile, climb stairs, do housework, or use a mobility aid 
compared to those without diabetes in the same age group (2). 
At the inception of the 21st century, it was estimated that 5.2% of all deaths globally 
were attributable to diabetes, ranking diabetes as the fifth leading cause of death after 
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communicable disease, CVD, cancer, and injury (28).  In the US, diabetes was the seventh 
leading cause of death listed on death certificates in 2006 (2).  Individuals with diabetes have 
twice the all-cause mortality rate and 2-4 times the CVD mortality rate of those without diabetes 
(29,30).  Specifically, life expectancy of people with diabetes aged 55-74 years is on average 4-8 
years shorter than that of those without diabetes (29).  Recent data show that heart disease and 
stroke were respectively noted on 68% and 16% of diabetes-related death certificates among the 
US people aged 65 years or older in 2004 (2). 
The prevalence and incidence of diabetes is increasing worldwide and in the US (31).  
The long-term impact of this growing burden is evidenced in models that estimate that one in 
three children born in the US in the year 2000 will develop diabetes in their lifetime (32).  With 
this growing number of people who will develop diabetes, the costs that health care system and 
society will bear in high medical utilizations/expenditures, decreased quality of life, and more 
years of life lost will be stupendous.  Therefore, although efficiently managing diabetes and 
preventing its complications are crucial to improve the life of people with diabetes, exploring 
primary prevention of diabetes through individual and community interventions to support 
people at risk of obesity and diabetes is also warranted. 
 
2.1 TYPE 1 DIABETES 
 
2.1.1 Definition  
Type 1 diabetes (T1D) is the form of the disease primarily due to pancreatic islet β-cell 
destruction, and is characterized by absolute insulin deficiency and thus dependence on insulin 
therapy for the preservation of life.  Individuals with T1D are metabolically normal before the 
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disease is clinically manifest, but the process of β-cell destruction can be detected earlier by the 
presence of certain autoantibodies.  T1D usually is characterized by the presence of anti-GAD, 
anti-islet cells, or anti-insulin antibodies, which reflects the autoimmune processes that lead to β-
cell destruction.  Individuals who have one or more of these antibodies can be subclassified as 
having type 1A diabetes, or immune-mediated T1D.  Type 1B, or idiopathic, diabetes is 
characterized by low insulin and C-peptide levels similar to those in type 1A.  Such individuals 
are also prone to ketoacidosis, like those in type 1A, although they have no clinical evidence of 
autoimmune autobodies.  Many of these individuals are of African or Asian origin.  They may 
suffer from episodic ketoacidosis, but the pathogenetic basis for their insulinopenia remains 
obscure (24,33).  
 
2.1.2 Epidemiology 
T1D is one of the most common chronic diseases of childhood, but may be present in all age 
groups (34,35).  In most populations, T1D constitutes about 5-15% of all diagnosed cases of 
diabetes, although classification can be difficult in older age groups (36).  The prevalence of β-
cell autoimmunity appears proportional to the incidence of T1D in various populations; for 
instance, the countries of Sweden, Sardinia, and Finland have the highest prevalence of islet cell 
antibody (3-4.5%) and are associated with the highest incidence of T1D, varying from 22 to 35 
per 100,000 (37).  T1D is diagnosed more frequently in the winter months (35).  Risk factors for 
T1D may be autoimmune, genetic, and environmental (2).  The major genetic susceptibility to 
T1D is linked to the HLA complex on chromosome 6.  These genetic backgrounds interact with 
environmental factors (possibly certain viruses, foods, and climate) to initiate the immune-
mediated process that leads to β-cell destruction (35).   
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Prevalence 
Several prevalence studies of T1D in the US in years 1961-1992 show that the prevalence of 
T1D in people with age <20 years ranged from 0.6 per 1,000 to 2.5 per 1,000, with most 
estimates clustering around 1.7 per 1,000.  Also, the estimated prevalence of T1D in the total US 
population (all age groups) was 1.2 per 1,000 in 1970 (38).  T1D onset is believed to occur 
predominantly in youth, but it can begin at any age.  A study based on the 1976-80 Second 
National Health and Nutrition Examination Survey (NHANES II) estimated the prevalence of 
adult-onset T1D in the US, which showed that 7.4% of all diabetic people diagnosed at age 30-
74 years were adult-onset T1D, representing 0.3% of the US population in this age group (38).  
In addition, the SEARCH for Diabetes in Youth Study, which aimed to estimate the prevalence 
and incidence of diabetes in youth with age <20 years in the US, found that the prevalence of 
T1D was 1.54 cases per 1,000 youth in 2001 and T1D accounted for about 85% of all diagnosed 
diabetes in this age group (39).  Lastly, recent data in 2007 showed that T1D accounted for 5.7% 
(or 1 million people) of all diagnosed diabetes in the US (40). 
 
Incidence 
A previous study, which evaluated T1D trends in Allegheny County, PA, from 1965 to 1989, 
indicated that the incidence of T1D among people aged <20 years was 18.2 per 100,000 each 
year (41).  Another study showed that T1D incidence in an adult US population (age ≥20 years) 
in 1945-1969 from Rochester, MN was 9.2 per 100,000 each year (42).  Applying these two 
incidence rates to the whole US population in 1990 revealed that about 29,713 Americans 
developed T1D each year, including 13,171 new T1D cases in people aged <20 years and 16,542 
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in people aged ≥20 years (38).  Recently, the SEARCH for Diabetes in Youth Study based on 
2002-2003 data documented 15,000 youth (age <20 years) with newly diagnosed T1D annually 
in the US, indicating that the incidence of newly diagnosed diabetes cases among youth was 19.0 
per 100,000 each year for T1D.  Also, T1D accounted for about 78% of all newly diagnosed T1D 
and T2D cases annually in this age group (43). 
 There are several characteristics of variation in incidence of T1D.  First, there is 
geographical variation.  One of the most striking issues in T1D is the very wide, over 400-fold 
difference in incidence of childhood-onset T1D worldwide (36).  Scandinavia and the 
Mediterranean island of Sardinia have the highest incidence rates in the world, while oriental and 
equatorial populations have the lowest ones.  A child in Finland is 400 times more likely to 
develop diabetes than one in certain regions of China.  Even within Scandinavia, with genetically 
homogenous populations and equally developed societies living at the same latitude, incidence 
rates vary widely from a high of 45 per 100,000 in Finland (2006) to 28 in Sweden and 20 in 
Denmark.  In addition, the great geographical variation can also be seen within the same country, 
even in countries with relatively homogenous populations; however, these differences remain 
unexplained at this time.  While incidence rates are much higher in European populations, the 
absolute number of new cases is almost equal in Asia and Europe since the population base is so 
much larger in Asia.  For instance, it is estimated that of the 400,000 total new T1D cases 
occurring annually in all children under age 14, about half are in Asia even though the incidence 
rates in that continent are much lower (34). 
 Second, incidence is increasing.  There is a steady increase in the incidence of T1D in 
most populations studied.  For example, the incidence of T1D in Austria doubled from 
7.3/100,000 in 1979-1984 to 14.6/100,000 in 2000-2005.  Studies from Croatia, France, 
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Germany, Finland, Newfoundland, and China all show that the incidence of T1D is increasing at 
a rate of 2-5% annually (34).  In the US, during the first three decades of the 20th century, the 
incidence rate of T1D in the white population younger than age 15 years was fairly constant; 
however, during the next three decades, the rate almost tripled (44). 
Third, there is an effect of migration.  In some populations, migrants tend to take on the 
incidence rates of the host countries within one or two generations.  For example, a UK study 
found that T1D incidence rates among children of South Asian origin were almost identical with 
those of local whites and were more than 20-fold higher than those reported from their ancestral 
homelands in South Asia.  This may suggest that children who move from low-incidence areas to 
high-incidence areas can acquire the higher risk due to environmental factors (34). 
 Fourth, there is variation with age.  T1D incidence peaks at the ages of 4-6 and 10-14 
years (45).  For example, in Norway during 1978-1982, the incidence tended to decrease from 
age 15 years and stabilize up to age 20-30 years (36).  The age distribution of T1D onset is 
similar across different European populations, but the average age of presentation tends to be 
higher in African and Asian (low risk) populations.  These peaks may coincide with higher 
exposure to infectious agents (at entry to school) and higher insulin demand (due to insulin 
resistance at puberty).  About half of all T1D present as adults and new cases continue to present 
past age 70 years (34). 
Fifth, there is racial/ethnic variation.  Striking racial differences are observed in T1D risk 
in multiracial populations, although not of the same magnitude as the geographical differences 
(34).  In the US, non-Hispanic white youth (age <20 years) has the highest rate of new cases of 
T1D.  Non-Hispanic whites between ages 10 and 14 have an incidence rate of 32.9 per 100,000 
person-years, which is comparable to Scandinavian populations.  At the same age, the incidence 
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rate (per 100,000 person-years) among African-Americans is 19.2 and that in Hispanics is 17.6.  
Asian-Americans, with an incidence of 8.3 and American-Indians with that of 7.1, have the 
lowest incidence rates in the US population (43).  Among non-Hispanic white youth aged 10-19 
years, the rate of new cases of T1D is higher than for T2D.  For Asian-American and American-
Indian youth aged 10-19 years, the opposite is true - the rate of new cases of T2D is greater than 
the rate for T1D.  Among African-American and Hispanic youth aged 10-19 years, the rates of 
new cases of T1D and T2D are similar (43).  
Sixth, there is seasonal variation.  Pooled data from many different countries show 
significant seasonality in date of diagnosis for T1D in all age groups.  These data show a 
maximum incidence in the winter period around December to January and a minimum in 
summer around June to July.  Data from Australia and New Zealand show similar seasonality 
(peak incidence in winter, which in the southern hemisphere is in June and July).  The 
amplitudes of these differences are smallest for the youngest age group and largest for the oldest 
age group.  Detailed records from Denmark also show that this seasonal variation seems to vary 
by year.  On the other hand, in several populations, seasonality is absent.  It is possible that some 
environmental factor (e.g., vitamin D, sunshine, or viral exposure) plays a role in the observed 
seasonality, but its effect may also be overshadowed in some populations by other genetic and 
environmental factors (34). 
Finally, there is variation by gender.  Generally, males and females have similar risk of 
T1D, with the pubertal peak of incidence in females preceding that in males by 1-2 years.  In 
low-risk populations, such as Japan, there is a female preponderance with females outnumbering 
males by 1.4:1, while high-risk countries tend to have a male preponderance (34,36). 
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Mortality 
Prior to the introduction of insulin in 1922, the mortality rate in people with T1D was extremely 
high; it was estimated from the Joslin Clinic in Boston, US, that the annual mortality rate for 
1897-1914 to be 824 per 1,000 diabetic children aged <10 years, and 600 per 1,000 diabetic 
children aged 10-20 years.  These rates declined for years 1914-1922, but still remained very 
high at close to 400 per 1,000 diabetic children (46).  The use of insulin therapy led to improved 
metabolic control, having a significant impact on T1D mortality.  Joslin Clinic data revealed an 
ongoing decline in mortality for both males and females aged 5-24 years between the years 1930 
and 1958 (47).  In addition, the Pittsburgh Epidemiology of Diabetes Complications Study 
experience reported that 20-year cumulative mortality decreased from 22% in 1950-1959 to 
3.5% in 1975-1980 for people with T1D (48).  Moreover, a study, which evaluated the mortality 
for people diagnosed with T1D at age <18 years from a US population-based registry, reported 
that people diagnosed during 1975-1979 showed significantly improved survival compared to 
those diagnosed 10 years earlier (49).  Similar mortality trends over the 20th century were also 
reported in Denmark and Australia.  Since the 1980s, mortality rates have stabilized (46).   
 Despite considerable improvements in survival over the past century, people with T1D 
still die at a greater rate than people without the disease.  Data from US diabetic patients indicate 
that life expectancy in those with T1D aged <20 years at diagnosis is reduced by at least 15 
years, with the probability of survival among those diagnosed with childhood-onset diabetes 
reducing from 88% at 20 years of disease duration to 83% after having diabetes for 25 years 
(50).  Moreover, the mean reduction in life expectancy appears to be greater for younger children 
than for older children, and in those diagnosed with T1D at younger age than in those diagnosed 
at an older age.  The estimated relative risks for total mortality vary considerably, with reported 
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risks being 2- to 15-fold in people with T1D.  However, it should be noted that these estimates 
may actually underestimate the relative risk of mortality, since most studies rely on standardized 
mortality ratios, which are calculated by comparing the mortality rates observed in T1D people 
to those in the general population, which also includes people with diabetes (46). 
 Several studies suggest that mortality rates vary substantially across countries, which may 
reflect differences in access to health care (46).  For example, the Diabetes Epidemiology 
Research International Mortality Study was conducted to investigate T1D mortality patterns in 
Finland, Japan, Israel, and the US.  People diagnosed between 1965 and 1979 at age <18 years 
with T1D were included in the study cohort and were followed up until January 1, 1985.  This 
study revealed that Japan and the US had much higher age-specific all-cause mortality rates than 
did Finland and Israel (51). 
In addition, men have higher absolute all-cause mortality rates than women.  This is true 
for people with and without diabetes, and for those with T1D and T2D.  However, when 
comparing men with T1D to men without diabetes, and women with T1D to women without 
diabetes, many studies (but not all) report higher relative mortality risks for T1D women than 
men.  Overall, T1D appears to diminish the protective effects of female gender observed in 
populations without diabetes (46). 
The cause of death for people with T1D differs by age and disease duration.  In general, 
metabolic disturbances account for a large proportion of deaths in younger people and among 
those who have had diabetes for a shorter time, whereas deaths in older people or people who 
have had T1D for longer are more likely a result of renal disease or CVD (46,50).  Although few 
studies investigate whether T1D is associated with an increased risk of non-CVD mortality, data 
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from large population-based studies suggest that the risk of death from cancer is not significantly 
higher among people with T1D than that in the general population (52-54). 
Although mortality rates for T1D in Western developed nations are significantly lower 
since the introduction of insulin, similar improvements have not necessarily been achieved in 
poorer developing ones.  While poorer health outcomes and higher mortality rates may be due to 
a range of factors, it is suggested that the inadequate supply of insulin is the most important 
factor (55). 
 
2.1.3 Etiological Factors 
T1D is a discrete disorder and its pathogenesis involves environmental triggers that may activate 
autoimmune mechanisms in genetically susceptible individuals, leading to progressive loss of 
pancreatic islet β-cells.  Predisposition is mediated by a number of genes that interact in a 
complex manner with each other and the environment (56). 
 
Familial Clustering of T1D 
Familial clustering of T1D is well established, and the highest risk is seen in monozygotic twin 
siblings of people with T1D.  The absolute risk in first-degree relatives (other than monozygotic 
twins) of people with T1D seems to be about 4-7%, about 10-15 times the risk in the 
corresponding general populations.  Although part of this could theoretically be due to shared 
environmental factors, the majority of the familial clustering is likely due to genetic factors (36).  
For instance, in the US, the prevalence in siblings with T1D familial clustering approached 6%, 
while the prevalence in the general population was only 0.4%, yielding a relative risk of 15 
(6/0.4) (34).  In Europe, 4-15% of newly diagnosed cases had a parent or sibling with T1D, with 
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higher proportions in high-incidence nations (57); overall, 3.6% of cases had a sibling, 1.8% a 
mother and 3-4% a father with T1D.  There is an approximately two-fold higher risk in children 
of fathers with T1D compared with children of mothers with T1D (57-60).  In Finland, when the 
parents rather than the children were probands, the cumulative risk by age 20 years was 7.8% in 
children of fathers with T1D, compared to 5.3% among mothers with T1D, which is an 
approximately 10-fold increased risk compared to the general population (60). 
 
Genetic Contribution of T1D  
The etiological contribution of genetic susceptibility to T1D is clearly demonstrated by twin and 
family studies.  It has been suggested that the concordance rate of T1D in monozygotic twin 
pairs is 25-60%, compared to 7.5-15% in dizygotic twin pairs (61).  The heritability, namely the 
proportion of the total phenotypic variation of the liability to T1D ascribable to genes, is 
estimated to be 0.75-0.88 (62,63).  Family studies show rather consistent estimates of recurrence 
risks of T1D at about 5-10% among siblings and children of T1D people (64,65).  It is noted that 
these risks are lower than those in dizygotic twin pairs, which may indicate that the environment 
shared by twins might be etiologically important as well.   
 Quantitatively most important genetic locus influencing risk of T1D is the HLA class II 
region, which explains about 40% of the familial clustering of the disease (66).  The HLA-
DQB1*0602 allele is protective against T1D, while the alleles DQA1*03-DQB1*0302 and 
DQA1*05-DQB1*0201 are associated with an increased risk (67,68).  Another gene consistently 
found to be associated with T1D is the insulin (INS) gene, where the VNTR class I allele confers 
increased risk and the class III allele confers reduced risk of T1D (69,70).  At least nine non-
HLA-linked regions have some evidence of linkage to T1D (71). 
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 The degree of haplotype sharing in siblings from T1D families influences the recurrence 
risk considerably, with an estimated recurrence risk of about 15-20% for HLA-identical siblings, 
a risk of about 6% for haplo-identical sibs and close to 0% for non-identical sibs.  Notably, the 
estimated risk for HLA-identical siblings seems to be considerably lower than the concordance 
rate in monozygotic twins.  On the other hand, the risk for HLA-identical siblings is considerably 
higher than the risk among unrelated individuals that carry high-risk HLA-markers.  The non-
HLA-linked susceptibility to T1D agrees with the higher concordance rate among monozygotic 
twins compared with HLA-identical siblings, although a higher degree of sharing of environment 
in twins also may contribute to this difference (61). 
 
Environmental Determinants of T1D   
The most striking evidence of a non-genetic contribution to T1D relates to the fact that the 
concordance rate in monozygotic twins is far below unity (61).  Since monozygotic twins 
partners share all their segregating genes, this difference can be attributed to the influence of 
non-genetic exposure or epigenetic phenomena (72).  The search for environmental determinants 
of T1D has been intensified over many years and has focused on viral infection, nutritional 
factors, stressful life events, socioeconomic status, and the intrauterine environment (61). 
The development of T1D may be associated with congenital rubella infection, 
cytomegalovirus infection, mumps, Coxsackie B infections and enteroviruses.  Exposure to 
nitrosamines in women at the time of conception may increase the risk of T1D in the male 
offspring.  There seems to be some consensus that long breast feeding and supplementation with 
vitamin D in infancy partially protects against T1D, while early exposure to cow’s milk protein, 
cereals and heavy weight in infancy are thought to be risk factors.  Birth weight is also associated 
                                
18 
 
with both the HLA and INS VNTR genes in non-diabetic populations; studies on the putative 
interaction between these genes, birth weight, and diabetes are so far lacking.  In addition, it is 
possible that stressful life events and psychological dysfunction, through elevated stress hormone 
levels, increase the demand for endogeneous insulin production and thereby accelerate clinical 
precipitation of T1D in individuals with ongoing β-cell destruction.  Lastly, conflicting results 
are reported regarding the associations between socioeconomic status and T1D: some found 
higher incidence of T1D in regions with relatively low average income levels, whereas other 
found an opposite trend.  Such associations are probably explained by unknown events and 
factors in lifestyle that may influence the risk of developing T1D and socioeconomic status (61). 
 So far, there are limited publications regarding the gene-environment interaction in T1D.  
However, given available information, there is strong support for the hypothesis that T1D 
develops as the consequence of interaction(s) between genetic factors and non-genetic 
determinants, leading to an immune-mediated process of β-cell destruction which may be 
ongoing for several years before T1D presents clinically (61).  Therefore, future studies of 
potential etiological determinants, focusing on host and environmental risk factors and gene-
environment interactions, will provide more understanding about the causes of T1D and lead to 
interventions for disease prevention. 
 
2.2 TYPE 2 DIABETES 
 
2.2.1 Definition 
Type 2 diabetes (T2D) is characterized by disorders of insulin action and insulin secretion, either 
of which may be the predominant feature.  Both are usually present at the time that diabetes 
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becomes clinically manifest.  Although the specific etiology of T2D is not clearly known, 
autoimmune destruction of the β-cells does not occur (24).  People with T2D usually have 
insulin resistance and relative, rather than absolute, insulin deficiency.  At the time of diagnosis 
of diabetes, and often throughout their lifetimes, these patients do not need insulin treatment to 
survive, although ultimately many require it for glycemic control.  T2D is associated with 
progressive β-cell failure with increasing duration of diabetes (73).  Ketoacidosis seldom occurs 
spontaneously but can arise with stress associated with another illness such as infection.  Most 
people with T2D are obese when they develop diabetes, and obesity aggravates the insulin 
resistance.  T2D frequently goes undiagnosed for many years since the hyperglycemia develops 
gradually and T2D in the earlier stages is not severe enough to produce the classic symptoms of 
diabetes; however, such patients are at increased risk of developing micro- and macrovascular 
complications.  Their circulating insulin levels may be normal, or elevated but insufficient to 
control blood glucose levels within the normal range because of the insulin resistance.  Insulin 
resistance may improve with weight reduction or pharmacotherapy and results in normalization 
of glycemia.  T2D is seen frequently in women who have a previous history of gestational 
diabetes and in individuals with other characteristics of the insulin resistance syndrome, such as 
hypertension or dyslipidemia (24). 
 
2.2.2 Epidemiology 
T2D is the predominant form of diabetes worldwide, accounting for over 90% of all cases of 
diabetes globally (56).  T2D is increasingly common in both adults and children, indeed 
epidemic, mainly because of increases in the prevalence of a sedentary lifestyle and obesity 
(56,74).  T2D accounts for about 90-95% of all diagnosed cases of diabetes (2), and even, 
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virtually all cases of diabetes in people >45 years are due to T2D (75).  Moreover, cases of T2D 
represent a very large proportion of new cases of diabetes developing in adults (76).  Therefore, 
for epidemiological studies and/or the US national surveys, diabetes that develops in adults may 
be considered as T2D, although this unquestionably results in some misclassification of the type 
of diabetes (75,76).  Both the prevalence and incidence of T2D increase dramatically with age, 
while the prevalence of T2D also varies among different ethnic populations (74).  The 
pathogenesis of T2D remains unclear; however, perhaps the most important is the heterogeneity 
of T2D because of an interplay between a variety of genetic and environmental factors.  The 
syndrome of T2D, simply speaking, is due to deficient insulin action.  This results from 
inadequate insulin secretion and/or diminished tissue response to insulin (aka. insulin resistance) 
at one or more points in the complex pathways of hormone action.  These impairments 
frequently coexist in the same patient, and it is often unclear which abnormality is the primary 
cause of the hyperglycemia (77).  Many clinical studies have affirmed that several lifestyle and 
pharmacotherapy interventions can delay or prevent T2D developing in high-risk populations 
and that good glycemic control and other interventions can slow its devastating complications 
(74).  Hence, broad implementation of guidelines and goals established by the American 
Diabetes Association and others, as well as progress in efficient processes of care, which could 
help eliminate health disparities, need to be the national priorities (3,78,79). 
 
Prevalence 
T2D affects about 3% of the population worldwide.  In the US, T2D is one of the most critical 
public health issues today, reaching epidemic rates - the prevalence is higher, affecting 6-7% of 
the population and is increasing at an astounding rate (77).  Recent US national surveys showed 
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that the estimated number of total diabetes (i.e., diagnosed and undiagnosed diabetes) among 
adult people (age ≥20 years) in 2007 was 23.5 million, representing 10.7% of all people in this 
age group or 7.8% of the population, while that among people aged 60 years or older was 12.2 
million, representing 23.1% of all people in this age group or 4.0% of the population (2).  In 
addition, T2D accounted for 94.3% (or 16.5 million people) of all diagnosed diabetes in the US 
in 2007 (40).  There have been many studies demonstrating an increasing prevalence of diabetes 
during last century.  The most reliable data on the prevalence of diagnosed T2D according to 
calendar time were obtained for the population of Rochester, MN.  The age- and sex-adjusted 
prevalence of diagnosed T2D in the population aged 45 years or older in the census years 1970, 
1980, and 1990 increased from 3.5% to 4.5% and then to 5.1% respectively (80).  Recent US 
national surveys also showed this increasing pattern of prevalence; the prevalence of total 
diabetes among adult people in years 2002, 2005, and 2007 increased from 9.3%, 9.6%, and to 
10.7% respectively (2,81,82). 
 In 2005-2006 (83), the crude estimated prevalence of total diabetes in adult people (age 
≥20 years) was 12.9%, of which ~40% was undiagnosed.  The prevalence increased with age and 
peaked at age 60-74 years (crude 30.0%), falling slightly in older ages (crude 29.1%).  
Prevalence was similar in men (crude 12.4%) and women (crude 13.3).  The prevalence of T2D 
also differs among ethnic populations.  In 2005 (81), relative to non-Hispanic whites, the 
prevalence of total diabetes among adult people was higher in non-Hispanic blacks (1.8 times), 
Hispanic/Latino Americans (1.7 times), American Indians and Alaska Natives (2.2 times), and 
Asian Americans and Pacific Islanders (>2.0 times).  Growth in the aging population as well as 
greater racial/ethnic diversity in the US are causing projected increases in the prevalence of 
diagnosed diabetes among adult people from 7.7% in 2005 to 16.0% by 2050 (25).   
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Of even greater concern is the fact that T2D has now emerged as a critical health issue in 
overweight and obese children, especially within minority overweight African-American, 
Hispanic American, and Native American adolescents.  In addition to an increasing prevalence 
of adiposity, the increasing proportion of youth with apparent T2D is related to an increase in 
sedentary lifestyle and an inheritable predisposition (56,84-88).  The prevalence of T2D in youth 
is on the rise in the US.  Previous population- and clinic-based studies as well as case series in 
1988-1998 (85,86) showed that the highest prevalence of T2D in children and adolescents 
reached 50.9 per 1,000 Pima Indians aged 15-19 years in Arizona.  From 1967-1976 to 1987-
1996, the prevalence increased 6-fold for Pima Indians adolescents (85).  Recently, the SEARCH 
for Diabetes in Youth Study, which is the largest surveillance effort on diabetes in youth (age 
<20 years) conducted in the US to date, found that the prevalence of T2D was estimated at 0.22 
cases per 1,000 youth in 2001 and T2D accounted for about 12% of all diagnosed diabetes in this 
age group (39).  The prevalence of T2D was extremely rare (0.01 cases per 1,000 youth) among 
younger youth aged 0-9 years compared to that (0.42 cases per 1,000 youth) among older youth 
aged 10-19 years.  Moreover, among the older youth, the proportion of diabetes accounted for by 
T2D varied dramatically across racial/ethnic groups, from just 6% for non-Hispanic whites to 
76% for American Indians (39). 
 
Incidence 
Prospective population-based T2D incidence studies that perform serial diagnostic examinations 
for diabetes are sparse and are conducted on the populations that are not nationally representative 
(76,89).  Most incidence studies in the US and Canada, particularly those that are nationally 
representative, use cross-sectional survey data, medical records, registries, or health care 
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administrative data to identify newly diagnosed cases of diabetes and are unable to detect new 
cases of disease that have not been diagnosed (89).  Previously, the incidence of diagnosed 
diabetes in the US increased during the 1960s but changed little between 1968 and 1992 (75).  
However, from 1997 to 2003, the crude incidence of diagnosed diabetes in the US population 
aged 18-79 years increased 41%, from 4.9 per 1,000 to 6.9 per 1,000 (26).  During this period, 
the incidence increased in most sociodemographic subgroups in the US.  Medicare 
administrative data indicated that the incidence was also increasing among the aged (90).  
Between 1994 and 2001, the incidence increased 37% in this high-risk population.  In addition, 
population-based studies in the US conducted in earlier periods also indicate that the incidence of 
T2D is increasing (89).  For instance, between the periods 1970-1974 and 1990-1994, age-
adjusted incidence in Rochester, MN, residents aged 30 years or older rose 67% for men and 
42% for women (91).  Also, incidence increased rapidly (almost tripling) from 1987 to 1996 
among Mexican Americans and non-Hispanic whites aged 25-64 years participating in the San 
Antonio Heart Study (92). 
 Recently, in 2005 and 2007, an estimated 1.5 and 1.6 million Americans were newly 
diagnosed with diabetes in people aged 20 years or older (2,81).  Each year, the number of newly 
diagnosed cases of diabetes exceeds the number of deaths among adults with diabetes (90,93), 
adding to the increasing prevalence of diabetes.  This imbalance between the number of deaths 
among people with diabetes and the number of people entering the prevalent pool is likely to 
continue to grow (89).   
 In addition to increased age, increased body mass index (BMI) coincides with the 
increasing trend in T2D incidence in the US (76,89).  Various measures of adiposity are 
associated with the incidence of diabetes.  Diabetes incidence increases sharply with BMI, and 
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obesity is a major factor in the development of diabetes.  Regardless of BMI, weight gain and 
abdominal fat and waist circumference are also associated with diabetes incidence.  In addition, 
physical inactivity, independent of the effects of obesity, further elevates the risk of diabetes.  A 
number of other lifestyle factors are associated with incidence, including smoking, no or 
excessive alcohol consumption, and various aspects of diet (89).  Lastly, the occurrence of T2D 
is similar in men and women, but there is large variability in the occurrence of T2D according to 
racial/ethnic groups.  Furthermore, large variability in the occurrence of T2D within the same 
racial/ethnic group according to geography also exists, which may be accounted for by different 
frequencies of environmental factors, such physical inactivity and obesity (76). 
 Although T2D remains rare in the general pediatric population, the incidence of T2D in 
children and adolescents has increased dramatically in the last decade, especially in minority 
populations (3).  Previous data (94) indicated a 10-fold increase in incidence of T2D in youth 
aged 10-19 years between 1982 (0.7 per 100,000 annually) and 1994 (7.2 per 100,000 annually).  
Moreover, in the past, it was believed that the overwhelming majority of children and 
adolescents with diabetes had T1D, and only 1-2% of them were considered to have T2D or 
other rare forms of diabetes (84).  Later report suggested that as many as 8-45% of newly 
diagnosed cases of diabetes among children and adolescents in the US had T2D, and the 
variation in these reported percentages appeared to depend on age group, race/ethnicity, and 
sampling strategy (84,86).  Recently, the SEARCH for Diabetes in Youth Study based on 2002-
2003 data documented 3,700 youth (age <20 years) with newly diagnosed T2D annually in the 
US, indicating that the incidence of newly diagnosed diabetes cases among youth was 5.3 per 
100,000 each year for T2D.  T2D accounted for about 22% of all newly diagnosed T1D and T2D 
cases annually in this age group (43).  In addition, T2D was extremely rare among youth aged 
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<10 years.  While still infrequent, incidence rates were greater among youth aged 10-19 years 
compared to younger children, with higher rates among US minority populations compared with 
non-Hispanic whites (43).              
 
Mortality 
The 1986 National Mortality Followback Survey for a national sample of US decedents aged ≥25 
years estimated that deaths of people with T2D accounted for 17.2% of all deaths in the US 
residents in this age group.  Age-specific death rates for people with diabetes were 1.0% for 
those aged 25-44 years, 2.8% for aged 45-64 years, 5.8% for aged 65-74 years, 13.7% for aged 
≥75 years, and 5.4% for all diabetic people aged ≥25 years (95).  Several studies concluded that 
age-adjusted mortality for people with T2D was about twice that of people without diabetes (95).  
A few studies on predominantly Asian populations reported a 3-fold relative risk of all-cause 
mortality for people with diagnosed diabetes compared to those without diabetes (96-98), 
suggesting that the risk of all-cause mortality may be greater in these populations.  In addition, 
findings from the US NHANES I study (1971-1993) revealed that, among those with diabetes, 
non-Hispanic blacks had a 27% higher age-adjusted mortality rate than that observed in non-
Hispanic whites (29).  The difference between these different ethnic groups living in the US may 
reflect the overall poorer health experiences of non-Hispanic blacks. 
 It was estimated that middle-aged people with T2D experienced a reduction of 5-10 years 
in life expectancy (46).  Mortality data from the US NHANES I study suggested that median life 
expectancy was 8 years shorter for people with self-reported diabetes aged 55-64 years, and 4 
years shorter for those aged 65-74 years (29).  Although several studies reported that diabetes 
conferred an excess risk for all-cause mortality among older people, the risk for CVD mortality 
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tended to attenuate with increasing age (46).  The reduction in life expectancy for women with 
T2D was greater than that observed for men with T2D.  The reduction in life expectancy for 
women was greater at both younger age of disease onset and younger current age, whereas that 
for men only varied according to current age, not according to the age of disease onset (46).  In 
addition, several studies have shown that a positive relationship existed between increasing 
diabetes duration and mortality risk, and the excess mortality risk associated with diabetes also 
increased with earlier age of diagnosis (46).   
 The leading cause of death in people with T2D is heart disease; ischemic heart disease 
(40%) is the most common, with other leading causes of death being other heart disease, 
diabetes, malignant neoplasms, cerebrovascular disease, and pneumonia/influenza (46,95).  
Prospective cohort studies indicate that people with T2D have a two- to four-fold risk for CVD 
mortality compared to those without diabetes (46).  The excess mortality risk observed in people 
with diabetes remains significant after controlling for the influence of other risk factors, such as 
hypertension, dyslipidemia, and smoking.  This suggests that the coexistence of other known risk 
factors does not fully explain the increased mortality risk observed in people with diabetes, and 
other factors, either directly or indirectly associated with diabetes, must also be contributing to 
the unfavorable risk profile (46).            
 
2.2.3 Etiological Factors 
Currently, T2D is considered to occur in genetically predisposed people who are exposed to a 
series of environmental influences that precipitate the onset of clinical disease (99).  Substantial 
information is available on the genetic and environmental factors that are responsible for the 
development of T2D, and these are summarized below in Tables 2.1 (56) and 2.2 (77,100-102).  
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Table 2.1 Etiological determinants and risk factors of T2D 
Genetic factors 
      Genetic markers, family history, “thrifty gene(s)” 
Demographic characteristics 
      Sex, age, ethnicity 
Behavioral- and lifestyle-related risk factors 
      Obesity (including distribution of obesity and duration) 
      Physical inactivity, diet, stress 
      Westernization, urbanization, modernization 
Metabolic determinants and intermediate risk categories of T2D 
      Impaired glucose tolerance, insulin resistance 
      Pregnancy-related determinants (parity, gestational diabetes, diabetes in offspring of 
      women with diabetes during pregnancy, intra-uterine mal- or over-nutrition) 
 
Table 2.2 Candidate genes associated with T2D 
PPAR-gamma PPARGC1 KCNJ11 TCF7L2 
CDKAL1 HHEX SLC30A8 SLC2A1 
Chr11 GYS1 IRS1 INS 
KCJN11 ABCC8 CAPN10 IGF2BP2 
CDKN2A/2B FTO WFS1 HNF1B 
JAZF1 CDC123/CAMK1D TSPAN8 THADA 
ADAMTS9 NOTCH2   
 
Twin studies suggest that genetic makeup accounts for 60-90% of the susceptibility to 
T2D.  The concordance rate in monozygotic twins is 70-90% compared to only 15-25% in 
dizygotic twins.  Due to the age-dependent penetrance of T2D, the concordance rate in the 
monozygotic twin studies increases with age, approaching 100% with lifelong follow-up.  T2D 
and IGT cluster in families.  Thus, most patients have a positive family history, and the lifetime 
risk for developing T2D is increased up to 40% (more than five times the background rate) by 
having a first-degree relative with the disease.  If both parents have T2D, the risk to the offspring 
may be as high as 70%.  Available evidence supports a polygenic mode of inheritance with a 
considerable environmental factor input (103) (see Tables 2.1 and 2.2).  The striking ethnic 
variation in T2D prevalence supports the importance of genetic factors: In the US, the prevalence 
is 2-4% in Caucasians, 4-6% in African Americans, 10-15% in Mexican Americans, and 35% in 
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the Pima Indians in Arizona.  In adult Pimas, over 75% of whom are obese, a positive family 
history of T2D is a better predictor of the incidence of T2D than the combined effects of obesity, 
gender, and physical fitness (31,77). 
Environmental/behavioral influences interact with genetic factors to determine 
susceptibility to T2D by affecting insulin action and/or insulin secretion.  The prevalence of T2D 
has increased markedly in populations that have rapidly adopted a Western lifestyle (e.g., 
American Pima Indians) and in many populations that have migrated to regions with a more 
affluent lifestyle compared to their native country (56,77).  Obesity, physical inactivity, and 
dietary influences are clearly important factors that may increase the risk of diabetes in a 
genetically predisposed individual (77,104).  Obesity is strong independent risk factor, and the 
duration of obesity is also highly predictive of T2D (105).  Sedentary people are more likely to 
develop T2D.  The antidiabetogenic effect of moderate regular physical activity is likely related 
to the beneficial effects on insulin action and prevention of obesity: The protective effect appears 
to be greatest in those at highest risk for T2D, such as obese people and those with a positive 
family history (77,106).  In addition, T2D evolves in stages.  Insulin resistance is thought to be 
an inherited initial defect in most patients and risk factors, such as obesity, sedentary lifestyle, 
and aging, may be additive.  At the early stage, fasting insulin levels and glucose-stimulated 
insulin responses are increased and sufficient to maintain normal glucose tolerance.  People who 
develop IGT typically have increased fasting and postprandial insulin levels that do not fully 
compensate for insulin resistance.  Eventually, compensation fails in some people because islet 
β-cell function declines.  The etiology of this decline may be due to a number of factors such as 
genetic abnormalities affecting β-cell function and/or due to acquired defects (e.g., glucotoxicity 
and lipotoxicity) (77).  The proportion of insulin-resistant people who progress to T2D varies 
                                
29 
 
between ethnic groups.  In most populations, the conversion rate from IGT to T2D is 2-5% per 
year over 10 years (107).  In this Diabetes Prevention Program Research Group study, the 
conversion rate was as high as 11% (108).  A small percentage of people with IGT may revert to 
normal glucose tolerance, while others remain with IGT for many years. 
 
2.2.4 Screening for Type 2 Diabetes           
Undiagnosed T2D is common, with an estimated lag of 5-7 years between the onset of diabetes 
and diagnosis (109-111).  It is estimated that, in up to 30% of affected people, the disease are 
undiagnosed (112).  People with IGT and undiagnosed T2D are at significantly increased risk for 
coronary heart disease, stroke, and peripheral vascular disease.  Hence, the delay in the diagnosis 
of T2D causes an increase in micro- and macrovascular diseases.  In addition, affected people 
have a greater likelihood of having dyslipidemia, hypertension, and obesity.  Therefore, it is 
important for the health care provider to screen for T2D in a cost-effective manner in people who 
demonstrate major risk factors for T2D as summarized below in Table 2.3 (3). 
Age, ethnicity, and family history are also important risk factors for T2D as are certain 
lifestyle behaviors and co-morbid conditions (see Table 2.3).  Certain risk factors, such as 
hypertension, low HDLc, and high triglycerides, are associated risk factors but not necessarily 
causal (31).  Increasing prevalence of obesity is one of the most important factors since it is 
closely linked to increasing prevalence of T2D.  In the US, surveys found that for every 1 kg 
increase in weight, there is a 4.5-9.0% increase in the risk of incident diabetes (113,114).  In 
addition, several analyses suggest that the relationship between ethnicity and diabetes prevalence 
is not solely based on genetic predisposition but rather a complex net of social factors, such as 
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lower income and education level, which are more prevalent in certain ethnic groups.  These 
factors independently confer a higher risk of obesity and diabetes (31). 
  The American Diabetes Association advises against routine screening for T2D outside 
the health care setting due to low likelihood of follow-up care and the need of discussion for 
abnormal results (3).  Screening for T2D will also help detect people at increased future risk for 
diabetes (i.e., pre-diabetes).  Either A1C, fasting plasma glucose (FPG), or 2-hour 75-gram oral 
glucose tolerance test (OGTT) is appropriate to test for diabetes or pre-diabetes (3).  The OGTT 
may be necessary for diagnosing diabetes when the FPG is normal, but the FPG is preferred for 
screening based on cost and convenience.  Adults should be screened at 3-year intervals 
beginning at age 45 years; testing should be considered at an earlier age or be carried out more 
frequently if diabetes risk factors are present (see Table 2.3) (3).  A recent study further supports 
this recommendation, suggesting that screening for T2D in the US population is cost-effective 
when started between the ages of 30 and 45 years, with screening repeated every 3-5 years (115).  
Asymptomatic children who are age 10 years or who experience the onset of puberty before age 
10 should be screened every 3 years for T2D if they are overweight and have two or more risk 
factors listed in Table 2.3. 
Effective management of T2D to ensure immediate improved well-being and for 
prevention of both micro- and macrovascular complications requires near-normalization of blood 
glucose levels by diet, lifestyle modifications, and glucose lowering medications, as well as 
attention to other risk factors, involving control of blood pressure and dyslipidemia, and use of 
antiplatelet agents (3,77). 
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Table 2.3 Criteria (risk factors) for testing for T2D in asymptomatic adults and children 
Adults Children (age <18 years) 
Overweight (BMI ≥25 kg/m2)a Overweight (BMI >85th percentile for age 
and sex, weight for height >85th percentile, or 
weight >120% of ideal for height) 
Physical inactivity  
Family history of diabetes (first-degree 
relative) 
Family history of T2D in first- or second-
degree relative 
Ethnic predispositionb Ethnic predispositionb 
History of GDM, PCOS, or delivery of a baby 
weighing >9 lb (4.1 kg) 
Maternal history of diabetes or GDM during 
the child’s gestation 
Hypertension: SBP/DBP ≥140/90 mmHg or 
on therapy for hypertension 
Conditions associated with insulin 
resistance (e.g., hypertension, dyslipidemia, 
PCOS, or small for gestational age 
birthweight) 
Dyslipidemia: HDLc cholesterol level <35 
mg/dl (0.90 mmol/l) and/or a triglyceride 
level >250 mg/dl (2.82 mmol/l) 
Pre-diabetes: A1C ≥5.7%, IGT, or IFG on 
previous testing 
 
Clinical conditions associated with insulin 
resistance (e.g., severe obesity, acanthosis 
nigricans) 
Signs of insulin resistance (e.g., acanthosis 
nigricans) 
History of CVD  
Abbreviations: T2D, type 2 diabetes; BMI, body mass index; GDM, gestational diabetes 
mellitus; PCOS, polycystic ovary syndrome; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; HDLc, high-density lipoprotein cholesterol; A1C, glycated hemoglobin; IGT, impaired 
glucose tolerance; IFG, impaired fasting glucose; CVD, cardiovascular disease. 
aAt-risk BMI may be lower in some ethnic groups. 
bEthnic predisposition refers to members of a high-risk ethnic population, including African 
American, Latino American, Native American, Asian American, or Pacific Islander.  
 
2.3 PRE-DIABETES 
 
2.3.1 Definition 
In 1997 and 2003, the American Diabetes Association (ADA) Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus (33,117) recognized an intermediate group of 
individuals whose glucose levels, although not meeting criteria for diabetes, are nevertheless too 
high to be considered normal.  This group was defined as having impaired fasting glucose (IFG) 
(i.e., fasting plasma glucose [FPG] levels of 110 mg/dl [6.1 mmol/l] to 125 mg/dl [6.9 mmol/l]), 
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impaired glucose tolerance (IGT) (i.e., 2-hour plasma glucose [2-h PG] levels of 140 mg/dl [7.8 
mmol/l] to 199 mg/dl [11.0 mmol/l] after a standard 75-gram load on the oral glucose tolerance 
test [OGTT]), or both.  In late 2003, the ADA issued a new expert report (116), recommending 
lowering the threshold for IFG from 110 mg/dl (6.1 mmol/l) to 100 mg/dl (5.6 mmol/l).  With 
these definitions above, there is overlap between the two groups.  To study the separate 
characteristics of IFG and IGT, classifications of isolated IFG and isolated IGT that are mutually 
exclusive have been created (isolated IFG = FPG of 100-125 mg/dl with the 2-h PG of <140 
mg/dl; isolated IGT = 2-h PG of 140-199 mg/dl with the FPG of <100 mg/dl).  The combined 
characteristics of IFG and IGT are studied by identifying populations that fulfill both criteria 
(FPG = 100-125 mg/dl and 2-h PG = 140-199 mg/dl).  Conversely, normal glucose tolerance is 
defined as FPG <100 mg/dl and 2-h PG <140 mg/dl (see Table 2.4).  The isolated classifications 
indicate that both forms of glucose testing are undertaken and only one of the two tests is 
abnormal. 
 Individuals with IFG and/or IGT are referred to as having pre-diabetes, indicating the 
relatively high risk for the future development of diabetes (3).  In addition to IFG and IGT, the 
ADA in 2010 also recommends considering an A1C range of 5.7-6.4% as identifying individuals 
with high risk for future diabetes and to whom the term pre-diabetes may be applied (1).  It 
should be noted that the 2003 ADA Expert Committee report (116) reduced the lower FPG cut-
off point to define IFG from 110 mg/dl (6.1 mmol/l) to 100 mg/dl (5.6 mmol/l), in part to make 
the prevalence of IFG more similar to that of IGT.  This change in the cut-off point increased the 
overall prevalence of IFG approximately three- to four-fold, although it is clear that IGT and IFG 
do not define the same individuals (118).  This change was highly criticized by other groups led 
by the European Diabetes Epidemiology Group (119).  Also, the World Health Organization 
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convened a Technical Guideline Development Group which published its report in 2006, 
recommending retaining the lower cut-off point for IFG at 110 mg/dl (6.1 mmol/l) (120).  This 
lack of concordance has the potential to confuse researchers and clinicians (121,122).  Due to 
applying different diagnostic criteria, data from studies should be read cautiously and may not 
longer be directly comparable if “diabetes”, “IFG”, or “IGT” do not refer to the same thing in 
different studies. 
Table 2.4 Diagnostic thresholds for diabetes and other categories of hyperglycemia 
Category American Diabetes Association 2003 (116-118) 
Test 
FPG level 2-h PG on the 75-g OGTTa 
mg/dl mmol/l mg/dl mmol/l 
NGT <100 <5.6 <140 <7.8 
IFG 100-125 5.6-6.9 <200 <11.1 
      Isolated IFG 100-125 5.6-6.9 <140 <7.8 
IGT <126 <7.0 140-199 7.8-11.0 
      Isolated IGT <100 <5.6 140-199 7.8-11.0 
Combined IFG/IGT 100-125 5.6-6.9 140-199 7.8-11.0 
Diabetesb ≥126 ≥7.0 ≥200 ≥11.1 
Abbreviations: NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired 
glucose tolerance; FPG, fasting plasma glucose; PG, plasma glucose; OGTT, oral glucose 
tolerance test. 
aThis refers to the 2-hour plasma glucose concentration after a standard 75-gram glucose load on 
the oral glucose tolerance test. 
bWhen both tests are performed, IFG or IGT should be diagnosed only if diabetes is not 
diagnosed by the other test. A diagnosis of diabetes needs to be confirmed on a separate day. The 
American Diabetes Association in 2010 also recommends including the use of glycated 
hemoglobin (A1C) to diagnose diabetes, with a cut-off point of ≥6.5% (1). 
 
2.3.2 Epidemiology 
Worldwide, it is estimated that about 344 million people (or 7.9%) in the age group 20-79 have 
IGT in 2010, the vast majority of whom live in low- and middle-income countries.  By 2030, a 
projected 472 million people (or 8.4%) in the age group 20-79 will have IGT, suggesting that at 
least 472 million adults will have pre-diabetes (123).  Epidemiologic studies demonstrate that 
IFG (110-125 mg/dl) has lower prevalence than IGT (124-126), since the majority of these 
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studies were done prior to the year of 2003 when a FPG level of 110 mg/dl (6.1 mmol/l) was 
used as the lower cut-off point for defining IFG.  However, using 100 mg/dl as the cut-off point 
for IFG, its prevalence markedly increased (118,127) and exceeded that of IGT (2,81,83,128).  In 
addition to the difference in prevalence of both categories, the overlap between the two is only 
partial (124,126). 
In the US, a cross-sectional sample of adults aged 40-74 years, who were tested during 
the period 1988-1994, showed that 33.8% had IFG, 15.4% had IGT, and 40.1% had pre-diabetes 
(IGT or IFG or both) (81).  When these percentages were applied to the entire US population in 
2000, an estimated 35 million adults aged 40-74 had IFG, 16 million had IGT, and 41 million 
had pre-diabetes (81).  More recent estimates from 2005-2006 NHANES data indicated that 
25.7% of US adults aged 20 years or older had IFG and 13.8% had IGT, with almost 30% having 
either (83). 
The 2003-2006 NHANES data (2) indicated that 25.9% of US adults aged 20 years and 
older had IFG, which was not significantly different from the prevalence in 1988-1994 (24.7%) 
and 1999-2002 (26.0%) (82).  Applying this percentage to the entire US population in 2007 
yields an estimated 57 million American people aged 20 years or older with IFG, suggesting that 
at least 57 million American adults had pre-diabetes in 2007 (2).  After adjusting for population 
age and sex differences, IFG prevalence among US adults aged 20 years or older in 2003-2006 
was 26.1% for Mexican Americans, 25.1% for non-Hispanic whites, and. 21.1% for non-
Hispanic blacks (2).  Prevalence of pre-diabetes is generally stable (31,83), although the 
prevalence of IFG and IGT varies considerably among different ethnic groups (118).  IFG and 
IGT also differ significantly in their age and gender distribution; the prevalence of both 
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metabolic disorders increases with advancing age, and IFG is more than two-fold higher in men 
whereas IGT is more frequent in women (31,118,124).   
 
2.3.3 Pathogenesis 
Although IFG and IGT are intermediate states between NGT and overt T2D, the epidemiological 
differences between them suggest that they represent distinct states of glucose intolerance, which 
are characterized by different pathophysiologic mechanisms (124,129-133).  Both IFG and IGT 
are insulin-resistant states, but they differ in site of insulin resistance.  Individuals with IFG 
predominantly have hepatic insulin resistance and normal muscle insulin sensitivity, while those 
with IGT have normal to slightly reduced hepatic insulin sensitivity and moderate to severe 
muscle insulin resistance.  Subjects with combined glucose tolerance (i.e., both IFG and IGT) 
manifest both forms of insulin resistance in severe form.  The pattern of impaired insulin 
secretion also differs between the two groups.  Subjects with isolated IFG manifest a decrease in 
first-phase insulin secretory response to intravenous glucose and early-phase insulin response to 
oral glucose.  However, late-phase plasma insulin response during OGTT is less severely 
impaired in IFG than in IGT; subjects with IGT have severe defects in both early- and late-phase 
insulin responses to intravenous and oral glucose (130).  In addition, there are four main risk 
factors for IGT: age, obesity, physical inactivity, and family history of T2D (see Table 2.5) 
(107).  The NHANES data in the US showed clearly the rise in IGT prevalence with age, the 
rates in Caucasians aged 65-74 years being 5-fold higher than in individuals aged 25-34 years.  
Body weight is also strongly predictive of late development of IGT, with a major increase in risk 
once body mass index exceeds 27 kg/m2.  Generally, the risk factors for IGT are the same as 
those for T2D (107). 
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A clearer understanding of the distinct pathophysiologic abnormalities which characterize 
IFG and IGT provides insights about interventions to slow/halt the progression to T2D.  Subjects 
with IFG, who manifest predominant liver insulin resistance, are most likely to benefit from 
agents, e.g., metformin, that reduce hepatic insulin resistance, while those with IGT, who 
predominantly have muscle insulin resistance plus severely impaired insulin secretion, are more 
likely to respond to agents that improve skeletal muscle insulin resistance, such as peroxisome 
proliferator-activated receptor-γ agonists, in combination with an insulin secretagogue, such as 
glucagon-like peptide-1 analog (130). 
Table 2.5 Risk factors for the development of IGT 
Advanced age 
Elevated body mass index 
Elevated triglycerides 
Physical inactivity 
Central obesity 
Family history of type 2 diabetes 
Low birth weight 
Low weight at age 1 year 
 
2.3.4 Clinical Significance of Pre-Diabetes 
IFG and IGT are not clinical entities in their own right, but they are associated with a 
progressively greater risk for progression to diabetes, as well as for death and morbidity due to 
micro- and macrovascular complications (1,5,117,118,124,129,134,135).  IFG and IGT appear as 
risk factors for diabetes because of their correlation with moderate to severe insulin resistance in 
muscle and/or liver as well as impaired β-cell function (124).  In contrast, the explanation for 
why IFG and IGT are also risk factors for CVD is less clear; that is, they may not in themselves 
be directly involved in the pathogenesis of CVD, but rather may serve as statistical risk factors 
by association because they correlate with those elements of the insulin resistance syndrome (i.e., 
metabolic syndrome) that are cardiovascular risk factors (33,117).    
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The transition from the early metabolic abnormalities to diabetes may take many years; 
however, several estimates indicate that the majority of individuals (perhaps up to 70%) with the 
pre-diabetic states eventually develop diabetes.  The natural history of both IFG and IGT is 
variable, with about 25% progressing to diabetes, 50% remaining in their abnormal glycemic 
states, and 25% reverting to NGT over an observational period of 3-5 years.  Individuals who are 
older, overweight, and have other diabetes risk factors are more likely to progress (118,136).  
Moreover, low insulin secretion and severe insulin resistance identify individuals more likely to 
progress to diabetes (137).  Several studies report an annual conversion rate to diabetes varying 
from 1-6% for individuals with IFG, but that varying from 2-14% for those with IGT (5).  
Individuals with both IFG and IGT may approximately double the rate of developing diabetes 
compared with those with just one of them (118). 
Numerous studies indicate that IFG and/or IGT are associated with a modest increase in 
the relative risk (~1.10-1.66) for CVD risk factors and CVD events (non-fatal and/or fatal), with 
IGT being a slightly stronger risk predictor (5,116,118,134,135,138).  Many cardiovascular risk 
factors (e.g., hypertension and dyslipidemia) are prevalent in IFG and IGT; however, after 
adjustment for known cardiovascular risk factors, both IFG and IGT remain as independent, 
albeit weak, risk factors for CVD in some studies (118,124).  Thus, it is likely that insulin 
resistance is an important risk factor for atherosclerosis (124).  In addition, the relative risk of 
all-cause mortality ranges from 1.03- to 1.48-fold higher in people with IFG or IGT compared 
with those with NGT (134,138). 
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2.3.5 Pre-Diabetes in Pediatric Population 
The prevalence of pre-diabetes is rapidly increasing in young adults and children.  The 1999-
2000 NHANES (139) data showed that the prevalence of IFG in US adolescents aged 12-19 
years was 7.0% and was higher in boys than in girls (10.0% vs 4.0%).  Prevalence of IFG was 
higher in overweight adolescents (17.8%) but was similar in those with normal weight and those 
who were at risk for overweight (5.4% vs 2.8%).  The prevalence of IFG was significantly 
different across ethnic groups (13.0, 7.0, and 4.2% in Mexican Americans, non-Hispanic white 
individuals, and non-Hispanic black individuals, respectively).  A clinic-based study in the US 
(140) showed that IGT was found in 25% of 55 obese children (age 4-10 years) and 21% of 112 
obese adolescents (age 11-18 years).  In this study, 51% of those with IGT were non-Hispanic 
white, 30% were non-Hispanic black, and 19% were Hispanic (compared to 58, 23, and 19%, 
respectively, in the population studied).  Recent studies also reported that as many as 10% of 
obese children have isolated IFG and 15% have isolated IGT, while similar to adults, only partial 
overlap between IFG and IGT was reported in children (141).  In addition, the most recent 
NHANES 2005-2006 data (128) estimated that the national population-based prevalence rates of 
IFG, IGT, and pre-diabetes (IFG and/or IGT) among US adolescents aged 12-19 years were 13.1, 
3.4, and 16.1%, respectively.  IFG accounted for nearly 80% of adolescents with pre-diabetes.  
Pre-diabetes risk was positively associated with being male and having hyperinsulinemia, but 
negatively associated with being a non-Hispanic black individual.  Moreover, hyperinsulinemia 
appeared to account for the association of weight status and clustering of cardiovascular risk 
factors with pre-diabetes. 
The metabolic abnormalities that underlie IFG and IGT in children are similar to those in 
adults (124,141,142).  Insulin resistance in skeletal muscle and liver and impaired β-cell function 
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both contribute to the development of IFG and IGT in children.  The insulin resistance in 
children with pre-diabetes is also associated with the metabolic abnormalities, which are 
characteristic of the insulin resistance syndrome (139,143) and which are likely to result in an 
increased future risk for CVD in this age group, although longitudinal studies have not addressed 
this concern.   
Similar to adults, children with pre-diabetes have an increased risk for T2D.  In a 
longitudinal study involving 102 obese children who were followed for up to 2 years, about one 
third with pre-diabetes at baseline developed T2D (144).  Weight gain seemed to be the most 
important risk factor of predicting development of T2D in children with IGT; children who 
gained excessive weight during the follow-up period had a greater risk for progression to T2D 
compared with those who gained the least amount of weight (144).  This observation underscores 
the importance of encouraging weight loss and increased physical activity in obese children. 
Further clarification of population-based prevalence and investigation to improve 
understanding of the diagnosis, clinical significance, and optimal management of pre-diabetes in 
childhood is required. 
 
2.3.6 Management of Pre-Diabetes  
Early identification and treatment of people with pre-diabetes have the potential to reduce or 
delay the progression to diabetes, related CVD, and microvascular disease (145).  A number of 
well-designed and executed clinical trials demonstrate the value of lifestyle modification or 
pharmacological therapy to prevent or delay the onset of diabetes (3).  The ADA treatment 
recommendations for individuals with pre-diabetes are summarized in Table 2.6 (3,118).  The 
completed prevention trials indicate that an intensive lifestyle intervention provides the great 
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reduction in the occurrence of diabetes, along with a modest reduction in CVD risk factors, and 
has a favorable safety profile.  The lifestyle modification studies are associated with virtually no 
serious untoward effects.  In addition, lifestyle modification is likely to have other beneficial 
health-related effects (118). 
Recently, a consensus statement from the American College of Endocrinology and the 
American Association of Clinical Endocrinologists (ACE/AACE) (145) recommended that, as 
pre-diabetes progresses, pharmacotherapy directed at hyperglycemia and the individual coronary 
heart disease risk factors may be required.  Also, strict control of all known risk factors for CVD 
and microvascular complications in people with T2D by aggressive management of glycemia, 
hypertension, and dyslipidemia and use of aspirin (as well as smoking cessation) has proved to 
be highly beneficial.  Currently, there are no medications that have been approved in the US for 
prevention of diabetes in adults, nor are there any approved pharmacological options for use in 
children and adolescents.  However, there is strong evidence from randomized controlled trials 
that metformin or acarbose reduces the progression of pre-diabetes to diabetes.  While both 
agents are less effective than intensive lifestyle interventions, they do have relatively good safety 
profile.  Therefore, it would not be unreasonable to consider either of them for treatment of 
selected people with pre-diabetes. 
Recognizing the limitations of data in pre-diabetes, the ACE/AACE committee (145) 
recommended that pre-diabetic people achieve the same target blood pressure currently 
recommended for people with diabetes - that is, a systolic pressure less than 130 mmHg and a 
diastolic pressure less than 80 mmHg.  Angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers should be first-line agents, with calcium channel blockers as appropriate 
second-line treatment approaches.  In addition, people with pre-diabetes should also have the 
                                
41 
 
same lipid goals as those with established diabetes.  As such, statin therapy is recommended to 
achieve low-density lipoprotein cholesterol levels of 100 mg/dl or below.  Attention should be 
given to achieving goals for non-high-density lipoprotein cholesterol levels of 130 mg/dl or less 
(and/or apolipoprotein B ≤90 mg/dl).  Additional use of fibrates, bile-acid sequestrants, 
ezetimibe, and other agents should be considered as appropriate.  Bile-acid sequestrants may 
play a unique role in pre-diabetes because one of these drugs, colesevelam, reduces glucose 
levels and is approved for treatment of diabetes, addressing both cardiovascular and diabetes risk 
factors.  Moreover, low-dose aspirin is recommended for all people with pre-diabetes for whom 
there is no identified excess risk for gastrointestinal, intracranial, or other hemorrhagic 
conditions. 
Lastly, the ACE/AACE committee (145) recommended that the management of the 
children or adolescents at increased risk for the development of T2D in childhood or later in life 
should use many of the measures recommended to prevent or delay the progression to diabetes in 
adults at increased risk. 
Table 2.6 Treatment recommendations for individuals with pre-diabetes 
Population Treatment/Follow-upa 
IFG or IGT or glycated hemoglobin of 5.7-6.4% Lifestyle modification (i.e., 5-10% 
weight loss and moderate intensity 
physical activity ~30 minutes/day) 
Individuals with IFG and IGT and any of the following: 
      ▪ Age <60 years 
      ▪ Body mass index ≥35 kg/m2 
      ▪ Family history of diabetes in first-degree relatives 
      ▪ Elevated triglycerides 
      ▪ Reduced high-density lipoprotein cholesterol levels 
      ▪ Hypertension 
      ▪ Glycated hemoglobin >6.0% 
Lifestyle modification (as above) 
and/or metforminb 
Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance. 
aMonitoring for the development of diabetes in those with pre-diabetes should be performed every year. 
bMetformin will be given at 850 mg twice per day. Other medications may be included if they prove to be 
effective, have a good safety/tolerance profile, and are of relatively low cost.  
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2.4 COMPLICATIONS OF DIABETES 
 
The increasing prevalence of diabetes leads to an increase in associated complications that result 
in morbidity and mortality (146).  In the US, recent data show that diabetes complications 
contribute to 810 deaths, 230 amputations, 120 cases of kidney failure, and 55 cases of blindness 
daily.  Among people with diabetes, CVD is the leading cause of death, while heart disease and 
stroke account for about 65% of all deaths (81,147).  There are two types of complications 
related to diabetes: (1) acute complications, including diabetic ketoacidosis, hyperosmolar 
hyperglycemic state, and hypoglycemia; and (2) chronic complications, including micro- and 
macrovascular complications. 
 
2.4.1 Acute Complications 
Hyperglycemic crises, including diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic 
state (HHS), and hypoglycemia are acute and potentially life-threatening complications of 
diabetes (89,148).  However, there are encouraging trends in the rates of these acute 
complications.  In the US diabetic population, rates of hospitalizations for DKA (from years 
1985 to 2005) and those of mortality due to hyperglycemic crises (from years 1980 to 2005) 
declined (149,150); and in the elderly Medicare population, rates of emergency department 
admissions for metabolic crisis and ketoacidosis declined between 1992 and 2001 (151).  
Generally, in the US, incidence and death rates due to acute complications related to diabetes are 
higher among Blacks than among Whites (149,150). 
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2.4.1.1 Hyperglycemic Crises 
DKA and HHS are the two most serious acute metabolic complications of diabetes.  Both of 
these conditions carry significant likelihood of morbidity and mortality, including cerebral 
edema, permanent neurological injury, and death (148,152).  DKA is characterized by the triad 
of uncontrolled hyperglycemia, metabolic acidosis, and increased total body ketone 
concentrations, while HHS is characterized by severe hyperglycemia, hyperosmolality, and 
dehydration in the absence of significant ketoacidosis.  These metabolic disturbances result from 
the combination of absolute or relative insulin deficiency and an increase in counter-regulatory 
hormones (e.g., glucagon, catecholamines, cortisol, and growth hormone).  Most people with 
DKA have autoimmune T1D; however, people with T2D are also at risk during the catabolic 
stress of acute illness such as trauma, surgery, or infections (148,152-154). 
Hospitalizations for DKA in the US are increasing; in the decade from 1996 to 2006, 
there was a 35% increase in the number of cases, with a total of 136,510 cases with a primary 
diagnosis of DKA in 2006 (152).  Most people with DKA were between the ages of 18-44 years 
(56%) and 45-65 years (24%), with only 18% of people aged <20 years; two-thirds of those with 
DKA had T1D and 34% had T2D, 50% were female, and 45% were nonwhite (152).  HHS 
incidence appears to be increasing, but it is unclear if this is a real increase or artifact of 
improved detection.  Approximately one-third of adults experiencing acute hyperglycemic crisis 
have mixed DKA and HHS, but the frequency of isolated HHS varies from 15 to 45% depending 
on the selection criteria (153).  DKA is the most common cause of death in children and 
adolescents with T1D and accounts for half of all deaths in diabetic people aged <24 years.  In 
adults with DKA, the overall mortality is <1%; however, it is more common (mortality rate 
>5%) in the elderly and in people with concomitant life-threatening illnesses.  Mortality 
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attributed to HHS is considerably higher than that attributed to DKA, with a mortality rate of 4-
25%.  The prognosis of both conditions is substantially worsened at the extremes of age in the 
presence of coma, hypotension, and severe comorbidities.  Death in these conditions is rarely due 
to the metabolic complications of hyperglycemia or ketoacidosis but relates to the underlying 
precipitating illnesses (152,153).  The most common precipitating factor for developing DKA 
and HHS is infection.  Other risk factors include discontinuation of or inadequate insulin therapy, 
pancreatitis, myocardial infarction, cerebrovascular accident, and medications.  In addition, new-
onset T1D or discontinuation of insulin in established T1D commonly leads to the development 
of DKA.  In young people with T1D, psychological problems complicated by eating disorders 
may be a contributing factor in 20% of recurrent ketoacidosis.  Underlying medical illness that 
provokes the release of counter-regulatory hormones or compromises the access to water is 
likely to result in severe dehydration and HHS.  In most people with HHS, restricted water intake 
is due to the patient being bedridden and is exacerbated by the altered thirst response of the 
elderly (152). 
Direct medical care charges associated with DKA episodes represent 28% of the direct 
medical care charges for all patients, and 56% for those with recurrent DKAs (155).  DKA 
accounts for an annual average of 135,000 hospitalizations at an estimated annual direct medical 
expense and indirect cost of more than US$2.4 billion (156).  There are no reliable data 
concerning the cost of HHS because of weakness of the incidence data.  However, on an 
individual basis, cost per event is several times higher than that for uncomplicated DKA (153). 
Successful treatments of DKA and HHS require correction of dehydration, 
hyperglycemia, and electrolyte imbalances; identification of comorbid precipitating events; and 
above all, frequent patient monitoring.  Hypoglycemia and hypokalemia are two common 
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complications with overzealous treatment of DKA with insulin and bicarbonate, respectively, but 
these complications occur less often with the low-dose insulin therapy.  Frequent blood glucose 
monitoring (every 1-2 hours) is mandatory to recognize hypoglycemia.  Hyperchloremic non-
anion gap acidosis, which is seen during the recovery phase of DKA, is self-limited with few 
clinical consequences (152).  In fact, many cases of DKA and HHS in people with known 
diabetes can be prevented by better access to medical care, proper diabetes management 
education, adequate treatment and self-monitoring of blood glucose, and effective 
communication with a health care provider during an intercurrent illness (152,153). 
 
2.4.1.2 Hypoglycemia 
Hypoglycemia is the most common life-threatening complication of diabetes treatment, causing a 
spectrum of acute complications from mild cognitive impairment to coma, seizure, and sudden 
death (153).  The ADA developed five hypoglycemia categories to help investigators report 
hypoglycemic events in clinical trials, including severe hypoglycemia, documented symptomatic 
hypoglycemia, asymptomatic hypoglycemia, probable symptomatic hypoglycemia, and relative 
hypoglycemia (157).  The ADA recommends that, at a minimum, hypoglycemic events should 
be reported in each of the first three categories.  Thus, since severe hypoglycemia is infrequent, 
the vast majority of reported episodes will require a corresponding plasma glucose concentration 
<70 mg/dl (3.9 mmol/l), with (documented symptomatic hypoglycemia) or without 
(asymptomatic hypoglycemia) typical symptoms (157).  In people with diabetes, hypoglycemia 
is characterized by the interplay of relative or absolute insulin excess, compromised 
physiological defenses against falling plasma glucose concentrations, and multiple risk factors 
(153,158,159). 
                                
46 
 
A meta-analysis of 14 studies in T1D, which included 1,028 patients on intensified 
insulin therapy and 1,039 patients on conventional insulin therapy, showed that the median 
incidence of severe hypoglycemia was 7.9 and 4.6 episodes per 100 patient-years, respectively.  
On the other hand, patients with T2D generally experience less frequent severe hypoglycemia 
than those with T1D.  For example, in patients with T2D on insulin therapy and sulfonylureas 
therapy, the incidence of severe hypoglycemia is approximately 0.83 and 1.5 episodes per 100 
patient-years (160).  Hypoglycemia contributes significantly to excess mortality in people with 
diabetes.  Sudden nocturnal death in young people with T1D has been reported, and it appears to 
be responsible for about 6% of deaths in diabetic people aged <40 years.  In these cases, 
nocturnal hypoglycemia is a likely precipitant consistent with demonstrated impairment of 
counter-regulatory hormone response during sleep and with high frequency of nocturnal 
hypoglycemia (153).  Risk factors for hypoglycemia include: 1) unmodifiable demographic 
predictors (i.e., age, male gender, and increased duration of diabetes); 2) endogenous insulin 
deficiency; 3) a history of hypoglycemia, hypoglycemia unawareness, or both; 4) imperfect 
insulin replacement; 5) recent moderate or intensive exercise; 6) sleep; 7) alcohol consumption; 
8) renal failure; 9) lack of adequate health insurance and access to care; 10) coexisting 
autoimmune conditions (e.g., thyroid autoimmune disease) (153,157). 
Using the incidence rate of reported severe hypoglycemia from Colorado (161) and the 
average annual cost of severe hypoglycemia estimated at US$174 per person (162), the direct 
medical cost of severe hypoglycemia in the US children was at least US$26 million per year in 
the late 1990s (153). 
Teaching a patient to recognize and treat hypoglycemia is a key component of diabetes 
care.  When patients detect the symptoms discussed above, they should perform a blood glucose 
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test.  If the reading is <70 mg/dl, they should consume 15-20 g of carbohydrate (163).  
Hypoglycemia can be preventable by improved insulin delivery, using continuous glucose 
monitors, patient education, and behavioral interventions (135,163). 
 
2.4.2 Chronic Complications 
Diabetes, a group of chronic diseases characterized by hyperglycemia, can lead to serious 
chronic complications, such as blindness, lower-limb amputations, kidney damage, and CVD 
(i.e., angina, myocardial infarction, stroke, peripheral artery disease, and congestive heart 
failure), but people with diabetes can lower the occurrence of these and other diabetes 
complications by controlling blood glucose, blood pressure, and blood lipids (2,164).  The 
importance of protecting the body from diabetes/hyperglycemia cannot be overstated; the direct 
and indirect effects on the human vascular tree are the major source of morbidity and mortality in 
both T1D and T2D.  Generally, the major injurious chronic effects of hyperglycemia are 
separated into microvascular complications (diabetic retinopathy, neuropathy, and nephropathy) 
and macrovascular complications (coronary heart disease, stroke, and peripheral arterial disease) 
(10,165). 
 
2.4.2.1 Microvascular Complications  
 
Retinopathy 
Diabetic retinopathy (DR) is a retinal vascular disorder characterized by typical microvascular 
funduscopic changes.  These typical funduscopic lesions can be broadly divided into two stages, 
nonproliferative or proliferative retinopathy, with varying degrees of severity in each subset.  
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They can either precede or follow alterations in retinal function thereby highlighting the 
importance of timely examinations to detect incipient changes (166).  Although numerous 
classifications of DR have been developed, principally for use in clinical trials, the American 
Academy of Ophthalmology has adopted a new and simplified classification for use in routine 
clinical practice (167).  The levels in this system consist of five scales with increasing risks of 
retinopathy, including no apparent retinopathy, mild nonproliferative diabetic retinopathy 
(NPDR), moderate NPDR, severe NPDR, and proliferative diabetic retinopathy (PDR) (167-
170).  The characteristic fundus lesions associated with NPDR include cotton wool spots, 
microaneurysms, dot and blot hemorrhages, retinal vascular caliber changes, hard exudate 
formation, retinal capillary closure, and macular edema (166).  With further ischemic injury, 
compensatory chemical mediators, mostly notably vascular endothelial growth factor, induce the 
growth of fragile new blood vessels at the inner surface of the retina.  This stage, called PDR, is 
characterized by neovascularization of the optic disc and neovascularization elsewhere (170).  
Two leading causes of diabetes-related vision loss are diabetic macular edema (DME) and 
complication from retinal neovascularization (abnormal blood vessel growth) (171).  DME can 
occur at any stage of DR, while neovascularization is one of important features in PDR 
(170,171).  The vascular disruptions of DR/DME are characterized by abnormal vascular flow, 
disruptions in permeability, and/or closure or nonperfusion of capillaries (168). 
DR may be not only the most common microvascular complication of diabetes, but the 
leading cause of new cases of blindness in the work-age population (age 20-74 years), 
accounting for 12% of all new cases of blindness and leading to 12,000 to 24,000 new cases of 
blindness each year in the US (2,17,165,170).  In people with T1D, clinically significant 
retinopathy almost never occurs in the first 5 years after diagnosis of diabetes or before puberty, 
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while a fifth of people with newly discovered T2D have retinopathy at the time of diagnosis 
(10,171).  However, the prevalence of DR will be getting high with longer duration of diabetes; 
20 years after diagnosis of diabetes, >95% of people with T1D and >60% of people with T2D 
will have some degree of retinopathy (10,170,171).  The proportion of visual impairment in 
people with diabetes approximately doubles that in people without diabetes (172).  Recent data 
showed that in 2008, the crude percentage of adults with diabetes who report visual impairment 
was 20.5%, representing a slight decrease from 26.1% in 1997 (150).  Also, the risk of blindness 
in people with diabetes is 20 times higher than that in those without diabetes (10).  In the 
Pittsburgh Epidemiology of Diabetes Complications Study, the 2-year incidence of DR was 33% 
in T1D (173), while in the Wisconsin Epidemiologic Study of Diabetic Retinopathy, the 10-year 
incidence of DR was 75% in the younger-onset T1D group, 70% in the older-onset T2D group 
on insulin treatment, and 50% in those not on insulin treatment (174). 
Retinopathy in people with diabetes may be a marker of systemic vascular diseases and is 
linked with cardiovascular morbid-mortality and all-cause mortality (167,175).  The single best 
predictor of DR is the duration of diabetes, while other risk factors that increase the risk of, or 
are associated with, DR include severity of hyperglycemia, the presence of nephropathy, 
hypertension, and dyslipidemia (3,166,167,170,175).  Diabetes-related blindness and visual 
impairment places a significant burden on society.  The federal budgetary cost of blindness was 
estimated to be $4.1 billion in the US for the year 1990, and 97% of these costs were accounted 
for by the working-age adult group.  Health care and economic burdens of DR are further 
compounded by the resulting decline in quality of life; hence, the true impact on society cannot 
be estimated on a monetary basis alone (168).  However, DR is one of the most prevalent but 
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preventable blinding diseases in the US; with early detection, DR can be treated with modalities 
that have been proven to decrease the risk of severe vision loss by >90% (170). 
 
Neuropathy 
The diabetic neuropathies are heterogeneous, affecting different parts of the nervous system and 
may present with diverse clinical manifestations.  They may be focal or diffuse, and the most two 
common among the neuropathies are chronic sensorimotor distal symmetric polyneuropathy 
(DPN) and diabetic autonomic neuropathy (DAN) (176,177).  Although DPN is a diagnosis of 
exclusion, complex investigations to exclude other conditions are rarely needed (3).  With 
immensely varying clinical features of diabetic neuropathy, people with diabetes may present to 
a wide spectrum of specialties, from dermatology to podiatry, or from urology to cardiology 
(177).  The diabetic polyneuropathies (DPN and DAN) are clearly of multifactorial etiology, and 
a number of metabolic and vascular defects are now implicated in their pathogenesis (178). 
The neuropathies are among the most frequent of the long-term complications of 
diabetes; about 60-70% of people with diabetes have mild to severe forms of nervous system 
damage.  The results of such damage include impaired sensation or pain in the feet or hands, 
slowed digestion of food in the stomach, carpal tunnel syndrome, erectile dysfunction, or other 
nerve problems.  Almost 30% of people with diabetes aged 40 years or older have impaired 
sensation in the feet (i.e., at least one area that lacks feeling) (2).  More specifically, DPN is by 
far the most common subgroup of the diabetic neuropathies, accounting for more than 80% of 
patients with clinical diabetic neuropathies (179).  Although the prevalence of DPN varies, it 
appears that at least one manifestation of DPN is present in at least 20% of adults with diabetes 
(176).  Prevalence data for DAN range from 1.6 to 90% depending on tests used, populations 
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examined, and type and stage of disease (176).  DPN is associated with a number of modifiable 
and nonmodifiable risk factors, including the degree of hyperglycemia, lipid and blood pressure 
indexes, diabetes duration, and height, while risk factors for the development of DAN include 
diabetes duration, age, and long-term poor glycemic control and DAN may cosegregate with 
factors predisposing to macrovascular events such as raised blood pressure and dyslipidemia 
(176). 
Diabetic neuropathy is one of the major contributing causes of amputation and foot 
ulceration, which are common and major causes of morbidity/disability in all people with 
diabetes and may lead to mortality in some people with diabetes (2,3,177).  The risk of 
amputation in people with diabetes is 40 times higher than that in those without diabetes (10).  In 
the US, an estimated 15% of people with diabetes will have a diabetic foot ulcer during their 
lifetime; of these, 6-43% will ultimately undergo a lower-extremity amputation (17).  Among 
people with diabetes who have had an amputation, as many as 85% may have had a preceding 
foot ulcer (17).  Recent data showed that more than 60% of nontraumatic lower-limb 
amputations occurred in people with diabetes in the US, and in 2004, about 71,000 nontraumatic 
lower-limb amputations were performed in people with diabetes (2).  The risk of ulcers or 
amputations is increased in diabetic people who have the following risk factors: previous 
amputation, past foot ulcer history, peripheral neuropathy, foot deformity, peripheral vascular 
disease, visual impairment, diabetic nephropathy (especially patients on dialysis), poor glycemic 
control, and cigarette smoking (3,175). 
Recent the US national diabetes surveillance data showed that the crude hospital 
discharge rates for lower-extremity ulcer/inflammation/infection, neuropathy, and nontraumatic 
lower-extremity amputation in 2003 were 6.9, 6.8, and 5.2 per 1,000 people with diabetes, 
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respectively (150).  Also, the financial cost of diabetic ulceration and/or amputations is 
staggering (177).  Therefore, the early recognition and appropriate management (i.e., prevention 
and treatment) of neuropathy as well as ulcers and amputations in people with diabetes is 
important to reduce the burden of these complications. 
 
Nephropathy 
Diabetic nephropathy (DN) is a renal damage caused by microangiopathic affection.  DN is a 
chronic vascular complication exclusive of diabetes characterized by alterations in renal 
microcirculation, leading to a series of functional and structural damages, mainly in the 
glomerulus (180).  Without therapeutic interventions, serum creatinine levels increase and 
patients go on to develop end-stage renal disease (ESRD; i.e., kidney failure requiring dialysis or 
transplantation).  Microalbuminuria (or incipient nephropathy) in the range of 30-299 mg/24 h is 
the earliest stage of DN in T1D and a marker for development of nephropathy in T2D (3,181).  
Without specific interventions, about 80% of people with T1D who develop persistent 
microalbuminuria have their urinary albumin excretion increase at a rate of about 10-20% per 
year to the stage of macroalbuminuria (i.e., clinical albuminuria or overt nephropathy; ≥300 
mg/24 h or ≥200 µg/min) over a period of 10-15 years, with hypertension also developing along 
the way.  Once overt nephropathy occurs, without specific interventions, the glomerular filtration 
rate (GFR) gradually falls over a period of several years at a rate that is highly variable from 
individual to individual (2-20 ml/min per year).  ESRD develops in 50% of type 1 diabetic 
people with overt nephropathy within 10 years and in >75% by 20 years (181). 
A higher proportion of people with T2D are found to have microalbuminuria and overt 
nephropathy shortly after the diagnosis of their diabetes, because diabetes is actually present for 
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many years before the diagnosis is made and also because the presence of albuminuria may be 
less specific for the presence of diabetic nephropathy, as shown by biopsy studies.  Without 
specific interventions, 20-40% of type 2 diabetic people with microalbuminuria progress to overt 
nephropathy, but by 20 years after onset of overt nephropathy, only about 20% will have 
progressed to ESRD.  Once the GFR begins to fall, the rates of fall in GFR are again highly 
variable from one individual to another; however, overall they may not be substantially different 
between people with T1D and those with T2D (181). 
Generally, DN occurs in 20-50% of people with diabetes (3,180).  Diabetes is the single 
leading cause of ESRD in the US, accounting for 44% (48,215/108,928) of new cases of treated 
ESRD in 2006 (182).  The risk of ESRD in people with diabetes is 25 times higher than that in 
those without diabetes (10).  Encouragingly, from 1996 to 2006, the age-adjusted diabetes-
related ESRD incidence in the US decreased by 3.9% per year from 343.2 to 197.7 per 100,000 
diabetic populations (182), probably because of a reduction in the prevalence of ESRD risk 
factors, improved treatment and care, and other factors.  In addition, several factors can influence 
the development of DN, including genetic factors, poor glycemic control, hypertension, 
dyslipidemia, smoking habit, retinopathy, and microalbuminuria or progression to proteinuria 
(175,180). 
Microalbuminuria, in addition to being the earliest manifestation of nephropathy, is a 
well-established marker of greatly increased cardiovascular morbidity and mortality for people 
with diabetes (3,181).  Diabetic people with microalbuminuria who progress to 
macroalbuminuria are likely to progress to ESRD (3).  ESRD is a costly and disabling condition 
with a high mortality rate.  In 2006, ESRD costs reached nearly $23 billion, >6% of the Medicare 
budget, and mortality rates were about eight times greater among people aged 20-64 years with 
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ESRD treated by dialysis than among those in the general population of similar age (182).  
However, recent studies have now demonstrated that the onset and course of DN can be 
ameliorated to a very significant degree by several interventions, and these interventions have 
their greatest impact if instituted at a point very early in the course of the development of this 
complication (3,181). 
 
2.4.2.2 Macrovascular Complications 
 
Cardiovascular Disease 
Macrovascular complications commonly develop in individuals with T1D and T2D.  This is of a 
particular concern as the increasing prevalence of diabetes now also affects adolescents and 
younger adults, thus promoting the earlier development of long-term complications.  Diabetes 
itself accounts for 75-90% of the excess coronary heart disease (CHD) risk and enhances the 
effects of other cardiovascular risk factors (183).  Cardiovascular disease (CVD) is the leading 
cause of morbidity and mortality in individuals with diabetes and accounts for the greatest 
component of health care expenditures for diabetes (3,165,184).  The types of CVD that 
accompany diabetes mainly include CHD (angina or myocardial infarction), stroke, congestive 
heart failure, and peripheral arterial disease (164). 
Cardiovascular diseases are defined as diseases and injuries of the circulatory system: the 
heart, the blood vessels of the heart, and the system of blood vessels throughout the body and to 
(and in) the brain (185).  Angina is the pain that arises when the blood supply to the heart muscle 
itself is temporarily insufficient.  This is usually due to narrowing of the arteries feeding the 
heart muscle.  When one of these arteries becomes fully blocked, a myocardial infarction occurs, 
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which kills heart muscle and is often fatal (186).  People with diabetes without previous 
myocardial infarction have as high a risk of myocardial infarction as people without diabetes 
who had a previous myocardial infarction (187).  Stroke occurs when areas of the brain die from 
arterial blockage or arterial breakage and bleeding.  Stroke is sometimes fatal but it also often 
causes paralysis and loss of speech (186).  Heart failure results when the heart cannot pump 
strongly and fluid backs up in the legs, lungs, and other tissues (186).  Peripheral arterial disease 
results from blockages in arteries that feed the legs; it causes pain while walking and can lead to 
claudication, major surgery, and the need for amputation (186).  Peripheral arterial disease is one 
of the major contributing causes of amputation and foot ulceration, which are common and major 
causes of morbidity/disability in all people with diabetes (2,3). 
 
Pathogenesis 
A range of hemodynamic and metabolic factors are considered responsible for the development 
and progression of macrovascular complications in diabetes (188).  Specifically, the central 
pathological mechanism in macrovascular complications is the process of atherosclerosis, which 
leads to narrowing of arterial walls throughout the body (165).  Atherosclerosis is thought to 
result from chronic inflammation and injury to the arterial wall in the coronary or peripheral 
vascular system.  In response to endothelial injury and inflammation, oxidized lipids from low-
density lipoprotein particles accumulate in the endothelial wall of arteries.  Angiotensin II may 
promote the oxidation of such particles.  Monocytes then infiltrate the arterial wall and 
differentiate into macrophages, which accumulate oxidized lipids to form foam cells.  Once 
formed, foam cells stimulate macrophage proliferation and attraction of T-lymphocytes.  T-
lymphocytes, in turn, induce smooth muscle proliferation in the arterial walls and collagen 
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accumulation.  The net result of this process is the formation of a lipid-rich atherosclerotic lesion 
with a fibrous cap.  Rupture of this lesion would lead to acute vascular infarction (165,189). 
In addition to atheroma formation, there is strong evidence of increased platelet adhesion 
and hypercoagulability in diabetes.  Impaired nitric oxide generation and increased free radical 
formation in platelets, as well as altered calcium regulation, may promote platelet aggregation.  
Elevated levels of type 1 plasminogen activator inhibitor may also impair fibrinolysis in people 
with diabetes.  The combination of increased coagulability and impaired fibrinolysis likely 
further increases the risk of vascular occlusion and cardiovascular events in diabetes (165,190).  
Diabetes increases the risk that an individual will develop a CVD.  Although the precise 
mechanisms through which diabetes increases the likelihood of atherosclerotic plaque formation 
are not completely defined, the association between the two is profound (165).  
 
Prevalence  
Globally, the prevalence of CHD in people with diabetes (both T1D and T2D) ranges from 1.0% 
to 25.2% in clinic-based populations and from 1.8% to 43.4% in population-based studies, while 
the prevalence of stroke in those people were from 1.0% to 11.3% and from 2.8% to 12.5%, 
respectively (186).  Recently, the US national diabetes surveillance data showed that the age-
adjusted percentage of people with diabetes aged 35 years and older self-reporting any CVD 
condition (i.e., CHD, stroke, or other heart diseases) declined from 36.6% in 1997 to 31.4% in 
2007 (150).  More specifically, no major changes were apparent in the age-adjusted percentage 
of CHD, stroke, or other heart diseases between 1997 and 2007.  In 2007, the age-adjusted 
percentage of people with diabetes aged 35 years and older with self-reported CHD was 20.2%, 
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almost 2.6 times that of self-reported stroke (7.9%) and 1.2 times that of self-reported other heart 
diseases (16.2%) (150). 
In addition, between 1997 and 2007, the percentage of adults with diabetes aged 35 years 
and older self-reporting any CVD condition was lower in adults aged 35-64 years than that 
among those older (i.e., people aged 65-74 or 75 years and older).  The percentage declined 
across the time period for adults aged 35-64 years; however, no consistent trend was observed 
for those aged 65-74 or 75 years and older.  In 2007, the percentage was 26.5% among people 
aged 35-64, 44.9% among those aged 65-74 years, and 48.4% among those aged 75 years or 
older (150).  Regarding gender differences, between 1997 and 2007, the age-adjusted percentage 
was higher for men than women, but declined for both men and women.  In 2007, the age-
adjusted percentage was 32.2% for men and 30.6% for women (150).  In terms of racial/ethnic 
differences, between 1997 and 2007, the age-adjusted percentage was highest among whites and 
lowest among Hispanics.  The age-adjusted percentage declined across the time period for 
whites; however, no consistent trend was seen among blacks or Hispanics.  In 2007, the age-
adjusted percentage was 32.4% among whites, 30.3% among blacks, and 21.3% among 
Hispanics (150). 
The prevalence of congestive heart failure in people with diabetes varies in different 
studies, partly because of differences in the definition of this disease and in the characteristics of 
study populations.  Three US studies, focusing on the role of congestive heart failure in people 
with diabetes, noted that the prevalence of congestive heart failure varied between 1.9% and 
22.3% (191-193).  In addition, the true prevalence of peripheral arterial disease in people with 
diabetes is difficult to determine, since many patients are asymptomatic, they do not report their 
symptoms, their pain perception is blunted by neuropathy, or different methods are used to 
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estimate its presence.  Both asymptomatic peripheral arterial disease and claudication are more 
common among people with diabetes.  Peripheral arterial disease in people with diabetes is both 
morphologically and physiologically distinguished from non-diabetic atherosclerosis (194).  
Studies showed that 15-65% of people with diabetes have peripheral arterial disease, while 2.1-
7.5% of those with diabetes have claudication (194,195). 
 
Incidence 
The incidence of CVD in people with diabetes varies in different studies, largely because of 
differences in the definition of the disease and in the characteristics of study populations.  
According to four occupational/population-based studies comparing the incidence of CVD in 
adults with and without diabetes in the US, all found an increased risk of incident CVD (fatal and 
non-fatal combined) among diabetic individuals (196).  The Framingham Heart Study found that 
the age-adjusted CVD incidence rate per 1,000 person-years was 128.8 for diabetic men and 
106.5 for diabetic women (197).  The Honolulu Heart Study found that the age-adjusted CHD 
(including non-fatal myocardial infarction and fatal CHD) incidence rate per 1,000 person-years 
was 11.6 for diabetic men (198).  The Nurses’ Health Study revealed that the CHD (including 
non-fatal myocardial infarction and fatal CHD) and stroke (including non-fatal and fatal stroke) 
incidence rates per 1,000 person-years were 4.2 and 1.5 for diabetic women (199).  A 
community-based study in New Haven, CT showed that, during the 6-year follow-up, the 
weighted incidence of non-fatal myocardial infarction was 10.2% and 11.8% for diabetic men 
and women, while that of fatal CHD was 12.3% and 16.1%, respectively (200).  Other studies 
indicated that the incidence of CHD was approximately 1-2% per year among young 
asymptomatic people with T1D (184,201,202).  In addition, the most common cause of death in 
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people with diabetes is CVD, particularly CHD (186,196).  The national incidence data for the 
US came from a 9-year follow-up of the 1971-75 First National Health and Nutrition 
Examination Survey, in which the age-adjusted fatal CHD rates per 1,000 person-years for 
diabetic men and women aged 40-77 years at baseline were 28.4 and 10.5, respectively (196). 
The incidence of congestive heart failure in diabetes varied greatly, which was influenced 
by the time of follow-up, the mean age of patients, the state of metabolic control and the 
complications of diabetes (203).  Generally, studies showed that the congestive heart failure 
incidence rate per 1,000 person-years in people with diabetes ranged from 2.3 to 126 
(191,193,204).  More specifically, the Framingham Heart Study revealed that the congestive 
heart failure incidence rates per 1,000 person-years were 9 for diabetic men and 14 for diabetic 
women (204).  In addition, the incidence of peripheral arterial disease in people with diabetes 
depends on the usual atherosclerosis risk factors and duration of diabetes (195).  A Finnish study 
examined the 5-year incidence of claudication in a group of 133 middle-aged subjects with 
newly diagnosed T2D and found that the age-adjusted incidence of claudication was 20.3% for 
diabetic men and 21.8% for diabetic women (205).  The Framingham Heart Study found that 
male sex and age were associated with an increased risk of claudication.  The 4-year risks of 
intermittent claudication at ages 45-54 years were 0.9% for men and 0.4% for women, whereas 
at ages 65-74 years the risks were 2.5% for men and 1.5% for women.  Among those with 
intermittent claudication, 20% were diabetic, while among those without claudication, only 6% 
had diabetes (194).  The Cardiovascular Health Study including 5,888 men and women aged 65 
years or older found that the overall percentage of subjects with incident peripheral arterial 
disease was 9.5% over 6-year follow-up.  Among the incident cases of peripheral arterial disease, 
18.8% had diabetes, compared with the non-cases, 10.5% of whom had diabetes (194). 
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Individuals with diabetes are at two- to fourfold increased risk of CVD events compared 
with age- and sex-matched individuals without diabetes (2,206).  More specifically, diabetes is 
associated with a two- to fivefold increased risk of myocardial infarction, and with a two- to 
fourfold increased risk of stroke (2,10).  Also, claudication is twice as common in people with 
diabetes as those without diabetes (195).  Recently, a large collaborative meta-analysis 
confirmed that diabetes confers about a two-fold excess risk for a wide range of vascular 
diseases (including CHD, major stroke subtypes, and deaths attributed to other vascular causes), 
independently from other conventional risk factors (207).  Interestingly, several studies showed 
that diabetes reduces the usual female cardioprotection; that is, the absolute rates of CVD in 
people with diabetes are higher in men than in women (as in the general population), but the 
relative risk (comparing those with and without diabetes) is higher in women than in men 
(relative risk: 2-4 for women and 1.5-2.5 for men) (17,184).  This gender difference may be 
mediated in large part by more adverse cardiovascular risk profiles among women with diabetes, 
combined with possible disparities in treatment that favor men (208,209). 
In addition, the incidence of CVD among diabetic people with prior CVD was higher 
than that among those without prior CVD.  A study by Haffner et al. reported that, among 
diabetic people, the incidence rates of myocardial infarction (fatal or non-fatal) and stroke (fatal 
or non-fatal) per 100 person-years in those with prior myocardial infarction were 45.0 and 19.5, 
while those rates in those people without prior myocardial infarction were 20.2 and 10.3 (187).  
Another study by Giorda et al. showed that the age-standardized incidence rates of stroke (fatal 
or non-fatal) per 1,000 person-years in diabetic men and women with a history of CVD were 
13.7 and 10.8, while those rates in those men and women with no history of CVD were 5.5 and 
6.3 (210).  In addition, diabetes is defined as a CHD risk equivalent; that is, the incidence of 
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myocardial infarction among diabetic people without previous CHD was similar to that among 
non-diabetic people with preexisting CHD (187).  Although this equivalency has not been 
consistently documented (184), this observation is a useful impact on CVD prevention in 
diabetes by alerting more of the medical community to the importance of considering treatment 
targets based on the presence of diabetes and the entire CVD risk factor profile (211). 
 
Morbidity  
The high rates of morbidity and mortality associated with diabetes are, most notably, due to 
CVD.  In diabetic individuals, CVD accounts for 75-80% of deaths and hospitalizations, 
approximately 75% of which are due to CHD, as well as for a heavy burden of disability and 
expense (212-214).  Recent estimates in the US indicated that the age-adjusted hospital discharge 
rates for major CVD, CHD, heart failure, stroke, and peripheral arterial disease as first-listed 
diagnosis per 1,000 diabetic populations in 2003 were 56.4, 21.5, 18.5, 8.7, and 3.3, respectively 
(150).  Among these, the age-adjusted hospital discharge rates for major CVD increased from 
1980 through 1996, then decreased and leveled off through 2003 (150). 
 
Mortality 
Among diabetic patients aged 65 years or older in the US in 2004, 68% of deaths were from 
CHD and 16% were from stroke (2).  For example, people with T2D have a shortened life 
expectancy, with up to 75% dying of macrovascular complications (11).  In the United Kingdom 
Prospective Diabetes Study, fatal CVD events were 70 times more common than deaths from 
microvascular complications (10).  Adults with diabetes have heart disease death rates about 2 to 
4 times higher than adults without diabetes (2).  More specifically, diabetes is associated with a 
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1.2- to 2.0-fold increase in mortality risk after acute myocardial infarction (212), while diabetic 
patients with heart failure have three times the mortality risk than non-diabetic patients with 
heart failure (184).  In addition, a recent meta-analysis further revealed that diabetes is about a 
third more strongly related to fatal than to non-fatal myocardial infarction, perhaps suggestive of 
more severe forms of coronary lesions in people with diabetes than in those without, differential 
response of the myocardium to ischemia, or possibly in part, differential coding of deaths from 
CHD (207). 
 
Risk Factors 
The risk of developing new CVD is high in diabetes, in part because of its frequent association 
with other risk factors for CVD.  The most important risk factors for CVD are family history, 
smoking, dyslipidemia, hypertension, diabetes, obesity, and socioeconomic factors (215).  Other 
markers of CVD risk in people with diabetes include age, sex, diabetic retinopathy, autonomic 
neuropathy, erectile dysfunction, microalbuminuria, and proteinuria (216).  Specifically, 
predictors of cardiovascular mortality in T1D include microalbuminuria, overt nephropathy, 
hypertension, smoking, and age, while those in T2D include overt proteinuria, presence of CHD, 
hypertension, and A1C levels (10). 
Several interventions, some of which are relatively inexpensive, can dramatically reduce 
the risk of CVD, including stopping smoking, general blood pressure control, low-dose daily 
aspirin, ACE-inhibitor pills, and statin drugs (186).  In addition, while T1D and T2D share most 
risk factors for CHD and stroke, there are notable differences.  The traditional cardiovascular risk 
factors of hyperglycemia, dyslipidemia, elevated blood pressure, smoking, and metabolic 
syndrome are of importance, but they do not explain the excess risk of CHD in T1D patients 
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(184).  CVD prediction models that are valid in non-diabetic people (Framingham score) or in 
T2D patients (the UK prospective diabetes study risk engine) poorly predict CVD events in T1D 
patients (217).  This area is currently a subject of intensive investigation (218), and recently, 
Zgibor et al. first developed and externally validated a CHD risk prediction model specific to 
T1D (219). 
 
2.5 HEALTH UTILIZATION PATTERNS AND ECONOMIC BURDEN OF DIABETES 
 
Both the resource utilization and the spending, which are associated with the clinical 
consequences of diabetes (e.g., vascular complications) and the modification of its risk factors 
(e.g., obesity), are tremendous (147).  For example, annual spending on direct costs related to 
CVD is $432 billion nationwide (220), and the annual cost of CVD may range from $8,200 to 
$13,100 per person depending on the presence of diabetes (221).  Moreover, annual health care 
spending related to just one of the risk factors for diabetes (i.e., overweight or obesity) has been 
estimated at $92.6 billion (222). 
 
Health Utilization Patterns of Diabetes      
Health seeking and health utilization behaviors are influenced by several individual, provider and 
system level factors.  In the case of diabetes, ill health and morbidity as well as preventative care 
motives result in incrementally more health service utilization (223).  Specifically, a substantial 
amount of attributed health resource use is for chronic complications of diabetes.  In particular, 
CVD, neurological symptoms, and renal complications are associated with high resource use 
attributed to diabetes (14).  In the US, 24.3 million hospital inpatient days, 64.7 million physician 
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office visits, and 5.6 million emergency visits are attributed to diabetes annually.  The diabetes 
population aged 65 years or more uses a larger portion of health resources, reflecting the burden 
of diabetes placed on the Medicare program (14). 
Various studies demonstrate that people with diabetes use more hospital inpatient care, 
outpatient and physician office visits, emergency visits, nursing facility stays, home health visits, 
visits with other health professionals, and prescription drugs and medical supplies than their 
peers without diabetes (14,147,223,224).  For instance, among men aged 60-64 years, those with 
diabetes have eight times the number of hospital inpatient days, seven times the number of 
emergency visits, and six times the number of physician office and outpatient visits for heart 
failure compared to their peers without diabetes (14).  Having diabetes doubles one’s risk of 
hospitalization compared to not having diabetes, and this risk is amplified by the development of 
diabetes-related complications (14,223).  Although studies from most regions of the world report 
late-stage macrovascular or microvascular complications as the leading cause of diabetes-related 
hospitalizations, lower income settings such as Ethiopia confront a greater proportion (almost 
two-thirds) of admissions in the form of acute episodes of dysglycemia (223).   
A population-based study was conducted to compare prescription utilization between 
patients with type 2 diabetes and those who did not have diabetes, which found that the mean 
number of prescriptions dispensed for all drugs, excluding antidiabetic agents, was higher across 
all age groups for patients with diabetes.  After adjusting for age, patients with type 2 diabetes 
were 1.7 times more likely to be dispensed a drug than those who did not have diabetes.  
Cardiovascular drugs accounted for 28.8% of the total prescriptions for patients with type 2 
diabetes.  The likelihood of being dispensed a prescription was increased across all drug classes, 
including those not normally considered to be associated with diabetes (225).  In addition, 
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patients with diabetes complications are considered high users; they use a greater number of 
high-cost services than patients without complications.  For example, the Centers for Disease 
Control and Prevention Diabetes in Managed Care Work Group shows that diabetic individuals 
with multiple complications or comorbidities use significantly more specialty care services (5.8-
6.3 times), make significantly more emergency visits (3.3-5.5 times), and have significantly 
more hospitalizations (3.3-11.9 times) than do those without complications (226). 
 
Economic Burden of Diabetes 
Diabetes imposes a serious economic burden on national health care system worldwide.  
Quantitative calculations suggest that direct and indirect costs of diabetes worldwide 
cumulatively total US$376 billion in 2010 (9).  Almost half of all global expenditure occurred in 
the US, which is home to only 8% of those affected by diabetes nationwide (9,223).  Several 
recent studies estimated and projected the cost of diabetes in the US.  A study in 2008 sponsored 
by the ADA reported that the total estimated annual cost of diabetes in 2007 is US$174 billion, 
accounting for 11% of national health expenditures and including US$116 billion in direct health 
care costs attributed to diabetes and US$58 billion in reduced national productivity (14).  A study 
in 2010 (227) used this base cost and estimated additional costs contributed by undiagnosed 
diabetes (228), pre-diabetes (229), and gestational diabetes (230), for a total of $218 billion in 
2007.  This estimate includes $153 billion in higher medical costs and $65 billion in reduced 
productivity.  The average annual cost per case is $2,864 for undiagnosed diabetes, $9,975 for 
diagnosed diabetes ($9,677 for type 2 diabetes and $14,856 for type 1 diabetes), and $443 for 
pre-diabetes (medical costs only).  For each American, regardless of diabetes status, this burden 
represents a cost of approximately $700 annually (227).  In 2012, the total estimated cost of 
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diagnosed diabetes in the US reached $245 billion (231), and the health care expenditures for 
diabetes in the US are expected to be between $264 and $474 billion in years of 2030-2034 
(9,16,232). 
In the US, one out of every five health care dollars is spent caring for someone with 
diagnosed diabetes, while one in ten health care dollars is attributed to diabetes (14).  The largest 
components of direct medical expenditures attributed to diabetes are hospital inpatient care (50% 
of total cost), diabetes medication and supplies (12%), retail prescriptions to treat complications 
of diabetes (11%), and physician office visits (9%).  General medical condition (40%) and 
cardiovascular complications (36%) constitute the top 2 largest contributors to the attributed 
medical cost of diabetes for hospital inpatient care.  Together, the general medical conditions and 
cardiovascular complications are responsible for 91% of US expenditures for inpatient care and 
76% of hospital inpatient costs attributed to diabetes (14).  Indirect costs include increased 
absenteeism ($2.6 billion) and reduced productivity while at work ($20.0 billion) for the 
employed population, reduced productivity for those not in the labor force ($0.8 billion), 
unemployment from disease-related disability ($7.9 billion), and lost productive capacity due to 
early mortality ($26.9 billion) (14). 
Increased health seeking and utilization in people with diabetes and associated 
complications result in greater medical costs incurred, compared to the general population 
without diabetes.  In the US, people with diabetes, on average, have medical expenditures that 
are 2.3 times higher ($11,744 vs. $5,095) than those for this same population without diabetes, 
suggesting that diabetes is responsible for $6,649 in excess expenditures per year per person with 
diabetes (14).  From an employer perspective, it is determined that workers with diabetes 
generate an average of $4,410 more in medical and productivity costs annually than do those 
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without diabetes (233).  In addition, lifetime costs associated with diabetes and its complications 
have been estimated as well.  Tao et al. (234) reported that, for a newly diagnosed T1D patient 
aged between 3 and 45 years, his/her expected rest-of-lifetime medical costs attributable to 
diabetes was $115,230.  Caro et al. (235) estimated that the 30-year cumulative cost of managing 
complications in a patient with T2D was $47,240.  Roughly, one half of these costs were 
associated with macrovascular complications.  Moreover, it was noted that macrovascular 
disease is a greater determinant of cost in the early years than are microvascular complications; it 
accounts for 85% of cumulative costs over the first 5 years and 77% over the first 10 years.  
These findings may suggest that modification of cardiometabolic risk in patients with diabetes 
can reduce the cost of complications of the disease more than modification of microvascular 
complications. 
The tremendous economic burden of diabetes makes the disease an important clinical and 
public health problem.  Also, this highlights the needs and benefits of prevention and control, as 
well as informs cost-effective models of diabetes prevention and intervention.  Notably, early 
and aggressive management may delay or even prevent diabetes and many of its complications 
(e.g., CHD, hypertension, and depression), leading to improved quality of life and reduced health 
care expenditures in the general population (224,236,237). 
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3.0 QUALITY IMPROVEMENT STRATEGIES FOR DIABETES PREVENTION AND 
CONTROL 
 
With increasing prevalence and incidence, there is a pandemic of diabetes that represents a huge 
public health problem.  Of particular concern is the increasing prevalence of diabetes with 
reports indicating diagnosed diabetes among people aged 20 years or more increased from 6.5% 
in 1999-2002 to 7.8% in 2003-2006 in the US (238).  Moreover, diabetes is accompanied by a 
multitude of severe, long-term complications, which contributes to excess morbidity and 
mortality, more health utilization, and higher health care expenditures.  Without a suitable 
population-based health response, the epidemic of obesity coupled with an aging population will 
relentlessly increase these burdens of diabetes.  Breakthroughs in management of diabetes and 
systematic delivery of effective clinical intervention strategies once diabetes is manifest may 
ameliorate the enormous human and financial costs of the disease, but that is not the solution.  
Primary prevention of diabetes and its complications should be the critical public health priority 
of the current era (32). 
Although evidence-based clinical practice recommendations that are known to improve 
clinical outcome and process measures in diabetes care are trumpeted by ADA, disappointingly 
most patients with diabetes do not receive care in this manner (239).  There is a challenge of 
managing diabetes effectively once it has developed.  Less than 10% of people with diabetes 
reach the ADA goal of the three combined clinical outcome measures (i.e., A1C <7%, blood 
pressure <130/80 mmHg, and low-density lipoprotein cholesterol (LDLc) <100 mg/dl) that are 
important risk factors for diabetes complications (240-243), and process measure performance 
remains far below the ADA recommendations (239).  Recent data indicated that the control for 
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glycemic (A1C <7%), blood pressure (SBP/DBP <130/80 mmHg), and cholesterol (LDLc <100 
mg/dl) [ABC] therapeutic goals in people living with diabetes have improved over time from 
1988 to 2010 (244).  In 2007-2010, 52.5% of people with diabetes achieved A1C <7.0%, 51.1% 
achieved BP <130/80 mmHg, 56.2% achieved LDL <100 mg/dL, and 18.8% achieved all three 
ADA-recommended clinical outcomes; however, this indicates that only about 1 in 5 patients 
with diabetes reached the recommended therapeutic goals for glycemia, blood pressure, and 
LDLc at the same time in 2007-2010 (244).  Despite significant improvement during the past 
decade, achieving the ABC goals remains suboptimal among adults with diabetes.  In addition, 
improvements in controlling A1C, blood pressure, cholesterol levels may be projected to 
increase life expectancy for people with newly diagnosed diabetes in 2005 by 1.0 year (13), but 
significant opportunity remains for further improvement.  Diabetes remains a major health 
challenge in the US, and thus no effort should be spared to improve quality of diabetes care. 
 
3.1 THE INTERVENTIONS FOR DIABETES PREVENTION 
 
Randomized controlled trials show that individuals at high risk for developing T2D (those with 
IFG, IGT, or both) can significantly decrease the rate of onset of diabetes with particular 
interventions (245).  These include intensive lifestyle modification programs (29-67% relative 
risk reduction after 2.5-6 years) and use of the pharmacological agents: metformin, α-glucosidase 
inhibitors, orlistat, and thiazolidinediones, each of which decreased incident diabetes to various 
degrees (25-81% relative risk reduction after 2.5-4 years) (3).  A meta-analysis to quantify the 
effectiveness of lifestyle and pharmacological interventions to prevent or delay T2D in people 
with IGT also provided supporting evidence; pooled hazard ratios were 0.51 (95% CI: 0.44 to 
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0.60) for lifestyle interventions vs. standard advice; 0.70 (0.62 to 0.79) for oral diabetes drugs vs. 
control; 0.44 (0.28 to 0.69) for orlistat vs. control; and 0.32 (0.03 to 3.07) for the herbal remedy 
jiangtang bushen recipe vs. standard diabetes advice (246).  Follow-up of all three large studies 
of lifestyle intervention showed sustained reduction in the rate of conversion to T2D, with 43% 
reduction at 20 years in the Da Qing study (247), 43% reduction at 7 years in the Finnish 
Diabetes Prevention Study (248), and 34% reduction at 10 years in the US Diabetes Prevention 
Program Outcomes Study (DPPOS) (249).  In addition, group delivery of the DPP intervention in 
community settings has the potential to be significantly less expensive while still achieving 
similar weight loss (250). 
Based on the results of clinical trials and the known risks of progression of prediabetes to 
diabetes, American Diabetes Association recommends that people with an A1C of 5.7-6.4%, 
IGT, or IFG should be counseled on lifestyle changes with goals similar to those of the DPP (7% 
weight loss and moderate physical activity of at least 150 min/week).  Regarding 
pharmacotherapy for diabetes prevention, metformin has a strong evidence base and 
demonstrated long-term safety.  Metformin therapy for prevention of T2D may be considered in 
those with IGT, IFG, or an A1C of 5.7-6.4%, especially for those with BMI >35 kg/m2, aged <60 
years, and women with prior gestational diabetes mellitus (245). 
 
3.2 THE INTERVENTIONS FOR DIABETES CONTROL 
 
Once diabetes is diagnosed, several current treatments have proven efficacy in substantially 
reducing morbidity and mortality.  In fact, the progress in treatment strategies during the past 
two decades has led to more options and better technology, so they now provide greater efficacy 
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and fewer or less severe side effects.  The following recommended intervention strategies 
(245;251) are aimed for secondary and tertiary prevention of diabetes, which are management of 
diabetes and risk factors for complications, screening for and early treatment of complications, 
and treatment of complications and comorbidities. 
1) Improving glycemic control can decrease the risk of microvascular complications by 
40%; specifically, there would be a 25% risk reduction in microvascular complications per 1% 
reduction in A1C.  2) Better controlling blood pressure can reduce diabetes-related micro- (33%) 
and macrovascular (33-50%) complications and total mortality.  3) Lipid management with 
statins can reduce the risk of coronary events by 25-55% and total mortality by 43%.  4) Aspirin 
therapy for diabetic persons at high risk for CVD can reduce the risk of myocardial infarction 
(28%) and total CVD risk (18%).  5) Angiotensin converter enzyme (ACE) inhibitor therapy can 
reduce the risk of nephropathy (42%) among those with microalbuminuria and reduce the risk of 
CVD or death (22%) among all subjects at high risk, including those with diabetes.  6) Detecting 
and treating diabetic eye disease with laser therapy can reduce the risk for loss of eyesight by 
about 60-70%.  7) Appropriate foot care can reduce the risk of serious foot disease by 50-60%; 
specifically, comprehensive foot care programs can reduce amputation rates by 45-85%.  8) 
Influenza/pneumococcal vaccination for senior citizens with diabetes can reduce hospitalizations 
(32%) as well as respiratory conditions and death (64%). 
In addition, 9) diabetes self-management education (DSME) is associated with improved 
diabetes knowledge and improved self-care behavior, improved clinical outcomes (e.g., lower 
A1C, lower self-reported weight, improved quality of life and healthy coping), and lower costs.  
Better outcomes were reported for DSME interventions that were longer and included follow-up 
support (DSMS), which were culturally and age appropriate and were tailored to individual 
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needs and preferences, and which addressed psychosocial issues and incorporated behavioral 
strategies.  Both individual and group approaches are effective, and there is growing evidence for 
the role of community health workers and peer and lay leaders in delivering DSME and DSMS 
in conjunction with the core team.  Also, DSME is associated with increased use of primary and 
preventive services, lower use of acute, inpatient hospital services, and lower Medicare and 
commercial claim costs.  10) Maintaining regular moderate-intensity aerobic physical activity 
has been shown to improve blood glucose control, reduce cardiovascular risk factors, contribute 
to weight loss, and improve well-being.  11) Studies of individuals with diabetes consistently 
demonstrate that smokers have a heightened risk of CVD, premature death, and increased rate of 
microvascular complications.  Smokers with newly diagnosed T2D found that smoking cessation 
was associated with amelioration of metabolic parameters and reduced blood pressure and 
albuminuria in 1 year.  12) Screening for early renal disease (microalbuminuria) followed by 
appropriate treatment (ACE inhibitor or Angiotensin II receptor blockers) can slow the 
nephropathy progression and prevent or delay end-stage renal disease.  13) The early recognition 
and appropriate management of neuropathy in the patient with diabetes is important because a) 
nondiabetic neuropathies may be present in patients with diabetes and may be treatable; b) a 
number of treatment options exist for symptomatic diabetic neuropathy; c) up to 50% of DPN 
may be asymptomatic and patients are at risk for insensate injury to their feet; and d) autonomic 
neuropathy, and particularly CAN, is associated with substantial morbidity and even mortality. 
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3.3 QUALITY IMPROVEMENT STRATEGIES FOR DIABETES CARE 
 
Despite evidence showing improved clinical outcomes for patients with diabetes who receive 
various preventive and therapeutic interventions, many patients with diabetes do not receive 
them (245).  Unfortunately, recent data showed that only 1 in 5 patients with diagnosed diabetes 
reached all three ADA-recommended therapeutic targets for blood glucose, blood pressure, and 
LDL cholesterol (244), which are the key intermediate outcomes for diabetes complications.  
Although numerous strategies to improve adherence to the recommended standards have been 
implemented, a major barrier to optimal care is a delivery system that too often is fragmented, 
lacks clinical information capabilities, often duplicates services, and is poorly designed for the 
coordinated delivery of chronic care (245).  Indeed, given the current challenges of treating a 
complex disease like diabetes, novel methods of delivering diabetes care need to be implemented 
and tested for effectiveness, since most studies, to date, are efficacy studies with limited 
generalizability to the vast majority of complex patients. 
Two high-quality systematic reviews provide consistent supporting evidence that team 
changes are the one in the top two quality improvement strategies on diabetes management, 
which produce largest improvement in intermediate outcomes (i.e., A1C, systolic blood pressure, 
and LDL cholesterol) (252,253).  ADA suggests that collaborative, multidisciplinary teams are 
best suited to provide such care for people with chronic conditions such as diabetes and to 
facilitate patients’ performance of appropriate self-management (245).  Specifically, ADA 
recommends that diabetes care should be aligned with components of the Chronic Care Model 
(CCM) to ensure productive interactions between a prepared proactive practice team and an 
informed activated patient (245).  Numerous studies demonstrate that the CCM is an effective 
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framework for improving the quality of diabetes care (254); moreover, a recent systematic 
review provides evidence that CCM is effective in improving the health of people who have 
diabetes and receive care in the US primary care settings (255).  The CCM includes six core 
elements for the provision of optimal care of patients with chronic disease: 1) delivery system 
design (moving from a reactive to a proactive care delivery system where planned visits are 
coordinated through a team based approach); 2) self-management support; 3) decision support 
(basing care on evidence-based, effective care guidelines); 4) clinical information systems (using 
registries that can provide patient-specific and population-based support to the care team); 5) 
community resources and policies (identifying or developing resources to support healthy 
lifestyles); and 6) health systems (to create a quality-oriented culture).  Incorporating multiple 
components of the CCM together in the same intervention can help facilitate better CCM 
implementation (e.g., using the decision-support component to train providers on guidelines such 
as the ADA Standards of Care and using the delivery system design component to remodel the 
care delivery process to provide self-management support through DSME in primary care 
provider offices) (255).  Indeed, redefinition of the roles of the clinic staff and promoting self-
management on the part of the patient are fundamental to the successful implementation of the 
CCM (254). 
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4.0 COST-EFFECTIVENESS OF IMPLEMENTING THE INTERVENTIONS FOR 
DIABETES PREVENTION AND CONTROL 
 
4.1 COST-EFFECTIVENESS IN HEALTH AND MEDICINE 
 
The cost of health care in the US has gained national attention.  The first legislation to apply 
formal economic evaluation (i.e., cost-benefit/cost-effectiveness analysis) in the US came in 
1902 with the River and Harbor Act, which required the US Army Corps of Engineers to assess 
the costs and benefits of river and harbor projects (256).  In the 1970s and early 1980s, the 
economic evaluation of health care services became an academic interest.  However, 
inconsistency in the approaches used to perform such evaluations led to confusing and often 
conflicting results.  Because of a lack of uniformity in approach, these early economic analyses 
were of limited use in aiding decisions about which treatments to fund and for whom (257).  
Moreover, the major forces driving US health care costs include: (1) aging of the US population; 
(2) the burden of chronic diseases; (3) the availability of new technologies to improve the 
diagnosis or treatment of diseases; (4) labor shortages with the result of wage inflation; and (5) 
consumer’s demand for flexible choice in health care plans.  These factors result in increased 
health care spending on the part of health care purchasers (primarily employers and the US 
government) as well as patient consumers, leading to renewed interest in economic evaluation as 
a tool to curb expenditures (257).   
In 1993, the US Public Health Service (USPHS) recognized the need for consensus on 
methods for economic evaluation, specifically cost-effectiveness analysis (CEA) which is used to 
weigh the costs of treatment alternatives with their clinical effectiveness.  The USPHS convened 
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a group of 13 nongovernment scientists and scholars with expertise in economic evaluation, 
collectively referred to as the Panel on Cost-Effectiveness in Health and Medicine.  The panel 
was charged with assessing the current state-of-the-science in the CEA field and with providing 
recommendations for conduct of economic studies in order to improve their quality and 
encourage their comparability.  The resulting recommendations were compiled in what many 
refer to as the Gold Book or officially, Cost-Effectiveness in Health and Medicine (257,258). 
Economics is a discipline that studies how people choose to use limited resources to 
satisfy their unlimited wants so that the gain (or value) from the available resources can be 
maximized.  Indeed, facing limited resources and increases in demand from competing 
programs, health care providers and policy makers seek guidance from economic studies on how 
to use health care resources wisely (18).  The central purpose of CEA is to compare the relative 
value of different interventions in creating better health and/or longer life, and it would be 
considered as one of the guides to resource allocation in health and medicine (258).  When the 
intervention being considered is either more effective but has a higher cost or is less effective but 
has a lower cost than its comparator, an economic analysis is warranted in order to quantify the 
difference in the costs and health outcomes between the two alternatives.  Because new 
interventions typically cost more than existing options, the former scenario is frequently the case 
(257).  The results of such evaluations are typically summarized in an incremental cost-
effectiveness ratio (ICER), where the denominator reflects the gain in health/effectiveness from a 
candidate intervention and the numerator reflects the additional cost of obtaining that 
health/effectiveness gain.  A CEA provides information that can help decision makers sort 
through alternatives and decide which ones best serve their programmatic and financial needs.  
Decision makers may be federal, state, or local, and they may be in the public sector or in the 
                                
77 
 
private sector.  They may control dollars or they may run programs.  CEA provides a framework 
within which decision makers may pose a range of questions (258). 
The three primary techniques as a form of full economic evaluation that are used in 
health are cost-benefit analysis (CBA), CEA, and cost-utility analysis (CUA).  In CBA, costs and 
benefits are converted to monetary units.  In contrast, in CEA and CUA, costs are expressed in 
monetary units but health benefits are expressed in a natural unit (such as cases of disease) or 
quality-adjusted life-years (QALYs).  QALYs are a measure of health outcome in which each 
period of time is assigned a weight ranging from 0 to 1 that corresponds to health-related quality 
of life during that period.  A weight of 1 corresponds to perfect health, and a weight of 0 
corresponds to death, and then the weights are aggregated across time periods (18,259). 
CEA promises to inform decisions and enhance population health in an explicit, 
quantitative, efficient and systematic manner.  Yet, various factors have conspired to create 
resistance to its explicit use for priority-setting in the US: a lack of understanding about the 
conceptual approach, a mistrust of methods, a mistrust of motives, legal and regulatory 
constraints, political factors, and ethical objections.  The best explanation is that, at its roots, 
resistance to CEA in the US is grounded, not in methodological or legal barriers, but in 
Americans’ penchant for medical innovation and our distaste for limits – and in our deep-rooted 
suspicion of governments or corporations that impose them (256).   
Apparently, the importance of CEA in decision making should not be overstated.  
Although estimates derived from CEA can be an important source of advice to inform the 
judgment of officials making public policy and clinical decisions, it cannot provide definitive 
answers concerning whether a particular intervention should be adopted.  CEA estimate is only 
one aspect to consider in the multifactorial process of judging whether a particular intervention 
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should be adopted.  CEA does not address treatment preferences and the values (i.e., willingness-
to-pay) of patients, society, and other stakeholders; societal and legal aspects; or ethical issues.  
Judgment about these preferences – acceptability, feasibility and strategic planning – also should 
contribute substantially to the decision-making process concerning whether an intervention 
should be adopted (260,261).    
 
4.2 COST-EFFECTIVENESS OF THE INTERVENTIONS FOR DIABETES 
PREVENTION AND CONTROL 
 
Few researchers have conducted systematic reviews of the cost-effectiveness (CE) of diabetes 
interventions (18,262-264), and the most recent report published by the investigators in Centers 
for Disease Control and Prevention in 2010 was to synthesize the CE of interventions 
recommended by the 2008 American Diabetes Association (ADA) Standards of Medical Care in 
Diabetes to prevent and control diabetes, its complications, and comorbidities (260).  They 
categorized the strength of evidence about the CE of an intervention as strong, supportive, or 
uncertain.  CE was classified as cost saving (more health benefit at a lower cost), very cost-
effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-
effective (from $25,001 to $50,000 per LYG or QALY), marginally cost-effective (from $50,001 
to $100,000 per LYG or QALY), or not cost-effective (>$100,000 per LYG or QALY).  A total 
of 56 studies from 20 countries were included in the final data synthesis. 
Among 26 interventions were classified as supported by “strong” evidence concerning 
their CE, six interventions were cost saving, eight were very cost-effective, six were cost-
effective, two were marginally cost-effective, and four were not cost-effective (260).  These 
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interventions consisted of primary prevention, screening for undiagnosed type 2 diabetes, 
diabetic risk factor control, early prevention of diabetes complications, and treatment of diabetes 
complications.  First, the six cost-saving interventions with strong evidence were: 1) ACEI 
therapy for intensive hypertension control, as in the UK Prospective Diabetes Study (UKPDS), 
in persons with type 2 diabetes (T2D) compared with standard hypertension control; 2) ACEI or 
ARB therapy to prevent ESRD for T2D compared with no ACEI or ARB therapy; 3) early 
irbesartan therapy at the stage of microalbuminuria to prevent ESRD in people with T2D 
compared with treatment at the stage of macroalbuminuria; 4) comprehensive foot care to 
prevent ulcers in a mixed population with either T1D or T2D compared with usual care; 5) multi-
component interventions for diabetic risk factor control and early detection of complications 
compared with conventional insulin therapy for persons with T1D; and 6) multi-component 
interventions for diabetic risk factor control and early detection of complications compared with 
standard glycemic control for persons with T2D.  Second, the eight very cost-effective 
interventions with strong evidence included: 1) primary prevention through intensive lifestyle 
modification for T2D; 2) universal opportunistic screening for undiagnosed T2D in African 
Americans between 45 and 54 years old; 3) intensive glycemic control as implemented in 
UKPDS for T2D; 4) statin therapy for secondary prevention of cardiovascular disease in T2D; 5) 
counseling and treatment for smoking cessation in T2D; 6) annual screening for diabetic 
retinopathy and early treatment of it in T2D; 7) annual screening for diabetic retinopathy and 
treating the positive cases in T1D; and 8) immediate vitrectomy to treat diabetic retinopathy 
compared with deferral of vitrectomy in a mixed population with either T1D or T2D.  Third, the 
six cost-effective interventions with strong evidence were: 1) one-time opportunistic targeted 
screening for undiagnosed T2D in hypertensive persons aged 45 years and older compared with 
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no screening; 2) intensive insulin treatment for persons with T1D compared with conventional 
glycemic control; 3) UKPDS-like intensive glycemic control applied to the US health care 
system among adults younger than age 54 years with T2D compared with conventional glycemic 
control; 4) intensive glycemic control by a Diabetes Prevention Program type of intensive 
lifestyle intervention in persons with newly diagnosed T2D compared with conventional 
glycemic control; 5) statin therapy for primary prevention of cardiovascular disease in persons 
with T2D compared with no statin therapy; and 6) multi-component interventions including 
insulin therapy, ACEI therapy, and screening for retinopathy in persons with T1D compared with 
intensive insulin therapy.  Fourth, the two marginally cost-effective interventions with strong 
evidence were: 1) intensive glycemic control for all US residents with T2D diagnosed at age 25 
years and older compared with usual care; and 2) screening for diabetic retinopathy every two 
years compared with screening every three years in persons with T2D.  Fifth, the four 
interventions with strong evidence of not being cost-effective were: 1) one-time universal 
opportunistic screening for undiagnosed T2D and ensuring treatment among those aged 45 years 
and older compared with no screening; 2) one-time universal opportunistic screening for T2D 
compared with targeted screening; 3) intensive glycemic control in the US setting for patients 
diagnosed with T2D at older ages (55-94 years of age) compared with usual care; and 4) annual 
screening for retinopathy compared with screening every two years in T2D. 
Among 18 interventions were classified as having “supportive” evidence concerning their 
CE, 10 interventions were cost saving, seven were very cost-effective, one was cost-effective, 
and none were marginally cost-effective or not cost-effective (250).  First, the 10 cost-saving 
interventions with supportive evidence were: 1) screening using the sequential method (50-g 
glucose challenge test followed by 100-g glucose tolerance test [GTT]) for gestational diabetes 
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[GDM] in 30-year-old pregnant women between 24-28 weeks’ gestation compared with no 
screening; 2) screening for GDM using the 100-g GTT method compared with no screening; 3) 
the sequential method compared with the 75-g GTT screening for GDM; 4) 100-g GTT 
compared with the 75-g GTT screening for GDM; 5) diabetes self-management education for 
persons with T1D compared with no education; 6) full reimbursement policy for ACEI for 
patients with T1D compared with patients paying out-of-pocket; 7) full-reimbursement policy for 
ACEI for patients with T2D compared with patients paying out-of-pocket; 8) screening using a 
mobile camera at a remote area and processing data in a reading center compared with a retina-
specialist’s visit in a mixed population of T1D and T2D; 9) screening for diabetic nephropathy 
and ensuing ACEI or ARB therapy in persons with T1D compared with no screening; and 10) 
intensified foot ulcer treatment in a mixed population with T1D and T2D compared with 
standard treatment.  Second, the seven very cost-effective interventions with supportive evidence 
included: 1) primary prevention of T2D in women with GDM history, currently IGT, through 
intensive lifestyle intervention compared with usual care; 2) universal opportunistic screening for 
T2D in African Americans aged 25-44 years compared with no screening; 3) 100-g GTT 
compared with the sequential screening method for detecting GDM in 30-year-old pregnant 
women between 24-28 weeks’ gestation; 4) diabetes self-management education for persons with 
T2D compared with no education; 5) disease management programs using specialist nurse-led 
clinics to treat and control hypertension or hyperlipidemia in patients with T2D in a city in 
England or a culturally sensitive case-management training program to control diabetes and its 
risk factors in a Latino population with both T1D and T2D in a US county compared with usual 
care only; 6) self-monitoring of blood glucose (SMBG) three times per day compared with no 
SMBG in T2D non-insulin users; and 7) SMBG once per day compared with no SMBG in T2D 
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non-insulin users.  Third, the one cost-effective intervention with supportive evidence was the 
use of metformin to prevent T2D in obese persons with impaired glucose tolerance compared 
with standard lifestyle intervention. 
Investigators also concluded that the CE of optimal age to start screening for T2D was 
uncertain (260).  Two studies evaluated the CE of screening for undiagnosed T2D; one study 
reported that incremental CE ratios increased with initial screening age (265) while the other 
reported that they decreased with screening age (266).  However, according to a high-quality CE 
report using the Archimedes model to compare eight simulated screening strategies for T2D with 
a no-screening control strategy, screening for T2D in the US population is very cost-effective 
when started between the ages of 30 years and 45 years, with screening repeated every 3-5 years 
(115).  
Many ADA-recommended interventions intended to prevent/control diabetes are cost 
saving or very cost-effective and supported by strong evidence.  Health care providers and 
policymakers should use this information in making clinical and policy decisions in order to use 
resources efficiently.  Economic assessment studies should be based on standard research 
methods and reliable data to ensure validity and comparability of results.  Also, economic 
evaluations of new technologies or programs should continue to ensure that they add value. 
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5.0 SUMMARY 
 
The prevalence and incidence rates of diabetes and pre-diabetes are increasing rapidly 
throughout most regions of the developed and developing world.  This emerging pandemic is 
driven by the combined effects of aging of the population, growing levels of obesity and 
inactivity, and greater longevity among diabetic patients, which is attributable to improved 
management (267).  In the US, CDC estimated that approximately 25.8 million people had 
diagnosed and undiagnosed diabetes in 2010, indicating that the prevalence of diabetes among 
the whole US population has increased by 6% in 3 years from 7.8% in 2007 (2) to 8.3% in 2010 
(268).  More specifically, about 25.6 million or 11.3% of all adult Americans aged 20 years or 
older had diabetes, and another 79 million people in this age group had pre-diabetes (268).  If 
recent increases in diabetes incidence continue and diabetes mortality is relatively low, as many 
as 1 in 3 (or 33%) US adults aged 18-79 years could have diabetes by 2050 (269).   
The pandemic of diabetes continues at tremendous human and financial cost, leading to 
one of the globally major public health challenge.  Much of the expense that attends diabetes and 
its care is attributable to the development of long-term complications, such as retinopathy, 
nephropathy, and neuropathy, which cause more disabled cases of blindness, renal failure, and 
amputations than any other disease (270).  In addition, diabetes is associated with a 2- to 5-fold 
increase in cardiovascular disease, which contributes to premature mortality (270).  Increased 
health seeking and utilization in people with diabetes and associated complications result in 
greater medical costs incurred, compared to the general population without diabetes.  In 2007, 
the US national economic burden of pre-diabetes and diabetes was estimated to be $218 billion, 
including $153 billion in higher medical costs and $65 billion in reduced productivity from 
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higher levels of absenteeism, presenteeism, disability, and early mortality (227).  In 2012, the 
total estimated cost of diagnosed diabetes reached $245 billion (including $176 billion in direct 
medical costs and $69 billion in reduced productivity), a 41% increase from the previous 
estimate of $174 billion in 2007 (231).  Fortunately, disability and premature death are not 
inevitable consequences of diabetes.  Working together, people with diabetes, their support 
network, and their health care providers can reduce the occurrence of disability and premature 
death by controlling blood glucose, pressure and lipids, and by receiving several preventive care 
practices in a timely manner (12). 
Considering the evolving disease burden of diabetes, efforts exploring new intervention 
strategies to delay or prevent the complications of diabetes, or, even better, to delay or prevent 
the development of diabetes itself are urgently needed.  Moreover, the heavy economic burden of 
diabetes is one of the most pressing health policy issues and underscores the urgency to better 
understand the cost-mitigation potential of prevention and control strategies for diabetes.  
Demands for new competing strategies for delaying or preventing diabetes case and for 
comprehensive diabetes management are increasing, but resources that can be devoted to 
diabetes prevention and control are limited.  Hence, health care policy makers and providers 
need to seek guidance on how to prioritize health care resources wisely and efficiently. 
Health care costs for diabetes in the US are increasing unsustainably (227,231,267), and 
efforts to control high expenditures should focus on the value, in addition to the costs, of health 
care intervention strategies.  Whether an intervention strategy provides high value depends on 
assessing whether its health benefits justify its costs (271).  Economic evaluation or efficiency 
evaluation, which estimates the incremental cost-effectiveness ratio as the additional cost 
required to obtain additional health benefits, provides a key measure of the value of a health care 
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intervention strategy (271).  More specifically, economic evaluation can help inform the decision 
makers how to allocate resources across a defined number of competing intervention strategies to 
maximize health outcomes from the limited available resources.  Three primary techniques of 
evaluating an intervention strategy in health and medicine are considered a form of full economic 
evaluation, including cost-benefit analysis, cost-effectiveness analysis, and cost-utility analysis, 
but only the latter two are commonly used in the field of health care as the monetary valuation of 
health benefits is not acceptable on ethical and on practical grounds (259).  The use of economic 
evaluation to inform decision making in health and medicine has increased rapidly in the last two 
to three decades, and the literature on the cost-effectiveness of intervention strategies to prevent 
and control diabetes has been comprehensively reviewed recently (260). 
Prevention and control of diabetes involve complex interactions among patients, 
physicians, health care system, and society as a whole, with translational barriers that may occur 
at every level.  Although many efficacious and economically acceptable prevention and control 
strategies are currently available to reduce the burden of diabetes and its complications (260), 
translation of these evidence-based approaches from clinical trials into clinical and public health 
practice is not easy and remains limited.  A major contributor to suboptimal diabetes 
management is a delivery system that too often is fragmented, lacks clinical information 
capabilities, duplicates services, and is poorly designed for the delivery of the prevention and 
control strategies.   
With respect to diabetes prevention, the Diabetes Prevention Program (DPP) study 
funded by the US National Institutes of Health is one of the pivotal diabetes prevention trials to 
suggest that the lifestyle modification intervention is effective in providing much greater weight 
loss and a greater increase in physical activity (108,259), reducing risk factors of cardiovascular 
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disease (108,249,272) and components of the metabolic syndrome (273), and delaying or 
preventing the development of diabetes (108,249) in overweight individuals with pre-diabetes.  
Several delivery approaches of the DPP-based lifestyle intervention are successfully translated 
into a variety of practice settings to achieve reduction of risk factors for diabetes and 
cardiovascular disease. 
With respect to diabetes control, collaborative multidisciplinary teams are best suited to 
provide care for people with chronic conditions like diabetes and to facilitate patients’ 
performance of appropriate self-management (274).  The Chronic Care Model (CCM) may be 
well suited to the management of diabetes since it addresses complex issues in diabetes care by 
including six essential core elements to redefine the roles of the providers and promote self-
management on the part of the patient, which are for the provision of optimal care of people with 
chronic conditions (254,255).  The CCM is a multifaceted framework to redesign daily medical 
practices and enhance health care delivery, and it is used in many practice settings to guide 
systematic and individual improvements for chronic illness care, including diabetes.   
However, knowledge on the economic evaluation in these new strategies delivering 
diabetes prevention and control interventions is rare.  This dissertation conducts cost-
effectiveness analysis through a decision-analytic approach using computational modeling, 
which adds evidence to provide a better understanding of these strategies’ costs and benefits to 
practices, payers, and patients.  This evidence would not only inform health care policymakers 
and providers how to integrate traditional clinical skills with the use of new intervention 
strategies, but aid them in prioritizing these intervention skills/strategies to prevent or control 
diabetes and its complications. 
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6.0 METHODS 
 
6.1 SPECIFIC AIMS 
 
In conditions of limited resources and increasing demand for new competing programs or 
technologies for diabetes management, health care policymakers and providers seek guidance on 
how to use health care resources wisely.  Hence, the approaches exploring how the intervention 
for diabetes prevention and control is delivered, not only effectively, but efficiently, are needed 
to improve both clinical outcomes and process measures at the patient, provider, community, and 
health systems levels.  Cost-effectiveness analysis through a decision-analytic approach using 
computational modeling can be used to help inform health care policymakers and providers of 
the decisions about prioritizing intervention programs to be funded from limited available 
resources. 
This dissertation proposes to evaluate long-term cost-effectiveness of implementing 
interventions to prevent and control diabetes in the community and military settings.  The 
specific aims of this dissertation are: 
1. To assess cost-effectiveness of implementing the Chronic Care Model (CCM) 
intervention for diabetes control relative to a provider continuing medical 
education (PROV) intervention and to usual care in an underserved urban area of 
Pittsburgh, PA.  We hypothesize that the application of the CCM intervention for 
diabetes care in underserved communities is cost-effective relative to a PROV 
intervention and to usual care. 
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2. To estimate cost-effectiveness of implementing the CCM intervention for diabetes 
control relative to usual care in a military-based medical center in San Antonio, 
TX.  We hypothesize that the performance of the CCM intervention for diabetes 
care in a military-based setting is cost-effective relative to usual care. 
3. To analyze cost-effectiveness of implementing an Internet-based lifestyle 
intervention to reduce risk of type 2 diabetes (T2D) and cardiovascular disease 
(CVD) relative to usual care (or do nothing) in the primary care setting in 
Pittsburgh, PA.  We hypothesize that an Internet-based lifestyle intervention 
delivered in coordination with primary care medicine to reduce risk of T2D and 
CVD is cost-effective relative to usual care (or do nothing). 
 
6.2 STUDY DESIGN 
 
6.2.1 Overview 
This dissertation is to apply computational modeling, the Markov decision model, for evaluating 
long-term cost-effectiveness of implementing interventions to control and prevent diabetes in the 
community and military settings.  Model input parameters, including intervention cost and 
outcomes, disease progression rates, other direct medical/non-medical costs, mortality rate, and 
utilities, were directly obtained from the clinical trials that have been completed by our research 
teams, or were drawn from published literature.  The overall summary measure from the cost-
effectiveness evaluation is the incremental cost-effectiveness ratio (ICER), representing the 
incremental cost required to achieve one additional unit of health benefits if an intervention is 
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used instead of another.  The ICER can be expressed as US$ per quality-adjusted life-expectancy 
gained or US$ per clinical outcome/event averted. 
 
6.2.2 Data Sources and Model Parameters 
 
Specific Aim 1 
Data for Specific Aim 1 were primarily based on a randomized controlled trial completed by 
Piatt et al. (275).  Piatt et al. conducted the first multifaceted, cluster-design, randomized 
controlled trial to determine the effectiveness of implementing the comprehensive CCM in a 
community-based setting.  This trial took place in an underserved suburb of Pittsburgh, PA, 
between 1999 and 2003, and included a one-year follow-up.  Participating patients had a 
confirmed diagnosis of diabetes, based on ICD-9 codes, problem lists, laboratory results, or 
diabetes medication use.  Eleven primary care practices and their patients were randomly 
assigned to one of three study groups: CCM intervention, PROV intervention, or usual care.  The 
CCM group (three practices; 30 patients) involved implementation of all six CCM elements.  
The PROV group (three practices; 38 patients) consisted of providers attending one continuing 
medical education session, an in-person review of chart audit results by a certified diabetes 
educator, and the availability of a certified diabetes educator for consultation.  Providers in the 
usual care group (five practices; 51 patients) were mailed their practices’ chart audit results. 
The primary outcomes of this clinical trial included reductions in glycated hemoglobin 
(A1C), blood pressure, and lipid levels.  Secondary outcomes were improvements in quality of 
well-being, diabetes knowledge, empowerment, and the frequency of self-monitoring of blood 
glucose.  Following the one-year intervention, a significant decline in A1C (-0.6%, P = 0.008) 
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was observed in the CCM group.  The CCM group also reported improvements in high-density 
lipoprotein cholesterol (HDLc) levels (+5.5 mg/dl, P < 0.001), diabetes knowledge test scores 
(+6.7%, P = 0.07), empowerment scores (+0.2, P = 0.02), and the proportion of patients who 
self-monitored blood glucose (+22.2%, P < 0.001).  Taken together, CCM implementation in the 
community was effective in improving clinical and behavioral outcomes.  Because implementing 
the full CCM is resource intensive, we sought to determine its cost-effectiveness.  Model input 
parameters were directly obtained from this clinical trial or were drawn from published literature. 
 
Specific Aim 2 
Data for Specific Aim 2 were primarily based on a study completed at US Air Force Wilford 
Hall Medical Center (WHMC) in San Antonio, TX (276).  The Diabetes Outreach Clinic (DOC), 
in which the CCM intervention was applied, opened on January 3rd, 2006 and ended in 
December 2008 at US Air Force WHMC.  At that time, the DOC was operating as a “one-stop-
shop” for diabetes patients.  The DOC staff consisted of an endocrinologist, nurse practitioner, 
counselor, ophthalmologist, dietitian, certified diabetes educator, and support staff.  All patients 
were seen for both diabetes treatment as well as their primary care in the DOC. 
The population, defined as any individual with an ICD-9 diagnosis of diabetes (250.XX) 
in the WHMC San Antonio area from January 2005 and December 2008, was included in the 
analysis.  A total of 9,654 people with diabetes (1,171 DOC patients and 8,483 usual care 
patients) from military database were identified, and their records between January 2005 and 
December 2008 were obtained, including demographics, clinical data (A1C, systolic/diastolic 
blood pressure, as well as blood glucose, total cholesterol, HDLc, and low-density lipoprotein 
cholesterol (LDLc) levels), medical utilization (hospitalizations, primary care visits, and 
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specialty care visits), and pharmacy records.  For DOC patients, we defined the records from one 
year prior to DOC entry as the pre-DOC data (or baseline), and all records after DOC entry as 
the post-DOC data (or follow-up); while for UC patients, we defined the records from one year 
prior to January 2006 (i.e., DOC starting date) as the pre-DOC data (or baseline), and all records 
after that time as the post-DOC data (or follow-up).  Moreover, we only used data when patients 
were at age 18 years or more by following the Institutional Review Board policy.  Hence, a total 
of 9,405 diabetes patients (97.4% of the original population; 9,405/9,654) were identified to be 
the final study cohort in this analysis, including 1,171 DOC patients and 8,234 usual care 
patients. 
Effectiveness analysis from the DOC intervention in the military-based setting revealed 
that the DOC patients reported improvements in A1C (-0.6%, P < 0.001), total cholesterol levels 
(-11.6 mg/dl, P < 0.001), and LDLs levels (-6.5 mg/dl, P < 0.001).  Also, 98% (1,143/1,171) of 
DOC patients received diabetes self-management education.  Using the CCM intervention in a 
military clinic resulted in significantly improved control for glycemia and dyslipidemia, 
implying implementation of a team-based comprehensive diabetes clinic is a feasible and 
effective means for improving clinical outcomes in this population.  Since little is known about 
the cost-effectiveness of implementing the CCM intervention in a military-based setting, we 
sought to determine the cost-effectiveness of the DOC intervention.  Model input parameters 
were directly obtained from this study or were drawn from published literature. 
 
Specific Aim 3 
Data for Specific Aim 3 were primarily based on a pilot clinical trial completed by McTigue et 
al. (277).  McTigue et al. aimed to translate an evidence-based lifestyle program into the clinical 
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setting by adapting it for delivery via the Internet (i.e., an Online adaptation of the Diabetes 
Prevention Program lifestyle intervention (ODPP)).  They adapted the Diabetes Prevention 
Program’s lifestyle curriculum to an online format, comprising 16 weekly and 8 monthly lessons, 
and conducted the before-and-after pilot study for evaluating program implementation and 
feasibility.  The program incorporated behavioral tools such as e-mail prompts for online self-
monitoring of diet, physical activity, and weight, and automated weekly progress reports.  
Electronic counseling provided further support.  Also, physician referral, automated progress 
reports, and as-needed communications with lifestyle coaches integrated the intervention with 
clinical care.  Patient with age 18-80 years, a body mass index ≥25 kg/m2, at least one weight-
related CVD risk factor, and Internet access were eligible if referring physicians felt the lifestyle 
goals were safe and medically appropriate.  A total of 50 patients from a large academic general 
internal medicine practice were found eligible and enrolled in this pilot study between November 
16, 2006 and February 11, 2007. 
They evaluated a one-year pilot program for these 50 patients.  Change in body weight 
(kg) was the primary outcome measure, while change in blood pressure and the frequency of 
clinically significant weight loss were secondary outcomes.  Follow-up measurements were 
performed every 3 months (±2 weeks), and the final evaluation occurred between 50 and 56 
weeks of follow-up.  At each follow-up visit, the participants’ mean weight was significantly 
lower than that at baseline.  At the end of one year, the mean weight change among participants 
who completed the measured 12-month weight evaluation (n = 45) was -4.79 kg (95% 
confidence interval: -7.36 to -2.22); 31% of these participants had at least a 5% weight loss and 
18% at least a 7% weight loss.  Moreover, systolic blood pressure significantly dropped by 7.33 
mmHg (95% confidence interval: -10.75 to -3.92), while diastolic blood pressure changed 
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minimally (+0.44 mmHg; 95% confidence interval: -2.74 to +2.83).  This study demonstrated 
that an Internet-based lifestyle intervention may overcome significant barriers to preventive 
counseling and effectively facilitate the incorporation of evidence-based lifestyle interventions 
into primary care.  Since published information is lacking on the economical effectiveness of on 
Internet-based lifestyle intervention programs, we sought to assess the cost-effectiveness of an 
Internet-based lifestyle intervention to reduce risk of T2D and CVD in a sample of primarily 
obese adults in the primary care setting.  Model input parameters were directly obtained from 
this pilot clinical trial or were drawn from published literature. 
 
Parameters of Being Used to Obtain Transition Probabilities, Parameters of Costs, and 
Parameters of Health Utilities for the Markov Decision Model 
The following three tables (Tables 6.1, 6.2, and 6.3) show parameters of estimating transition 
probabilities, of costs (direct medical and direct non-medical costs), and of health utilities for the 
Markov decision model.  Also, the sources/references for these parameters are listed in tables, 
including three primarily referred studies (275-277) and other published literature.  Application 
of multiple sources in a modeling-based cost-effectiveness analysis is very common, and the 
source data that we select and use in our analyses are based on empirical data, pivotal studies, 
commonly cited references, or published studies at a nationally representative level. 
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Table 6.1 Parameters used to obtain transition probabilities for the Markov decision model 
Parameter Source (Author, Reference) 
Demographic data Piatt et al. (275); Siminerio et 
al. (276); McTigue et al. (277); 
Assumption   
      Age (years) 
      Gender (female/male) 
      Race (White/Afro-Caribbean/Asian-Indian) 
      Weight (kg) 
      Height (cm) 
      Body mass index (kg/m2) 
      Duration of diabetes (years) 
      Smoking status (non-smoker/ex-smoker/current smoker) 
Clinical data Piatt et al. (275); Siminerio et 
al. (276); McTigue et al. (277); 
Assumption 
      A1C (%) 
      Systolic blood pressure (mmHg) 
      Total cholesterol (mg/dl) 
      HDLc (mg/dl) 
      LDLc (mg/dl) 
      Creatinine clearance <100 ml/min (yes/no) 
      Atrial fibrillation (yes/no) 
      Macroalbuminuria (yes/no) 
      Microalbuminuria (yes/no) 
      Probability of progression in diabetes complications 
Mortality rates and relative risk of death Piatt et al. (275); Siminerio et 
al. (276); McTigue et al. (277); 
UKPDS risk engine (291-296); 
Zoungas et al. (297); Arias 
(283); Lenz et al. (302); Moss 
et al. (303); Fuller et al. (304); 
Assumption 
      Overweight or obesity 
      Stable diabetes 
      Complicated diabetes 
Abbreviations: A1C, glycated hemoglobin; HDLc, high-density lipoprotein cholesterol; LDLc, 
low-density lipoprotein cholesterol; UKPDS, United Kingdom Prospective Diabetes Study. 
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Table 6.2 Cost parameters for the Markov decision model 
Parameter Source (Author, Reference) 
Direct medical costs  
      Health care providers for diabetes self-management training 
      sessions, support groups sessions, point-of-service-education 
      sessions, and diabetes education classes and visits 
Piatt et al. (275); Siminerio et al. 
(276); US Bureau of Labor 
Statistics (285) 
      Laboratory tests for A1C, lipid panel, and urinalysis Piatt et al. (275); Siminerio et al. 
(276); Centers for Medicare & 
Medicaid Services (284) 
      Medications for glycemia control, hypertension control, and 
      dyslipidemia control 
Piatt et al. (275); Siminerio et al. 
(276); Red Book 2008 (287); 
Hoerger et al. (286); Assumption 
      Physician office visits for primary care and specialty care Piatt et al. (275); Siminerio et al. 
(276); Centers for Medicare & 
Medicaid Services (284) 
      Internet-based lifestyle intervention (e.g., orientation sessions 
      for participants and staff, coaching services, staff activity/time, 
      and information materials) 
McTigue et al. (277); US Bureau 
of Labor Statistics (285) 
      Diabetes complications (one-time and annual) Hoerger et al. (286); Herman et al. 
(300); Brandle et al. (305) 
      Death (one-time) Hoerger et al. (286) 
Direct non-medical costs  
      Patient time costs for (1) diabetes self-management training 
      sessions, support groups sessions, point-of-service-education 
      sessions, and diabetes education classes and visits; (2) physician 
      office visits for primary care and specialty care; and (3) 
      Internet-based lifestyle intervention (e.g., orientation session, 
      education lessons, and weekly activity review/report) 
Piatt et al. (275); Siminerio et al. 
(276); McTigue et al. (277); US 
Bureau of Labor Statistics (285); 
Smith et al. (288) 
      Patient monetary costs for (1) diabetes self-management 
      training sessions, support groups sessions,  
      point-of-service-education sessions, and diabetes education 
      classes and visits; and (2) physician office visits for primary 
      care and specialty care 
Piatt et al. (275); Siminerio et al. 
(276); US Bureau of Labor 
Statistics (285); Smith et al. (288) 
Abbreviation: A1C, glycated hemoglobin. 
 
Table 6.3 Health utility parameters for the Markov decision model 
Parameter Source (Author, Reference) 
No diabetes, overweight or obese Coffey et al. (289); Herman et al. 
(300); Zhou et al. (306); Trueman 
et al. (307) 
Diabetes without complications (or stable diabetes) 
Diabetes with microvascular complications 
Diabetes with macrovascular complications 
Diabetes with micro- and macrovascular complications 
Complicated diabetes 
Death 
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6.2.3 Model Structure 
 
Specific Aim 1 
We developed a Markov decision model (278-280) to estimate the incremental cost-effectiveness 
of the CCM intervention compared to the PROV intervention and usual care as implemented in 
Piatt et al.’s clinical trial (275).  We used a standard decision analysis software package, 
TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA), for model construction.  The 
model directly incorporated intervention costs and effectiveness data from Piatt et al.’s clinical 
trial (275) to estimate life expectancy, quality-adjusted life-expectancy (expressed as quality-
adjusted life-years, or QALYs), clinical outcomes (e.g., incidence of diabetes with chronic 
complications), as well as direct medical and non-medical costs associated with the intervention 
strategies. 
The model is illustrated below in Figure 6.1, which describes the progression of disease 
through microvascular complications, macrovascular complications, and mortality.  We assumed 
that all patients had uncomplicated diabetes at the start of the model.  Over time, diabetes can 
progress to microvascular complications only (including retinopathy, nephropathy, or 
neuropathy), macrovascular complications only (including coronary heart disease or stroke), 
and/or end-stage renal disease (ESRD).  We assumed that complications were irreversible and 
that patients in any health state could die in the next time period. 
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Figure 6.1 Markov-state diagram for the basic model structure for analyzing the cost-
effectiveness a Chronic Care Model intervention in an underserved community population 
 
Specific Aim 2 
We modified the model for Specific Aim 1 to estimate the incremental cost-effectiveness of the 
DOC intervention relative to usual care based on results from the study completed at US Air 
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Force WHMC in San Antonio, TX (276).  We used a standard decision analysis software 
package, TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA), for model 
construction.  The model directly incorporated intervention costs and effectiveness data from the 
DOC study (276) to estimate life expectancy, quality-adjusted life-expectancy (expressed as 
quality-adjusted life-years, or QALYs), as well as direct medical and non-medical costs 
associated with the intervention strategies. 
The model is illustrated below in Figure 6.2, which describes the progression of disease 
through microvascular complications, macrovascular complications, and mortality.  We assumed 
that all patients had uncomplicated diabetes at the start of the model.  Over time, diabetes can 
progress to microvascular complications only (including retinopathy, nephropathy, or 
neuropathy), macrovascular complications only (including coronary heart disease or stroke), or 
both.  We assumed that complications were irreversible and that patients in any health state could 
die in the next time period. 
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Figure 6.2 Markov-state diagram of the basic model structure for analyzing the cost-
effectiveness a Chronic Care Model intervention in a military population 
 
Specific Aim 3 
We used TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA) to modify our prior 
Markov decision model (281) to estimate the incremental cost-effectiveness of an Internet-based 
lifestyle intervention in the primary care setting as implemented in McTigue et al.’s pilot clinical 
trial (277).  The model directly incorporated intervention costs and effectiveness data from the 
pilot clinical trial (277) to estimate life expectancy, quality-adjusted life-expectancy (expressed 
as quality-adjusted life-years, or QALYs), clinical outcomes (e.g., incidence of diabetes without 
or with chronic complications), as well as direct medical and non-medical costs associated with 
the intervention strategies. 
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The model illustrated below in Figure 6.3 is used to evaluate the long-term costs and 
outcomes associated with weight loss or gain, and describes the progression of disease through 
stable diabetes (i.e., diabetes without any chronic complications), complicated diabetes (i.e., 
diabetes with any chronic complications), and mortality.  At the start of the base case model, the 
proportions of subjects in four health states were set to mirror the cohort in the McTigue et al.’s 
pilot clinical trial.  Over time, subject can progress to stable or complicated diabetes.  
Complications related to diabetes included retinopathy, nephropathy, neuropathy, stroke, or 
coronary heart disease.  We assumed that the transition to complicated diabetes was preceded by 
a stable diabetes stage in those subjects who developed diabetes, complications were irreversible, 
and subjects in any health state could die in the next time period.  Since diabetes progression was 
the primary outcome of interest in Specific Aim 3, the major weight-related comorbidities 
considered in the model were limited to diabetes, making the model conservative. 
 
 
 
Figure 6.3 Markov-state diagram of the basic model structure for analyzing the cost-
effectiveness an Internet-based lifestyle intervention 
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6.2.4 Study Outcomes 
The Table 6.4 below shows three categories of study outcomes which can be estimated from the 
computational modeling, including cost, effectiveness, and cost-effectiveness analysis outcomes. 
 
Table 6.4 Estimated economic and clinical outcomes in Specific Aims 1, 2, and 3  
Category Outcome variable Specific aim 1 Specific aim 2 Specific aim 3 
Cost 
outcomes 
Direct medical cost Yes Yes Yes 
Direct non-medical cost Yes Yes Yes 
Effectiveness 
outcomes 
QALYs Yes Yes Yes 
Stable diabetes (i.e., diabetes 
without any complications) - - Yes 
Diabetes with micro-, 
macrovascular complications, 
either, or both 
Yes Yes - 
Complicated diabetes (i.e., 
diabetes with any complications) Yes Yes Yes 
CEA 
outcomes 
Cost per QALY gained Yes Yes Yes 
Cost per stable diabetes case 
averted - - Yes 
Cost per diabetes complication 
or death averted Yes Yes - 
Cost per complicated diabetes 
case averted Yes Yes Yes 
Abbreviations: QALYs, quality-adjusted life-years; CEA, cost-effectiveness analysis. 
 
6.3 BASE CASE ANALYSIS 
 
Specific Aim 1 
We used a base case from a health care system perspective, which examined 68-year-olds with 
T2D who participated in three intervention strategies (CCM, PROV, or usual care) as 
implemented in Piatt et al.’s trial (275) at yearly cycles over a 3-year time horizon.  We 
examined a 3-year time horizon in the base case analysis because of uncertainty in long-term 
strategy effectiveness, and we lengthened the time horizon to 10 years in a sensitivity analysis. 
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Using baseline and 12-month data from Piatt et al.’s trial (275), we estimated the annual 
probabilities of intensive treatments and disease progression in the intervention groups.  To 
account for the cluster-design nature of Piatt et al.’s trial (275), we used a multivariable mixed-
effects logistic regression model that also adjusted for baseline characteristics with significant 
clinical differences (A1C and HDLc levels) and those with statistical differences (age at study 
entry, body mass index, and total cholesterol level) among the three intervention groups.  All five 
covariates were centered at their corresponding mean values.  We assumed that the treatment and 
health benefits associated with the interventions persisted after the study period and thus we 
applied the same probabilities of either receiving the intensive treatments or moving to another 
health state (state-transition or disease progression) to subsequent model cycles. 
We treated ESRD as a separate health state due to its relative rarity and high cost, 
estimating the annual probability of developing ESRD using the US Renal Data System Annual 
Data Report (282) and assuming the same probability for all interventions.  Mortality was a rare 
event in Piatt et al.’s trial (275).  We therefore estimated mortality using age-specific US 
mortality rates (283) and the relative risk of death for people with diabetes (30), and assumed 
identical mortality for all interventions.  For the ESRD state, we estimated mortality using the 
US Renal Data System Annual Data Report (282), again assuming the same ESRD mortality for 
all interventions. 
Annual direct medical costs related to health care provider consultations, intensive 
treatments, laboratory tests, physician office visits, diabetic complications, death, and 
medications were included in the model.  We did not include indirect costs, assuming their 
capture in the assessment of QALYs per the recommendation of the Panel on Cost-Effectiveness 
in Health and Medicine (258).  We used Medicare reimbursement data to estimate laboratory test 
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costs (A1C, lipid panel, and urinalysis) and physician office visits (284).  In addition, we used 
hourly wage costs for health care providers required by the intervention strategies based on 
National Occupational Employment and Wage Estimates (285).  We identified one-time and 
annual costs of diabetic complications, as well as one-time costs of death based on data from the 
models developed by the Centers for Disease Control and Prevention (CDC) and Research 
Triangle Institute International (286). 
We defined intensive treatments as additional prescribed medications for the treatment of 
three specific conditions in each intervention strategy, including pioglitazone was added for the 
intensive treatment of glycemia, ramipril was added for the intensive treatment of hypertension, 
and atorvastatin was added for the intensive treatment of dyslipidemia.  Using the average 
wholesale prices of these drugs (287), we calculated a weighted average cost of each intensified 
therapy and varied these costs in sensitivity analyses. 
In analyses from the societal perspective, we included both direct medical and non-
medical costs.  Direct non-medical costs included patient time and monetary costs for physician 
office visits, diabetes self-management training sessions, support groups sessions, and point-of-
service-education sessions.  Patient time costs for time missed from work or school to receive 
care and for time donated by others (e.g., for rides or babysitting) to allow care to occur were 
quantified based on data from Piatt et al.’s trial (275) or published literature (288), then valued 
based on the average hourly wage of a US nonfarm production worker in 2000 (285) and the 
average annual numbers of visits/sessions as derived from Piatt et al.’s trial (275).  In addition, 
patient monetary costs including costs of parking or transportation and of babysitting or 
childcare were quantified based on data from the published literature (288), then valued based on 
the average annual numbers of visits/sessions as derived from Piatt et al.’s trial (275). 
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Health utilities are a measure of health-related quality of life, with perfect health = 1 and 
death = 0.  In a cost-effectiveness analysis, this utility weight for each health state is multiplied 
by time in that state.  As an individual’s health changes over time, these products are summed to 
represent the total number of QALYs (258).  To estimate health utilities associated with T2D 
with or without complications in the model, we applied an additive prediction model to estimate 
health utilities according to demographic, treatment, and complication variables (289).  The 
baseline health utility of 0.689 is the health utility for a nonobese man with T2D who is treated 
with diet and exercise, and who has no cardiovascular risk factors or microvascular, neuropathic, 
or cardiovascular complications. 
In keeping with the reference case recommendations of the Panel on Cost-Effectiveness 
in Health and Medicine (258), we discounted future costs and benefits by 3% annually.  Also, we 
expressed costs in 2000 US dollars using the US Consumer Price Index (290), converting all 
monetary costs to the US dollar rate for the year 2000. 
 
Specific Aim 2 
We used a base case from a health care system perspective, which examined 50-year-olds with 
T2D who participated in two intervention strategies (DOC or usual care) as implemented in the 
DOC study (276) at yearly cycles over a 20-year time horizon. 
We aimed to evaluate the incremental cost-effectiveness over next 20 years following the 
intervention period, assuming that treatments continued for the duration.  We applied the United 
Kingdom Prospective Diabetes Study (UKPDS) risk engine/equations to predict long-term (over 
next 20 years) probabilities of developing micro- (291-293) and macrovascular (294-296; 
http://www.dtu.ox.ac.uk/riskengine/) diabetes complications based on post-intervention 
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demographic and clinical data in those diabetes patients who were alive and without any diabetes 
complications at the study end.  Each post-intervention clinical data was adjusted for imbalanced 
baseline characteristics as appropriate using regression analyses.  To be conservative, the effect 
of the intervention strategies on disease progression was assumed to be identical on patients who 
already had diabetes complications.  Annual transition probabilities of death and of disease 
progression related to diabetes were predicted using the UKPDS risk equations and/or derived 
from the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified Release 
Controlled Evaluation (ADVANCE) trial (297) and other published literature. 
Annual direct medical costs related to health care providers, laboratory tests, physician 
office visits, diabetes complications, death, and medications were included in the model.  We did 
not include indirect costs, assuming their capture in the assessment of QALYs per the 
recommendation of the Panel on Cost-Effectiveness in Health and Medicine (258).  We used 
Medicare reimbursement data to estimate laboratory test costs (A1C, lipid panel, and urinalysis) 
and physician office visits (284).  We used hourly wage costs for health care providers required 
by the intervention strategies based on National Occupational Employment and Wage Estimates 
(285).  We identified one-time and annual costs of diabetes complications, one-time costs of 
death, as well as medication costs for diabetes, hypertension, and cholesterol control using data 
from the models developed by the Centers for Disease Control and Prevention and Research 
Triangle Institute International (286). 
In analyses from the societal perspective, we included both direct medical and non-
medical costs.  Direct non-medical costs included patient time and monetary costs for physician 
office visits, and diabetes education classes/visits.  Patient time costs for time missed from work 
or school to receive care and for time donated by others (e.g., for rides or babysitting) to allow 
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care to occur were quantified based on data from the DOC study (276) or published literature 
(288), then valued based on the average hourly wage of a US nonfarm production worker (285) 
and the average annual numbers of visits and classes as derived from the DOC study (276).  In 
addition, patient monetary costs including costs of parking or transportation and of babysitting or 
childcare were estimated from the published literature (288), then valued based on the average 
annual numbers of visits and classes as derived from the DOC study (276). 
Health utilities are a measure of health-related quality of life, with perfect health = 1 and 
death = 0.  In a cost-effectiveness analysis, this utility weight for each health state is multiplied 
by time in that state.  As an individual’s health changes over time, these products are summed to 
represent the total number of QALYs (258).  To estimate health utilities associated with T2D 
with or without complications in the model, we applied an additive prediction model to estimate 
health utilities according to demographic, treatment, and complication variables (289).  The 
baseline health utility of 0.689 is the health utility for a nonobese man with T2D who is treated 
with diet and exercise, and who has no cardiovascular risk factors or microvascular, neuropathic, 
or cardiovascular complications. 
In keeping with the reference case recommendations of the Panel on Cost-Effectiveness 
in Health and Medicine (258), we discounted future costs and benefits by 3% annually.  Also, we 
expressed costs in 2010 US dollars using the US Consumer Price Index (290), converting all 
monetary costs to the US dollar rate for the year 2010. 
 
Specific Aim 3 
We used a base case from a health care system perspective, which examined the cohort of 53-
year-old adults who participated in the ODPP pilot study (277) at yearly intervals for 10 years. 
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We aimed to evaluate the incremental cost-effectiveness over next 10 years following the 
intervention period.  In the model, usual care was the absence of the online-based lifestyle 
intervention.  The intervention effectiveness of the ODPP on weight change was obtained from 
the ODPP pilot study (277), while the weight change status through usual care was derived from 
the same primary care population for the ODPP pilot study - based on patients who were referred 
for an in-person DPP-based lifestyle intervention, but did not enroll (298).  In the model, the 
incidence of diabetes as a function of baseline body mass index (BMI) and the odds ratios for 
diabetes risk as a function of weight change were derived from the published reports of studying 
a nationally representative sample of US adults (113,299).  These odds ratios for diabetes risk 
were adjusted for age, baseline BMI, sex, race, education, systolic blood pressure, skinfold ratio 
and reported change in physical activity (299). 
 Other clinical outcomes related to stable diabetes and complicated diabetes for both the 
Internet-based lifestyle intervention and usual care were derived from the DPP study (300), the 
UKPDS (295), and the Framingham Heart Study (301).  Mortality rates were based on age- and 
gender-specific US mortality (which accounts for baseline mortality) (283) and the relative risks 
for overweight/obesity (302), stable diabetes (303), and complicated diabetes (304).  To be 
conservative, the ODPP and usual care were assumed to have identical effects on the progression 
of disease in patients who already had stable diabetes, thus implying that the model only 
examined differences between strategies in delaying or preventing the development of stable 
diabetes. 
Costs related to stable diabetes and complicated diabetes were derived from published 
literature (300,305), while costs of the Internet-based lifestyle intervention (e.g., orientation 
sessions for participants and staff, coaching services, staff activity/time, and information 
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materials) and direct non-medical costs (e.g., costs of participant time for participating in the 
ODPP) were obtained from the ODPP pilot study (277).  To account for changes in life 
expectancy and quality of life for diabetes-related health states, we used QALYs, which adjust 
for quality based on a utility weight or preference, for the health state ranging from 0 (death, 
least preferred) to 1 (perfect health, most preferred).  Health utility scores associated with 
diabetes were derived from published literature, adjusted for demographic, treatment, and disease 
state variables (289,300,306,307). 
In keeping with the reference case recommendations of the Panel on Cost-Effectiveness 
in Health and Medicine (258), we discounted future costs and benefits by 3% annually.  Also, we 
expressed costs in 2010 US dollars using the US Consumer Price Index (290), converting all 
monetary costs to the US dollar rate for the year 2010. 
 
6.4 SENSITIVITY ANALYSES 
 
Many new intervention strategies or programs are more costly but also more effective.  In such 
cases, the new interventions may be considered cost-effective if the cost-effectiveness ratio is 
below some ceiling or threshold value such that the decision makers deem the added expense 
worth the added benefits.  However, different decision makers may value benefits differently.  
Hence, extensive sensitivity analyses will be conducted to assess variations on the assumptions 
of the base case model (308). 
First, we conducted one-way sensitivity analyses for model parameters to assess the 
effect of varying individual parameter estimates within clinically plausible ranges, identifying 
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those parameters whose variation changed the base case incremental cost-effectiveness ratio 
(ICER) by 20% or greater. 
Second, we performed several scenario analyses (one-way or two-way) to examine the 
effect of varying original assumptions made for the base case model on the base case ICER.  For 
example, (1) for Specific Aims 1, 2, and 3, we calculated the ICER of cost per QALY gained 
from societal perspective, and (2) for Specific Aim 2, we tested the original assumption that all 
DOC and usual care patients had uncomplicated diabetes at the start of the model by changing 
initial proportions of patients in five heath states (i.e., no complications, microvascular 
complications only, macrovascular complications only, both micro- and macrovascular 
complications, or death) at the start of the model to mirror the DOC cohort, and then to calculate 
the ICER of cost per QALY gained from societal perspective. 
Third, uncertainty around the ICER of cost per QALY gained will be assessed through 
the use of probabilistic sensitivity analysis.  We performed a probabilistic sensitivity analysis 
from a health care system or societal perspective, where model parameters were simultaneously 
varied over distributions (309).  Distributions for parameters were chosen based on the level of 
certainty and the characteristics of the parameter range, e.g. beta distribution was assigned for 
probabilities; uniform, triangular, or log normal distributions were assigned for costs; and normal 
or uniform distributions were chosen for utilities.  A value from each parameter’s probability 
distribution was randomly selected during each of 10,000 Monte Carlo iterations, and then these 
values were used to compute strategy cost-effectiveness for each iteration.  We used the cost-
effectiveness acceptability curve (310) to summarize probabilistic sensitivity analysis results, 
showing the likelihood that a given strategy would be favored for a given willingness-to-pay 
threshold (311).  A willingness-to-pay (or acceptability) threshold is the maximum amount that 
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society is willing to pay for an incremental gain in health (311).  Although there is no absolute 
threshold, it is argued (312,313) that this threshold should not be static and a plausible range of 
society’s willingness-to-pay threshold for incremental cost-effectiveness of modern health care 
may be between $100,000 and $300,000 per QALY gained. 
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7.1 ABSTRACT 
 
Context:  Applying the comprehensive six-element chronic care model (CCM) for diabetes care 
can improve patient and system outcomes, but its relative cost-effectiveness is not known. 
Objective:  To estimate the incremental cost-effectiveness of implementing the CCM relative to 
a provider continuing medical education intervention (PROV) and to usual care (UC). 
Design, Setting, and Patients:  A Markov decision model estimated the cost-effectiveness of 
type 2 diabetes management strategies in a CCM randomized controlled trial. Intervention costs 
and outcomes, and disease progression data were directly obtained from the clinical trial. Other 
costs, mortality rates, and utilities were drawn from published literature. 
Interventions:  CCM, PROV, and UC intervention strategies as implemented in the CCM 
randomized controlled trial. 
Main Outcome Measures:  Cumulative incidence of diabetes with either microvascular or 
macrovascular complications, direct medical and direct nonmedical costs (in 2000 US dollars), 
quality-adjusted life-years (QALYs), cost per QALY gained, and cost per diabetes complication 
averted. 
Results:  Compared to the PROV and UC strategies over a 3-year period, the CCM strategy 
reduced the incidence of diabetes with either microvascular or macrovascular complications by 
an absolute 41.3 and 3.9 percentage points, respectively. From a health care system perspective, 
the costs over 3 years for the CCM strategy compared to the UC strategy were $70,317 per 
QALY gained and $29,573 per diabetes complication averted; the CCM strategy dominated the 
PROV strategy in both analyses. Over 10 years, the costs per QALY gained from a health care 
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system and a societal perspective for the CCM strategy compared to the UC strategy were 
$42,179 and $113,280 respectively. 
Conclusions:  The application of the full chronic care model for diabetes care in underserved 
communities is a sound and cost-saving investment compared to the provider continuing medical 
education intervention, and is economically reasonable relative to usual care. 
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7.2 INTRODUCTION 
 
Diabetes is an increasingly and costly prevalent cause of morbidity and mortality, 
resulting in major clinical and public health problems in the United States (1-7). Quality diabetes 
care is essential to prevent acute complications and to reduce the risk of long-term complications 
(8). Although highly effective therapies and evidence-based treatment guidelines are available 
(8,9), diabetes care and outcomes often fall short of recommended standards (10-14). 
The Chronic Care Model (CCM) (15), a multifaceted framework for enhancing health 
care delivery, is used in many health care settings to guide systematic improvement for chronic 
illness care, including diabetes (16-18). The premise of the CCM is that quality care can be 
enhanced by six elements: self-management support, delivery system design, community 
resources, organizational support, decision support, and clinical information systems, enhancing 
patient-provider interactions and improve outcomes (19-27). Previous studies demonstrate the 
effectiveness of CCM-based diabetes interventions (16-19,22-26,28-37).  
An integral component of effectively implementing the CCM is the practice of patient-
centered, team-based care. Although the team interventions improve diabetes outcomes (25,38), 
little is known about the cost-effectiveness of this approach. In this analysis we estimate the 
costs, clinical outcomes, and cost-effectiveness of implementing the CCM based on the results of 
a randomized controlled trial (RCT) (25). 
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7.3 METHODS 
 
Piatt et al conducted the first multifaceted, cluster-design RCT to determine the 
effectiveness of implementing the comprehensive CCM in a community-based setting. This trial 
took place in an underserved urban community of Pittsburgh, PA, between 1999 and 2003, and 
included a 1-year follow-up (25). Participating patients had a confirmed diagnosis of diabetes, 
based on ICD-9 codes, problem lists, laboratory results, or diabetes medication use. Eleven 
primary care practices and their patients were randomly assigned to one of three study groups: a 
Chronic Care Model intervention (CCM), a provider continuing medical education intervention 
(PROV), or usual care (UC). The CCM group (3 practices; 30 patients) involved implementation 
and provision of all six CCM elements. PROV (3 practices; 38 patients) consisted of providers 
attending one continuing medical education session, an in-person review of chart audit results by 
a certified diabetes educator, and the availability of a certified diabetes educator for consultation. 
Providers in the UC group (5 practices; 51 patients) were mailed their practices’ chart audit 
results. Baseline patient characteristics are presented in Table 7.1. 
The primary outcomes of the RCT included reductions in glycated hemoglobin (A1C), 
blood pressure levels, and non-high-density lipoprotein cholesterol (non-HDLc) levels. 
Secondary outcomes were improvements in quality of well-being, diabetes knowledge, 
empowerment, and the frequency of self-monitoring of blood glucose. Following the 1-year 
intervention, a significant decline in A1C (-0.6%) and in non-HDLc levels, and an increase in the 
proportion of patients who self-monitor blood glucose were observed in the CCM group. The 
CCM also reported improvements in HDLc levels (+5.5 mg/dL), diabetes knowledge test scores 
(+6.7%), and empowerment scores (+0.2). Taken together, CCM implementation in the 
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community was effective in improving clinical and behavioral outcomes. Because the full CCM 
is resource intensive, we sought to determine its cost-effectiveness.  
 
The Markov Decision Model Framework 
 
Model Structure 
We developed a Markov decision model (39-41) to estimate the incremental cost-
effectiveness of the CCM compared to PROV and UC in the RCT (25). We used a standard 
decision analysis software package, TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, 
MA). The model directly incorporated intervention costs and effectiveness data as well as event 
probabilities from the RCT to estimate life expectancy, quality-adjusted life-expectancy (QALE) 
(expressed as quality-adjusted life-years, or QALYs), clinical outcomes (diabetes with chronic 
complications), and direct medical and nonmedical costs associated with the intervention 
strategies. In our initial base-case analysis, we examined 68-year-olds (the average age of the 
RCT patients) with type 2 diabetes who participated in three intervention strategies and 
evaluated clinical outcomes over a 3-year period. We examined a 3-year time horizon in the 
base-case analysis because of uncertainty in long-term strategy effectiveness, and we lengthened 
the time horizon to 10 years in a sensitivity analysis.  
The model is illustrated in Figure 7.1, which describes the progression of disease through 
microvascular complications, macrovascular complications, and mortality. We assumed that all 
patients had uncomplicated diabetes at the start of the model. Over time, diabetes can progress to 
microvascular complications (including retinopathy, nephropathy, or neuropathy), macrovascular 
complications (including coronary heart disease, neurological disease, or peripheral vascular 
                                
117 
 
disease), and/or end-stage renal disease (ESRD). We assumed that complications were 
irreversible and that patients in any health state could die in the next time period. 
 The base-case values, ranges, and probability distributions of all parameters are 
summarized in Tables 7.2-7.4. Using baseline and 12-month RCT data, we estimated the annual 
probabilities of intensive treatments and disease progression in the intervention groups (Table 
7.2). To account for the cluster-design nature of the RCT, we used a multivariable mixed-effects 
logistic regression model that also adjusted for baseline characteristics with significant clinical 
differences (A1C and HDLc levels) and those with statistical differences (age at study entry, 
body mass index, and total cholesterol level) among the three intervention groups (Table 7.1). 
All five covariates were centered at their corresponding mean values. We assumed that the 
treatment and health benefits associated with the interventions persisted after the study period 
(42) and thus we applied the same probabilities of either receiving the intensive treatments or 
moving to another health state (state-transition or disease progression) to subsequent model 
cycles. 
We treated ESRD as a separate health state due to its relative rarity and high cost, 
estimating the annual probability of developing ESRD using the US Renal Data System Annual 
Data Report (43) and assuming the same probability for all interventions. Mortality was a rare 
event in the RCT. We therefore estimated mortality using age-specific US mortality rates (44) 
and the relative risk of death for people with diabetes (45), and assumed identical mortality for 
all interventions. For the ESRD state, we estimated mortality using the US Renal Data System 
Annual Data Report (43), again assuming the same ESRD mortality for all interventions. 
Annual direct medical costs related to health care provider consultation, intensive 
treatments, laboratory tests, physician office visits, diabetic complications, and death were 
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included in the model (Table 7.3). We did not include indirect costs, assuming their capture in 
the assessment of QALYs per the recommendation of the Panel on Cost-Effectiveness in Health 
and Medicine (46). We used Medicare reimbursement data to estimate laboratory test costs 
(A1C, lipid panel, and urinalysis) and physician office visits (47). In addition, we used hourly 
wage costs for health care providers required by the CCM (i.e., registered nurses and medical 
assistants) based on National Occupational Employment and Wage Estimates (48). 
For each intervention strategy, we defined intensive treatments as additional prescribed 
medications in the treatment of specific conditions: pioglitazone was added for the intensive 
treatment of glycemia, ramipril was added for the intensive treatment of hypertension, and 
atorvastatin was added of the intensive treatment for dyslipidemia (Table 7.3). Using 2008 
average wholesale prices of these drugs (49), we calculated a weighted average cost of 
intensified therapy and varied these costs in sensitivity analyses. In addition, we identified one-
time and annual costs of diabetic complications and ESRD based on data from models developed 
by the CDC and Research Triangle Institute International (50). 
In analyses from the societal perspective, we included both direct medical and 
nonmedical costs. Direct nonmedical costs included patient time and monetary costs for 
physician office visits, diabetes self-management training sessions, support groups sessions, and 
point-of-service-education sessions (Table 7.3). Patient time costs for time missed from work or 
school to receive care and for time donated by others (e.g., for rides or babysitting) to allow care 
to occur were quantified based on data from the RCT or published literature (51), then valued 
based on the average hourly wage of a US nonfarm production worker in 2000 (48) and the 
average annual numbers of visits/sessions as derived from the RCT. We expressed costs in 2000 
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US dollars using the US Consumer Price Index (52), converting all monetary costs to the US 
dollar rate for the year 2000. 
Health utilities are a measure of health-related quality of life, with perfect health=1 and 
death=0. In a cost-effectiveness analysis, this utility weight for each health state is multiplied by 
time in that state. As an individual’s health changes over time, these products are summed to 
represent the total number of quality-adjusted life-years (QALYs) (46). To estimate health 
utilities associated with type 2 diabetes with or without complications, we applied an additive 
prediction model to estimate health utilities according to demographic, treatment, and 
complication variables (53). The baseline health utility of 0.689 is the health utility for a 
nonobese man with type 2 diabetes who is treated with diet and exercise and who has no 
cardiovascular risk factors or microvascular, neuropathic, or cardiovascular complications. Table 
7.4 shows the health utilities used in the model. 
 
Sensitivity Analyses 
We first conducted one-way sensitivity analyses for model parameters (Tables 7.2-7.4) to 
assess the effect of varying parameter estimates within clinically plausible ranges, identifying 
those parameters whose variation caused the incremental cost-effectiveness ratio (ICER) to 
become greater than $100,000 per QALY gained. We also examined the effect of lengthening the 
model time horizon, changing to a societal perspective, and hypothesizing lower mortality in 
CCM patients. In addition, we examined the cost-effectiveness of assuming identical 
microvascular or macrovascular complication rates among intervention strategies, given few 
RCT subjects and the possibility of spurious observed differences between interventions. 
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We performed a probabilistic sensitivity analysis, where model parameters were 
simultaneously varied over distributions (54). Distributions for parameters were chosen based on 
the level of certainty and the characteristics of the parameter range: beta or triangular 
distributions were assigned for probabilities; log normal, triangular, or uniform distributions 
were assigned for costs; and normal or uniform distributions were chosen for utilities. A value 
from each parameter’s probability distribution was randomly selected during each of 10,000 
Monte Carlo iterations, and then these values were used to compute strategy cost-effectiveness 
for each iteration. We used the cost-effectiveness acceptability curve (55) to summarize 
probabilistic sensitivity analysis results, showing the likelihood that a given strategy would be 
favored for a given willingness-to-pay threshold (56). A willingness-to-pay (or acceptability) 
threshold is the maximum amount that society is willing to pay for an incremental gain in health 
(56). Although there is no absolute threshold, Braithwaite and colleagues (57) argue that a 
plausible range of society’s willingness-to-pay for incremental cost-effectiveness of modern 
health care may be $100,000 per QALY or more. 
 
7.4 RESULTS 
 
Base-Case Analysis 
Table 7.5 summarizes clinical outcome and cost-effectiveness analysis results. Generally, 
clinical outcomes were most favorable for the CCM strategy, intermediate for the UC strategy, 
and worst for the PROV strategy. Compared to PROV, the CCM increased QALE by 0.0793 
QALYs and reduced the cumulative incidence of diabetes with microvascular complications by 
an absolute 36.4 percentage points, diabetes with macrovascular complications by an absolute 
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19.8 percentage points, and diabetes with either microvascular or macrovascular complications 
by an absolute 41.3 percentage points (results do not sum due to portions of the cohort having 
both microvascular and macrovascular complications). Compared to UC, the CCM increased 
QALE by 0.0162 QALYs and reduced the cumulative incidence of diabetes with either 
microvascular or macrovascular complications by an absolute 3.9 percentage points. 
Over a 3-year time horizon of the model, the UC cost least ($10,795), while PROV cost 
most ($12,427). The PROV produced the lowest QALE (1.7294 QALYs), while CCM produced 
the greatest (1.8087 QALYs). Compared to UC, the CCM cost $1,140 more over 3 years and 
produced a gain of 0.0162 QALYs, resulting in an ICER of $70,317 per QALY gained. 
Compared to UC, the PROV cost an additional $1,633 but produced 0.0631 fewer QALYs, and 
thus was dominated (more expensive and less effective) by UC. Finally, compared to PROV, the 
CCM cost $493 less but produced a gain of 0.0793 QALYs, and was thus cost-saving relative to 
PROV. 
For microvascular complications alone, the CCM cost $2,714 per microvascular 
complication averted compared to UC, and was cheaper and more effective than PROV. For 
macrovascular complications alone, UC was more effective and less costly than the other 
strategies. When considering either microvascular or macrovascular complications, the CCM 
again dominated PROV and cost slightly less than $30,000 per complication averted compared to 
UC.         
 
Sensitivity Analyses 
We performed one-way sensitivity analyses to assess the effect of individual variation of 
parameter values on model results. Parameter values were varied as shown in Tables 7.2-7.4. 
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Sensitive parameters were identified, whose variation resulted in an ICER higher than 
$100,000/QALY, with threshold values (i.e., values for those parameters where results were 
>$100,000/QALY) listed in Table 7.6. Cost parameters had relatively greater differences 
between the base-case value and threshold values. Results were sensitive to more subtle variation 
of diabetes complication utilities and to strategy-specific probabilities of complication onset and 
treatment intensification.  
Over a 10-year time horizon, the CCM compared to UC cost $42,179 per QALY gained 
from a health care system perspective and $113,280 per QALY gained from a societal 
perspective (Table 7.5, bottom) under the base-case assumption of no mortality difference 
between intervention strategies. If we hypothesized an 1% per year absolute mortality reduction 
with the CCM over 10 years, the CCM cost $14,164 per QALY gained from a health care system 
perspective and $32,028 per QALY gained from a societal perspective (data not shown). Finally, 
given the possibility of little or no complication rate differences between intervention strategies 
in the small RCT, we examined the cost-effectiveness of intervention strategies if no differences 
in either micro- or macrovascular complications existed between intervention strategies. In this 
analysis, the CCM cost $61,288 per QALY gained when identical microvascular complication 
rates among strategies were assumed and $256,481 per QALY gained when identical 
macrovascular complication rates (data not shown), suggesting that much of the CCM’s effect 
was due to modification of macrovascular complication rates.  
When parameter values were simultaneously varied over their corresponding probability 
distributions in the probabilistic sensitivity analysis, the PROV was unlikely to be favored over 
CCM or UC (Figure 7.2). Using a willingness-to-pay threshold of $50,000/QALY, the CCM was 
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favored in 45% of model iterations (compared to 50% for UC and 5% for PROV); with a 
$100,000/QALY threshold, the CCM was favored in 51%. 
 
7.5 DISCUSSION 
 
Health care organizations seeking to reform their practices in accord with the CCM must 
expend considerable resources. Although available evidence suggests that such a transformation 
can lead to improved patient care and outcomes, the impact on health care costs and revenues 
remains uncertain and probably varies by condition (17). Furthermore, health care providers and 
payers have become increasingly interested in understanding how to improve care and how to 
pay for it; hence, cost-effectiveness analysis from a health care system perspective is particularly 
compelling. To our knowledge, our study is the first to determine the cost-effectiveness of 
implementing the full CCM for diabetes care based on data from a community-based RCT. From 
the perspective of a health care system over 3 years, the CCM cost about $70,500/QALY 
compared to UC. Both CCM and UC were cost-saving relative to the PROV (the traditional 
approach to health care improvements). Over 10 years, the CCM was further more cost-effective 
from the health care system perspective, costing about $42,200/QALY compared to UC. 
Knowledge about quality improvement via the CCM for diabetes care is still nascent; few 
studies available in the literature document its consequences and cost-effectiveness (34,58-64). 
Some evidence suggests that improved glycemic control reduces total health care costs for 
people with diabetes and higher A1C levels (58,59), and that intensive blood pressure control for 
people with diabetes and hypertension is a cost-saving intervention (50,65). In addition, Gilmer 
et al. confirm that interventions focusing on clinical meetings to discuss patient care problems 
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and registries for diabetes care are associated with lower future costs (60), and those involving 
disease management programs, clinical management, and self-management training for diabetes 
management are considered to be cost-effective (61).  
One of the most thorough CCM cost-effectiveness studies was recently published by 
Huang et al, comparing the costs of implementing the CCM to the benefits of improved health 
outcomes in people with diabetes in US federally qualified community health centers (63). They 
found that reduced risk of blindness, ESRD, and coronary artery disease cost $33,386/QALY. 
Compared to that study, our estimate of the CCM’s cost-effectiveness over 10 years from the 
societal perspective, $113,280/QALY, is higher. This discrepancy is likely due to a number of 
differences between models: our patient cohort was older (68 vs. 54), less racially diverse, and 
transitioned through a model where a variety of assumptions were made to bias against the CCM 
(see below). Despite this, both studies found that community-based efforts to implement the 
CCM were economically reasonable, although our 10-year societal perspective results touch on 
the border of generally accepted willingness-to-pay thresholds for modern health care today (57). 
Furthermore, our work includes data from a RCT rather than pre-and-post comparisons, 
evaluates cost-effectiveness for implementing all six CCM elements for diabetes care, and 
compares a CCM-based intervention to other plausible strategies.  
Pay-for-performance contracts in diabetes care, where physician reimbursement is tied to 
diabetes treatment guideline adherence, are increasingly being viewed as a viable and desirable 
option by Medicare and private insurers (66).  National efforts encourage and will eventually 
mandate adherence to quality of care standards for certain types of reimbursement.  
Undoubtedly, quantifying the cost of implementing quality improvement efforts is important for 
staffing and patient access plans. Our analyses provide the first comprehensive attempt to 
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quantify the cost and effectiveness of full CCM implementation in a community setting. Using 
common metrics, economic evaluations can estimate the relative value of various interventions. 
Rather than depending on long-term, expensive trials, this information can often be supplied via 
a computational modeling approach, which provides a feasible and reasonable means to evaluate 
the cost-effectiveness of interventions for type 2 diabetes that produce benefits years or even 
decades after the interventions begin. These evaluation results will provide information for 
health care policy makers as they decide whether to adopt the interventions. 
Like all modeling efforts (67), the computational model developed here has several 
limitations. First, subjects in the RCT were representative of the population with diabetes in an 
underserved urban community, and thus extrapolation to other populations or health care settings 
requires caution. Second, we restricted our long-term predictions about costs, quality of life, and 
clinical outcomes to 3 and 10 years since we employed the empirically observed data on 
complications directly from the RCT with 12-month follow-up data. Indeed, to have longer 
length of simulated follow-up and more robust predicted rates of complications, we would 
consider using one of the publicly available epidemiological models of diabetes complications 
which would allow accounting for improvements in intermediate risk factors attributable to the 
CCM. Third, because of this short-term follow-up period, mortality was rare in the RCT. For this 
reason, we conservatively assumed identical mortality for all three intervention strategies, 
perhaps biasing the model against the CCM since evidence suggests reduced mortality with the 
CCM (17,68,69). Similarly, applying the same incidence of ESRD to all three intervention 
strategies biases our model against the CCM, which has the potential to reduce lifetime incidence 
of ESRD (17,63). In a sensitivity analysis, assuming identical macrovascular complication 
incidence rates among intervention strategies significantly worsened the CCM’s cost-
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effectiveness, again possibly biasing against the CCM given its evidence of improved outcomes. 
Fourth, due to lack of utility data, we applied the same literature-based utility weights to all three 
intervention strategies. Again, this is a conservative response that may underestimate the CCM’s 
potential to improve quality of life (36,37,70). 
The provision of usual care, as anticipated, costs less than facilitating more 
comprehensive approaches, such as provider continuing medical education or a comprehensive 
six-element CCM intervention. More surprising, however, the conventional approach used most 
widely for improving health care – provider continuing medical education – incurred greater 
costs than the CCM but yielded fewer benefits in terms of QALYs. Unfortunately, for a variety 
of reasons, quality improvement efforts have been directed to improving provider knowledge. 
Evidence demonstrates that improvements in patient knowledge do not necessarily translate into 
effective patient behavior change (71,72), and, apparently, this lesson may also apply to health 
care providers. Recently, a systematic review and meta-analysis report also provided evidence 
that compared with usual care, the quality improvement strategies solely targeting health care 
providers (e.g., clinician education, clinician reminders, or audit and feedback) did not seem to 
be beneficial for reduction in intermediate outcomes for diabetes control (i.e., A1C, LDL 
cholesterol, or systolic and diastolic blood pressure) (73). Indeed, our findings raise questions 
about these traditional quality improvement efforts for diabetes management and reaffirm the 
need for health systems to explore innovative new approaches beyond provider education. 
Status quo is not an option; reforms at the delivery system level are imperative to address 
significant lapses in quality of care as well as the high and rapidly increasing cost of care 
(74,75). A recent systematic review provides evidence that CCM is effective in improving the 
health of people who have diabetes and receive care in the US primary care settings (76). 
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American Diabetes Association (ADA) suggests that collaborative, multidisciplinary teams are 
best suited to provide such care for people with chronic conditions such as diabetes and to 
facilitate patients’ performance of appropriate self-management (77). Specifically, ADA 
recommends that diabetes care should be aligned with components of the CCM to ensure 
productive interactions between a prepared proactive practice team and an informed activated 
patient (77).  Furthermore, one of the most important tools to slow the growth of health care 
expenditures is providing reliable information regarding the cost-effectiveness of alternative 
interventions. Such information, especially when combined with appropriate incentives and 
improved access to supporting technology and nonphysician personnel, can slow the growth of 
health care spending (78). Although further work is needed in examining the costs associated 
with these types of multifaceted interventions, this report adds supporting evidence that not only 
is the CCM effective in improving practice and patient outcomes, it is also an economically 
reasonable approach to diabetes care. 
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7.7 TABLES AND TABLE LEGENDS 
 
Table 7.1 Baseline sociodemographic, clinical, and lifestyle behaviors characteristics of 
participants by three intervention strategies in the chronic care model randomized 
controlled trial 
 
Characteristics CCM (n=30) PROV (n=38) UC (n=51) P Valuea 
Demographic characteristics     
Mean age (SD), years 69.7 (10.7) 64.4 (8.9) 68.6 (8.6) .04 
Mean age at diabetes diagnosis (SD), years 60.0 (12.4) 53.1 (12.4) 55.8 (12.6) .34 
Mean duration of diabetes (SD), years 10.3 (8.4) 11.5 (9.0) 13.1 (10.9) .70 
Gender, n (%)    .58 
   Male 15 (50.0) 15 (39.5) 30 (58.8) 
   Female 15 (50.0) 23 (60.5) 21 (41.2) 
Race, n (%)    .54 
   Non-white 4 (13.3) 1 (2.6) 5 (9.8) 
   White 26 (86.7) 37 (97.4) 46 (90.2) 
Mean weight (SD), kg 83.6 (15.3) 91.9 (17.9) 88.3 (17.1) .45 
Mean height (SD), cm 167.3 (10.0) 167.7 (9.9) 171.0 (10.0) .61 
Mean BMI (SD), kg/m2 29.9 (5.4) 32.7 (5.8) 30.1 (4.4) .04 
Current insulin use, n (%)    .45 
   Yes 8 (26.7) 16 (42.1) 13 (25.5) 
   No 22 (73.3) 22 (57.9) 38 (74.5) 
Education, n (%)    .80 
   <High school education 15 (50.0) 22 (57.9) 31 (60.8) 
   ≥High school education 15 (50.0) 16 (42.1) 20 (39.2) 
Income, n (%)    >.95 
   <$20,000/year 12 (40.0) 19 (50.0) 20 (39.2) 
   ≥$20,000/year 15 (50.0) 17 (44.7) 25 (49.0) 
   Missing 3 (10.0) 2 (5.3) 6 (11.8) 
Clinical characteristics     
Mean A1C (SD), % 7.7 (1.5) 7.5 (1.6) 6.9 (1.3) .39 
Mean systolic blood pressure (SD), mmHg 143.1 (21.0) 142.7 (18.0) 147.5 (28.4) .87 
Mean diastolic blood pressure (SD), mmHg 73.1 (7.7) 78.7 (11.5) 75.8 (9.5) .30 
Mean total cholesterol level (SD), mg/dL 195.7 (49.0) 214.2 (48.0) 192.5 (31.0) .05 
Mean HDLc level (SD), mg/dL 39.3 (10.2) 48.4 (13.4) 43.7 (10.1) .39 
Mean non-HDLc level (SD), mg/dL 156.4 (50.7) 165.8 (50.1) 148.8 (31.3) .55 
Mean LDLc level (SD), mg/dL 103.7 (32.2) 115.9 (44.8) 104.9 (27.6) .32 
Mean triglyceride level (SD), mg/dL 259.7 (189.2) 270.8 (180.2) 239.1 (143.7) .61 
Microalbuminuria , n (%)     
   <30 µg/dL 20 (66.7) 27 (71.1) 38 (74.5) .80 
   ≥30 µg/dL 9 (30.0) 10 (26.3) 12 (23.5) 
   Missing 1 (3.3) 1 (2.6) 1 (2.0) 
Lifestyle behaviors     
Currently smoke, n (%)    .92 
   Yes  2 (6.7) 4 (10.5) 4 (7.8)  
   No  27 (90.0) 34 (89.5) 46 (90.2)  
   Missing  1 (3.3) 0 (0.0) 1 (2.0)  
Self-monitor blood glucose, n (%)    .79 
   Yes 24 (80.0) 31 (81.6) 42 (82.4) 
   No  6 (20.0) 7 (18.4) 9 (17.6)  
Physician office visits in the past 1 year, n (%)    .88 
   <2 visits  1 (3.3) 2 (5.3) 3 (5.9)  
   ≥2 visits 29 (96.7) 36 (94.7) 47 (92.2) 
   Missing  0 (0.0) 0 (0.0) 1 (2.0)  
                                
138 
 
Abbreviations: CCM, chronic care model; PROV, provider continuing medical education; UC, usual care; BMI, 
body mass index; A1C, glycated hemoglobin; HDLc, high-density lipoprotein cholesterol; LDLc, low-density 
lipoprotein cholesterol. 
aThe comparisons of all baseline characteristics among three study groups were conducted using the univariate 
mixed-effects linear regression or mixed-effects logistic regression model that incorporated correlation due to the 
clustering of patients within practices; however, the random clustering effect was taken out of the models if the 
clustering variance component was close or equal to zero. 
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Table 7.2 Probabilities of intensive treatments and disease progression, and the risk of 
death for the Markov decision model 
 
Parameter Value Reference or 
source 
 Base-case 
analysis 
Probabilistic sensitivity 
analysis distribution 
 
Probabilities of intensive treatments    
   Probability of intensive treatments for glycemia, %   CCM data 
      CCM 33.64 Beta (5.09 to 73.71) 
      PROV 42.96 Beta (12.60 to 76.75) 
      UC 40.00 Beta (14.36 to 69.23) 
   Probability of intensive treatments for hypertension, %   CCM data 
      CCM 30.00 Beta (14.68 to 47.66) 
      PROV 26.32 Beta (13.65 to 41.49) 
      UC 27.45 Beta (16.03 to 40.28) 
   Probability of intensive treatments for dyslipidemia, %   CCM data 
      CCM 5.62 Beta (0.011 to 26.10) 
      PROV 2.70 Beta (0.016 to 11.53) 
      UC 4.06 Beta (0.121 to 13.66) 
Probabilities of disease progression    
   Yearly probability of disease progression in diabetes 
   patients without Any complications, % 
  CCM data 
      Remain in the status without any complications   
         CCM 80.00 Beta (37.95 to 99.61) 
         PROV 42.86 Beta (18.62 to 69.39) 
         UC 77.78 Beta (45.13 to 97.43) 
      Develop microvascular complications   
         CCM 0.00 Triangular (0.00 to 4.00) 
         PROV 14.29 Beta (1.40 to 35.07) 
         UC 11.11 Beta (0.27 to 21.93) 
      Develop macrovascular complications   
         CCM 20.00 Triangular (16.00 to 20.00) 
         PROV 38.10 Beta (14.54 to 55.03) 
         UC 0.00 Triangular (0.00 to 4.44) 
   Yearly probability of disease progression in diabetes 
   patients with microvascular complications, % 
  CCM data 
      Develop macrovascular complications   
         CCM 50.00 Beta (20.50 to 79.63) 
         PROV 0.00 Triangular (0.00 to 20.00) 
         UC 0.00 Triangular (0.00 to 20.00) 
   Yearly probability of disease progression in diabetes 
   patients with macrovascular complications, % 
  CCM data 
      Develop microvascular complications   
         CCM 14.29 Beta (0.33 to 47.55) 
         PROV 0.00 Triangular (0.00 to 20.00) 
         UC 50.00 Beta (24.48 to 75.87) 
   Yearly probability of developing ESRD in diabetes 
   patients, % 
0.4114 Beta (0.3990 to 0.4237) 2008 USRDS 
Annual Data 
Report [43] 
Risk of death    
   Rate ratio of death in people with diabetes compared to 
   those without diabetes 
2.31 Not varied Gregg et al., 
[45] 
   Yearly probability of death in diabetes patients with 
   ESRD, % 
25.61 Beta (24.76 to 26.47) 2008 USRDS 
Annual Data 
Report [43] 
Abbreviations: CCM, chronic care model; PROV, provider continuing medical education; UC, usual care; ESRD, end-stage renal 
disease; USRDS, United States Renal Data System. 
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Table 7.3 Parameters of costs for the Markov decision model 
 
Parameter Value Reference or 
source 
 Base-case 
analysis 
Probabilistic sensitivity 
analysis distribution 
 
Direct medical costs    
   Added annual health care provider costs per patient for the 
   CCM strategy 
   
      Registered nurse/certified diabetes educator costs, US$ 687 Uniform (563 to 819) CCM data; 
US Bureau of 
Labor 
Statistics [48] 
      Medical assistant costs, US$ 238 Uniform (198 to 279) 
   Annual costs of drugs for the intensive treatments, 
   laboratory tests, and physician office visits per patient 
   
      Added costs of drugs for the intensive treatments, US$   2008 Red 
Book [49]          For glycemia 1,985 Uniform (993 to 2,978) 
         For hypertension 681 Uniform (341 to 1,022) 
         For dyslipidemia 1,099 Uniform (550 to 1,649) 
      Laboratory test costs, US$   CCM data; 
CMS [47]          During the first year   
            CCM 64 Uniform (32 to 96) 
            PROV 62 Uniform (31 to 93) 
            UC 59 Uniform (30 to 89) 
         After the first year   
            CCM 56 Uniform (28 to 84) 
            PROV 61 Uniform (31 to 92) 
            UC 55 Uniform (28 to 83) 
      Physician office visit costs, US$   CCM data; 
CMS [47]          CCM 713 Uniform (561 to 865) 
         PROV 389 Uniform (306 to 472) 
         UC 629 Uniform (495 to 763) 
   One-time and annual costs of complications per patient    
      One-time costs, US$   Hoerger et al. 
[50]          No complications 0 Not varied 
         Microvascular complications 1,710 Triangular (263 to 3,158) 
         Macrovascular complications 2,932 Log normal (0 to 23,189) 
         Microvascular and macrovascular complications 4,642 Log normal (263 to 26,347) 
      Annual costs, US$   Hoerger et al. 
[50]          No complications 0 Not varied 
         Microvascular complications 2,280 Triangular (1,140 to 3,420) 
         Macrovascular complications 1,199 Log normal (0 to 8,153) 
         Microvascular and macrovascular complications 3,479 Log normal (1,140 to 11,573) 
         ESRD 77,772 Triangular (38,886 to 116,658) 
   One-time costs of death per patient    
      Age=65-74 years, US$ 11,337 Not varied Hoerger et al. 
[50]       Age=75-84 years, US$ 10,080 Not varied 
Direct nonmedical costs    
   Annual time costs per patient    
      Costs for physician office visits, US$   CCM data; 
US Bureau of 
Labor 
Statistics 
[48]; Smith et 
al. [51] 
         CCM 666 Not varied 
         PROV 364 Not varied 
         UC 588 Not varied 
      Costs for DSMT sessions for the CCM strategy, US$ 263 Not varied 
      Costs for support groups sessions for the CCM strategy, US$ 168 Not varied 
      Costs for POSE sessions for the CCM strategy, US$ 70 Not varied 
   Annual monetary costs per patient    
      Costs for physician office visits, US$   CCM data; 
US Bureau of 
Labor 
Statistics 
[48]; Smith et 
al. [51] 
         CCM 36 Not varied 
         PROV 20 Not varied 
         UC 32 Not varied 
      Costs for DSMT sessions for the CCM strategy, US$ 14 Not varied 
      Costs for support groups sessions for the CCM strategy, US$ 12 Not varied 
      Costs for POSE sessions for the CCM strategy, US$ 8 Not varied 
Abbreviations: CCM, chronic care model; PROV, provider continuing medical education; UC, usual care; ESRD, end-stage renal 
disease; CMS, Centers for Medicare and Medicaid Services; DSMT, diabetes self-management training; POSE, point-of-service-
education. 
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Table 7.4 Parameters of health utilities and discount rates for the Markov decision model 
 
Parameter Value Reference or 
source 
 Base-case 
analysis 
Probabilistic sensitivity 
analysis distribution 
 
Health utilities    
   Diabetes without complications 0.689 Normal (0.662 to 0.716) Coffey et al. 
[53]    Diabetes with microvascular complications 0.599 Uniform (0.519 to 0.678) 
   Diabetes with macrovascular complications 0.615 Uniform (0.584 to 0.645) 
   Diabetes with microvascular and 
   macrovascular complications 
0.599 Uniform (0.519 to 0.678) 
   Diabetes with end-stage renal disease 0.611 Normal (0.560 to 0.662) 
Discount rates    
   Discount rate applied to costs, % 3.00 (2.00 to 5.00)a Assumed 
   Discount rate applied to quality-adjusted 
   life-expectancy, % 
3.00 (2.00 to 5.00)a Assumed 
a(a to b)=(minimum to maximum). This parameter was not varied in the probabilistic sensitivity analysis. 
 
Table 7.5 Incremental cost-effectiveness by interventions from base-case analysis and 
sensitivity analyses: Simulated economic and clinical outcomes in the chronic care model 
randomized controlled trial cohort 
 
Cost-effectiveness analysis Study group Cost (US$) Effectiveness ICER 
3 years, health care system perspective  
   Cost vs. Quality-adjusted life-expectancy UC $10,795  1.7925 QALY - 
CCM $11,935 1.8087 QALY 70,317 
PROV $12,427 1.7294 QALY Dominated 
   Cost vs. Cumulative incidence of diabetes 
   with microvascular complications 
UC $10,795 48.7% - 
CCM $11,935 6.72% 2,714 
PROV $12,427 43.1% Dominated 
   Cost vs. Cumulative incidence of diabetes 
   with macrovascular complications 
UC $10,795 24.4% - 
CCM $11,935 44.9% Dominated 
PROV $12,427 64.7% Dominated 
   Cost vs. diabetes with either microvascular 
   or macrovascular complications 
UC $10,795 48.7% - 
CCM $11,935 44.9% 29,573 
PROV $12,427 86.2% Dominated 
10 years, health care system perspective     
   Cost vs. Quality-adjusted life-expectancy  PROV $34,808 4.2498 QALY - 
UC $35,295 4.3645 QALY 4,247 
CCM $37,800 4.4239 QALY 42,179 
10 years, societal perspective     
   Cost vs. Quality-adjusted life-expectancy  PROV $37,437 4.2498 QALY - 
UC $39,539 4.3645 QALY 18,334 
CCM $46,267 4.4239 QALY 113,280 
Abbreviations: ICER, incremental cost-effectiveness ratio; CCM, chronic care model; PROV, provider continuing 
medical education; UC, usual care; QALY, quality-adjusted life-year. 
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Table 7.6 One-way sensitivity analyses of the chronic care model strategy compared to the 
usual care strategy for incremental cost-effectiveness thresholds >$100,000 per quality-
adjusted life-year gained 
 
Parameter Base-case 
value 
Threshold 
value 
Probabilities, %   
   Probability of intensive treatments for glycemia in CCM 33.64 >42.61 
   Probability of intensive treatments for glycemia in UC 40.00 <31.03 
   Probability of intensive treatments for dyslipidemia in CCM 5.62 >21.82 
   Yearly probability of CCM patients with macrovascular 
   complications developing microvascular complications 
14.29 >37.99 
   Yearly probability of CCM patients without complications 
   developing macrovascular complications 
20.00 <16.90 
   Yearly probability of UC patients without complications 
   developing macrovascular complications 
0.00 >8.15 
   Yearly probability of CCM patients without complications 
   developing microvascular complications 
0.00 >5.42 
   Yearly probability of UC patients without complications 
   developing microvascular complications 
11.11 >15.75 
Costs, US$   
   Annual costs of micro- and macrovascular complications 3,479 <1,993 
   One-time costs of micro- and macrovascular complications 4,642 <2,620 
   Annual costs of macrovascular complications 1,199 >1,956 
   One-time costs of macrovascular complications 2,932 >4,030 
Utilities   
   Utility for diabetes with micro- and macrovascular complications 0.599 >0.613 
   Utility for diabetes with macrovascular complications 0.615 <0.608 
   Utility for diabetes with microvascular complications 0.599 >0.611 
Abbreviations: CCM, chronic care model; UC, usual care. 
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7.8 FIGURES 
 
 
 
 
 
Figure 7.1 Markov-state diagram for the basic model structure 
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Figure 7.2 Probabilistic (second-order Monte Carlo) sensitivity analysis among all three intervention strategies 
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7.9 FIGURE LEGENDS 
 
Figure 7.1 Markov-state diagram for the basic model structure 
Ovals indicate health states. Subjects may remain within a health state (short curved arrow) or 
may move to a different health state (straight arrow or long curved arrow). 
 
Figure 7.2 Probabilistic (second-order Monte Carlo) sensitivity analysis among all three 
intervention strategies  
The acceptability curve depicts the likelihood of an intervention strategy being favored for a 
given cost-effective threshold (willingness-to-pay). CCM, PROV, and UC indicate chronic care 
model, provider continuing medical education, and usual care respectively. QALY indicates 
quality-adjusted life-year.  
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8.1 ABSTRACT 
 
Background:  Applying the Chronic Care Model (CCM) for diabetes management helps 
improve health outcomes and patient care.  The CCM was implemented at US Air Force Wilford 
Hall Medical Center through the Diabetes Outreach Clinic (DOC) in 2006, but its cost-
effectiveness in this setting is unknown. 
Methods:  We constructed a Markov decision model to estimate DOC cost-effectiveness 
compared to usual care (UC) over a 20-year period.  Based on empirical, post-intervention 
demographic and clinical data, we applied UKPDS risk equations to predict long-term 
probabilities of developing micro- or macrovascular complications.  Health care system and 
societal perspectives were considered, discounting costs and benefits at 3% annually.  
Intervention costs and outcomes were obtained from military data, while other costs, disease 
progression data, and utilities were drawn from published literature. 
Results:  From a health care system perspective, the DOC cost $45,495 per quality-adjusted life-
year (QALY) compared to UC; from a societal perspective, the DOC compared to UC cost 
$42,051/QALY (when the model started with the uncomplicated diabetes cohort), 
$61,243/QALY (when starting with the DOC cohort), or $61,813/QALY (when starting with the 
UC cohort).  In one-way sensitivity analyses, results were most sensitive to yearly costs for 
specialty care visits.  In probabilistic sensitivity analysis, the DOC was favored in 51% of model 
iterations using an acceptability threshold of $50,000/QALY and in 72% at a threshold of 
$100,000/QALY. 
Conclusions:  The DOC strategy for diabetes care, performed with the CCM methodology in a 
military population, appears to be economically reasonable compared to UC. 
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8.2 INTRODUCTION 
 
Diabetes is a major cause of morbidity and mortality in the US, resulting in substantial 
human and economic costs (1-3).  Diabetes management is complicated, requiring continuous 
patient involvement and the assistance of a team of health care professionals (4,5).  Despite the 
availability of effective medications and evidence-based practice recommendations (5,6), most 
diabetic patients do not achieve therapeutic goals, and significant opportunities remain to 
improve diabetes management (7-9).  Moreover, broad variations persist in the quality of 
diabetes care across both health care providers and practice settings (5).  
The Chronic Care Model (CCM) (10), a multifaceted framework to redesign daily 
medical practices and enhance health care delivery, is used in many health care settings to guide 
systematic and individual improvements in chronic illness management, including diabetes 
(4,11-14).  The premise of the CCM is that quality care is not delivered in isolation but that each 
of the CCM elements works in tandem (15).  Six key elements are identified by the CCM, 
including four interdependent elements at the practice level (self-management support, decision 
support, delivery system design, and clinical information systems); a higher-level element 
(organizations of health care) at the health systems, which plays an overarching role in guiding 
practice-level development; and a broader-level element (linkages of resources and policies) at 
the community, which provides necessary resources and establishes policies linked to chronic 
illness care (12,15-18).  Previous studies show that CCM-based diabetes interventions improve 
patient outcomes, including better processes of care (e.g., diabetic foot examinations and 
glycated hemoglobin [A1C] checks) and intermediate outcomes (e.g., A1C, blood pressure, and 
lipids), reduced risk for cardiovascular events, and higher health status and health-related quality 
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of life (4,11-16,19-35).  However, little is known about the cost-effectiveness of implementing 
the CCM for diabetes care. 
Through its TRICARE program, the US Department of Defense Military Health System 
(MHS) is one of the largest providers of health care in the US, providing care to approximately 
9.5 million beneficiaries at an annual cost of $48.5 billion (FY 2010) (36).  Diabetes is a critical 
issue for the MHS, with a prevalence of 5% among MHS enrollees and even greater prevalence 
rates in overweight (8-11%) and obese (16-37%) retirees and their dependents (37-42).  The total 
annual cost of TRICARE beneficiaries aged 20-65 years with diagnosed diabetes was 
approximately $300 million in 2006; the average additional medical cost per beneficiary 
diagnosed with diabetes was $2,150 annually (43,44). 
In an effort to improve outcomes and reduce the costs associated with diabetes, the US 
Air Force Wilford Hall Medical Center (WHMC) implemented the CCM in 2006 through the 
Diabetes Outreach Clinic (DOC), which restructured health care for diabetic beneficiaries by 
delivering services through a single, centralized location.  Our analysis aimed to estimate the 
costs, clinical outcomes, and cost-effectiveness of implementing the CCM for diabetes care in 
this military setting. 
 
8.3 METHODS 
 
The Diabetes Outreach Clinic at Wilford Hall Medical Center 
 
The DOC operated during the calendar years 2006-2008 at WHMC.  It was operating as a 
“one-stop-shop” for diabetic patients, which allowed patients to obtain comprehensive care with 
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one visit.  The DOC staff consisted of an endocrinologist, nurse practitioner, counselor, 
ophthalmologist, dietitian, certified diabetes educator, and support staff.  Diabetic patients were 
seen for both diabetes-related treatments and routine primary care in DOC. 
The population for these analyses included individuals with an ICD-9-CM diagnosis of 
diabetes (250.xx) receiving care in the WHMC San Antonio area between January 2005 and 
December 2008.  A total of 9,654 diabetic patients, including 1,171 DOC patients and 8,483 
usual care (UC) patients, from the military Population Health database were identified.  
Administrative data included demographics, clinical data (e.g., A1C, blood pressure, and lipids), 
medical utilization (e.g., primary and specialty care visits), and pharmacy records.  For DOC 
patients, we defined the records from one year prior to DOC entry as pre-DOC data (or baseline), 
and all records after DOC entry as post-DOC data (or follow-up); for UC patients, we defined 
the records from one year prior to January 2006 (i.e., DOC starting date) as baseline data, and all 
records after that time as follow-up data.  A total of 249 patients less than 18 years of age were 
excluded, and thus the study cohort in this analysis comprised 9,405 diabetic patients (or 97.4% 
of the original population), including 1,171 DOC and 8,234 UC patients (Table 8.5).   
 
The Framework of a Markov Decision Model  
 
Using TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA), we modified a 
prior Markov decision model (45) to estimate the incremental cost-effectiveness of DOC 
compared to UC.  The model directly incorporated intervention costs and effectiveness from 
military data to estimate life expectancy, quality-adjusted life-expectancy (expressed as quality-
adjusted life-years, or QALYs), clinical outcomes, as well as direct medical and nonmedical 
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costs associated with DOC and UC.  Our base case model examined 50-year-olds with type 2 
diabetes who participated in DOC or UC in yearly cycles over a 20-year time horizon from the 
health care system perspective.  Future costs and benefits were discounted at 3% annually (46), 
and the US Consumer Price Index (47) was used to convert all monetary costs to 2010 US 
dollars. 
 
Basic Model Structure 
 
The model is illustrated in Figure 8.1, which describes the progression of disease through 
microvascular complications, macrovascular complications, and mortality.  In this model, all 
patients were assumed to have uncomplicated diabetes at the start of the model.  Over time, 
diabetes could progress to microvascular complications (including retinopathy, nephropathy, or 
neuropathy), macrovascular complications (including coronary heart disease or stroke), or both.  
Complications were assumed to be irreversible.  To be conservative, DOC and UC were assumed 
to have identical effects on the progression of disease in patients who already had diabetes 
complications, thus implying that the model only examined differences between strategies in 
delaying or preventing the development of complications. 
In the model, cost-effectiveness was estimated over a 20-year period following the 
intervention period, assuming that treatments continued for the duration.  The United Kingdom 
Prospective Diabetes Study (UKPDS) risk equations were applied to predict treatment effects, 
i.e. long-term probabilities of developing microvascular (48-50) and macrovascular (51-53) 
complications, using empirical, post-intervention demographic and clinical data in those diabetic 
patients who were alive and without diabetes complications at study end.  Among 9,405 diabetic 
                                
 
 
 
 
152 
patients, 1,417 diabetic patients who fulfilled these criteria were identified (196 DOC and 1,221 
UC patients; Table 8.6).  Table 8.1 summarizes the parameters applied in the UKPDS risk 
equations and the Markov decision model. 
Model input parameters are shown in Tables 8.2-8.3 and Tables 8.7-8.11.  Probabilities 
of death and of micro- or macrovascular complications were predicted using the UKPDS risk 
equations and/or derived from the Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation study (54) (Tables 8.7-8.10).     
Annual direct medical costs related to health care providers, laboratory tests, physician 
office visits, diabetes complications, death, and medications were included in the model (Table 
8.2 and Table 8.11).  Indirect costs were not included, assuming their capture in the assessment 
of QALYs, per the recommendation of the Panel on Cost-Effectiveness in Health and Medicine 
(46).  Medicare reimbursement data were used to estimate costs of laboratory tests (A1C and 
lipid panel) and physician office visits (55).  Hourly wage costs for health care providers in both 
DOC and UC were based on National Occupational Employment and Wage Estimates (56).  
One-time and annual costs of diabetes complications, one-time costs of death, as well as 
medication costs for diabetes, hypertension, and cholesterol control were based on data from the 
models developed by the Centers for Disease Control and Prevention and Research Triangle 
Institute International (57). 
In analyses from the societal perspective, both direct medical and nonmedical costs were 
included.  Direct nonmedical costs included patient time and monetary costs for physician office 
visits, and diabetes education classes/visits (Table 8.2).  Patient time costs for time missed from 
work or school to receive care and for time donated by others (e.g., for rides or babysitting) to 
allow care to occur were quantified based on DOC data or published literature (58) and then 
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valued according to the average hourly wage of a US nonfarm production worker (56) and the 
average annual frequency of visits and classes as measured in DOC data.  In addition, monetary 
costs to the patient for expenses such as transportation, parking, and babysitting or childcare 
were estimated from published literature (58), and then valued based on the average annual 
frequency of visits and classes as derived from DOC data. 
Health utilities are a measure of health-related quality of life, with perfect health=1 and 
death=0.  In a cost-effectiveness analysis, this utility weight for each health state is multiplied by 
time in that state.  As an individual’s health changes over time, these products are summed to 
represent the total number of QALYs (46).  To estimate health utilities associated with type 2 
diabetes with or without complications, an additive prediction model was applied to estimate 
health utilities according to demographic, treatment, and complication variables (59).  The 
baseline health utility of 0.689 depicts a nonobese man with type 2 diabetes, who is treated with 
diet and exercise and has no cardiovascular risk factors, nor any microvascular, neuropathic, or 
cardiovascular complications (Table 8.3). 
 
Sensitivity Analyses 
 
One-way sensitivity analyses were conducted for model parameters (Table 8.9 and 
Tables 8.2-8.3) to assess the effect of varying parameter estimates within clinically plausible 
ranges and identify parameters whose variation changed the base case incremental cost-
effectiveness ratio (ICER) >20%.  Next, the ICER was recalculated using the societal perspective 
instead of the health care system perspective.  Finally, the original assumption that all DOC and 
UC patients had uncomplicated diabetes at the start of the model was tested by changing initial 
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proportions of patients in health states to mirror the DOC cohort and then the UC cohort, 
recalculating cost-effectiveness for each starting cohort from the societal perspective. 
A probabilistic sensitivity analysis was performed from the health care system 
perspective, where model parameters were simultaneously varied over distributions (60).  
Distributions for parameters were chosen to reflect the level of certainty and the characteristics 
of the parameter range: beta distribution was assigned for probabilities; uniform, triangular, or 
log normal distributions for costs; and normal or uniform distributions for utilities.  A value from 
each parameter’s probability distribution was randomly selected during each of 10,000 Monte 
Carlo iterations, and then these values were used to compute the cost-effectiveness among 
strategies of being studied for each iteration.  The cost-effectiveness acceptability curve (61) was 
used to summarize results, showing the likelihood that a given strategy would be favored for a 
given acceptability threshold, which is defined as the maximum amount that society is willing to 
pay for an incremental gain in health (62). 
 
8.4 RESULTS 
 
Over the study period, DOC patients had better glycemic control (from 7.8% to 7.2% vs. 
from 6.8% to 7.0%) and dyslipidemic control (total cholesterol: 173 mg/dL vs. 184 mg/dL; low-
density lipoprotein cholesterol: 93 mg/dL vs. 102 mg/dL), fewer annual primary care visits (2.0 
vs. 3.0), and more annual A1C (2.2 vs. 1.7) and lipids (1.7 vs. 1.4) checks compared to UC 
patients.  Tables 8.5 and 8.6 summarize the observed demographic, clinical, and medical 
utilization characteristics at baseline and follow-up.   
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Base Case Analysis 
 
Table 8.4 summarizes the cost-effectiveness results.  DOC cost $5,311 more than UC 
and produced 0.117 more QALYs, resulting in an ICER of $45,495 per QALY over 20 years 
from the health care system perspective. 
 
Sensitivity Analyses 
 
Figure 8.2 shows the results of one-way sensitivity analyses, where six parameters whose 
variations changed the base case ICER >20% were identified.  Of these, only the yearly cost for 
specialty care visits in the DOC patients could drive the ICER >$100,000/QALY.  Variation of 
parameters not shown in Figure 8.2 did not increase the ICER above $50,000/QALY.  Analysis 
from the societal perspective showed that DOC cost $4,909 more than UC and gained 0.117 
QALYs, resulting in an ICER of $42,051/QALY over 20 years (Table 8.4).  Changing the initial 
proportion of cohorts in the five health states at the start of model to mirror the complication 
rates of DOC patients and then again of UC patients resulted in ICERs of $61,243/QALY and 
$61,813/QALY respectively from the societal perspective (Table 8.4).  
When parameters were simultaneously varied over the distributions in the probabilistic 
sensitivity analysis, DOC was more likely to be favored with an acceptability threshold 
>$48,000/QALY (Figure 8.3).  In addition, at a threshold of $50,000/QALY, DOC was favored 
in 51% of model iterations; at $100,000/QALY, DOC was favored in 72%. 
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8.5 DISCUSSION 
 
The CCM is a multifaceted intervention intended to provide effective and comprehensive 
care for diabetes and other chronic conditions.  Although transformation of health care 
organizations using the CCM must expend considerable resources, in theory their expenditures 
will be offset downstream with the delay or elimination of diabetes-related complications.  In 
this regard, cost-effectiveness analysis from a health care system perspective may be particularly 
compelling.  Our study showed that, from a health care system perspective over 20 years, the 
CCM strategy performed through DOC in a military-based setting was quite cost-effective, 
costing about $45,500/QALY.  From a societal perspective, it was even more favorable, with an 
ICER less than $42,100/QALY. 
Diabetes care involves complex interactions among patients, physicians, health care 
system, and society as a whole, with barriers occurring at every level (11).  A major contributor 
to suboptimal diabetes care is a delivery system that too often is fragmented, lacks clinical 
information capabilities, duplicates services, and is poorly designed for the delivery of chronic 
care (5).  The American Diabetes Association suggests that the CCM may be well suited to the 
management of diabetes because it addresses these complex issues, redefines the role of 
providers, and promotes patient self-management (5,14). 
Knowledge on CCM cost-effectiveness in diabetes care is nascent (14); more research is 
needed to understand the costs and benefits to practices, payers, and patients.  We found only 
one full economic evaluation (63) published by Huang et al (64), comparing CCM 
implementation costs to the benefits of improved health outcomes in diabetic patients in US 
federally qualified community health centers.  In that study, CCM reduced lifetime risks of 
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blindness, end-stage renal disease, and coronary artery disease, resulting in an increase in 
benefits at a cost of $33,386/QALY.  Compared to that study, our estimate of CCM cost-
effectiveness over 20 years from the societal perspective, $42,051/QALY, is higher.  This 
discrepancy is likely due to a number of differences in models; for instance, our patient cohort 
was a military population, younger (50 vs. 55 years), less racially diverse, and transitioned 
through a model where some assumptions were made to bias against the CCM effect (see below).  
Furthermore, we used costs in 2010 US$ rather than 2004 US$, and included data from a two-
group effectiveness study rather than pre-and-post comparisons.  Despite these differences, both 
studies found that implementation of the CCM was economically reasonable and consistent with 
accepted societal cost-effectiveness thresholds (65). 
Cost-saving medical interventions are rare.  Most new diabetes treatment strategies are 
more effective but also more costly, requiring incremental resources per QALY gained (66).  
There is no absolute cost-effectiveness threshold, and the long-cited benchmark from the 
literature of $50,000/QALY is unsupported (65,67).  A recent analysis (67) argues that a more 
plausible threshold of society’s willingness to pay for modern health care ranges between 
$100,000 and $300,000 per QALY, which is substantially higher than the traditional threshold. 
Health care costs in the US are increasing unsustainably, and efforts to control 
expenditures should focus on the value of health care interventions, reflecting health benefits that 
justify their costs (68).  High-cost interventions may provide good value when they are highly 
beneficial.  The ICER estimates the additional cost required to obtain additional health benefits 
and provides a key measure of the value of a health care intervention (68).  Based on our 
analysis, the CCM strategy through DOC in a military-based setting appears to be a good-value 
care for diabetes, but unfortunately further data on DOC do not exist since it was closed in 2009 
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due to considerations on military priorities.  We recognize that the cost-effectiveness of an 
intervention should not solely determine its application; at the same time, however, cost-
effectiveness should be one of several factors when considering the delivery of high-value, cost-
conscious health care (68).  Furthermore, the goal of policy should be to preserve the delivery of 
interventions that do have good value (69). 
Like all modeling efforts (70), the computational model developed here has several 
limitations.  First, interpretations of study results are contingent on data quality and model 
assumptions.  Second, subjects in this analysis were representative of the diabetes population in a 
military community, although they may not be fully generalizable to other populations or health 
care settings.  Third, our effectiveness data were not from a randomized controlled trial, resulting 
in differences in baseline characteristics, but our analyses adjusted for significant differences in 
demographics and clinical characteristics at baseline.  Fourth, assuming an identical risk of 
disease progression for DOC and UC patients with diabetes complications was a conservative 
strategy that potentially biases the model against the CCM effect.  Fifth, because there is no 
empirical utility data, we applied the same literature-based utility weights to both strategies, 
which again may underestimate the CCM’s potential to improve quality of life (13,34,35).  
Lastly, our base case analysis was assumed to model the cost-effectiveness over a 20-year time 
frame; however, the base case ICERs over shorter time horizons, e.g. at five years 
($189,138/QALY) and ten years ($87,092/QALY), are still below the currently suggested cost-
effectiveness thresholds for modern health care (67). 
Status quo is not an option; reforms at the delivery system level are imperative to address 
significant lapses in quality of care as well as the high and rapidly increasing cost of care 
(71,72).  One potentially important tool for slowing the growth of health care expenditures is 
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reliable information regarding the cost-effectiveness of alternative interventions.  Information on 
the cost-effectiveness of implementing the CCM strategy for diabetes care is just beginning to 
emerge, and our study adds evidence to document that, compared to UC, the CCM strategy 
provides greater health benefits at an attractive cost.  From the perspective of a health care 
system or society, the CCM strategy provides good value.  When the CCM strategy is used for 
diabetes care in the military-based setting, not only is it effective in improving patient outcomes, 
but it is also an economically reasonable, promising investment. 
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8.7 TABLES AND TABLE LEGENDS 
 
Table 8.1 Parameters used in UKPDS risk equations and the Markov decision model 
 
Parameter used in UKPDS risk equations (based on 1,417 diabetic patients surviving 
without diabetes complications at study end) 
DOC (n=196) UC (n=1,221) 
Adjusted mean A1C (%)a 6.8 7.1 
Adjusted mean SBP (mmHg)a 128.4 130.2 
Adjusted mean total cholesterol (mg/dL)a 173.7 185.0 
Adjusted mean HDLc (mg/dL)a 49.6 48.2 
Adjusted mean LDLc (mg/dL)a 94.7 104.0 
Gender M: 100 (51.0%); F: 96 (49.0%) M: 506 (41.4%); F: 715 (58.6%) 
Age at study end (years)b 50 50 
Race (White/Afro-Caribbean/Asian-Indian)c Assumption Assumption 
Weight (kg)d 88.8 88.8 
Height (cm)d 167.9 167.9 
BMI (kg/m2)d 31.4 31.4 
Smoking status (Nonsmoker/Ex-smoker/Current Smoker)e Assumption Assumption 
Creatinine clearance <100 ml/min (Yes/No)f Assumption Assumption 
Atrial fibrillation (Yes/No)g Assumption Assumption 
Macroalbuminuria (Yes/No)h No No 
Microalbuminuria (Yes/No)i No No 
Duration of diabetesj Assumption Assumption 
Parameter used in the Markov decision model (based on all 9,405 diabetic patients) DOC (n=1,171) UC (n=8,234) 
Diabetes complications at study end, n (%)   
   No complications 196 (16.93) 1,221 (15.11) 
   Microvascular complications only 678 (58.55) 3,165 (39.18) 
   Macrovascular complications only 27 (2.33) 302 (3.74) 
   Micro- and macrovascular complications 257 (22.19) 3,391 (41.97) 
Adjusted mean yearly number of primary care visits per patient (SE; 95% CI; median)k 2.7 (0.2; 2.3-3.1; 2.0) 3.9 (0.1; 3.7-4.1; 3.0) 
Adjusted mean yearly number of specialty care visits per patient (SE; 95% CI; median)k 15.3 (0.4; 14.4-16.1; 9.0) 16.1 (0.3; 15.6-16.7; 10.3) 
Adjusted mean yearly number of A1C tests per patient (SE; 95% CI) 2.6 (0.04; 2.58-2.72) 2.1 (0.02; 2.07-2.17) 
Adjusted mean yearly number of lipid panel tests per patient (SE; 95% CI) 2.1 (0.03; 2.03-2.15) 1.6 (0.02; 1.55-1.63) 
Abbreviations: UKPDS, United Kingdom Prospective Diabetes Study; DOC, Diabetes Outreach Clinic; UC, usual care; A1C, glycated hemoglobin; SBP, 
systolic blood pressure; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol; M, male; F, female; BMI, body mass index. 
aThe mean value of each clinical data was adjusted for age at study entry, A1C at baseline, and gender. 
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bThe mean age at study end from 1,417 patients was used in the model. 
cWhite population was assumed for the base case analysis. 
dThe most current post-study data (mean weight, height, and BMI) from 1,417 patients were used in the model. 
ePatients were assumed to be non-smokers (since less than 10% of our population was the current smoker) for the base case analysis. 
fPatients were assumed to have creatinine clearance <100 ml/min for the base case analysis. 
gPatients were assumed to have no atrial fibrillation (since no DOC patients had atrial fibrillation and only 15 (1.2%) UC patients had atrial fibrillation) for the 
base case analysis. 
hPatients had no macroalbuminuria for the base case analysis. 
iPatients had no microalbuminuria for the base case analysis. 
jThe mean duration of diabetes for patients was assumed to be 5 years. 
kThe mean numbers were used for the base case analysis. 
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Table 8.2 Cost parameters for the Markov decision model 
 
Parameter Value Reference 
 Base case analysis Probabilistic sensitivity 
analysis distributiona 
 
Direct medical costs    
      Annual health care provider costs per patient for diabetes 
      education class and visit 
  DOC data; US Bureau of 
Labor Statistics [56] 
      Costs for GDC for the DOC and UC strategies, US$   
            Endocrinologist 23 Uniform (11 to 34) 
            Registered nurse/Certified diabetes educator 20 Uniform (16 to 24) 
            Exercise physiologist 8 Uniform (4 to 11) 
      Costs for DIGMA visit for the DOC strategy, US$   
            Endocrinologist/Nurse practitioner 32 Uniform (16 to 48) 
            Rotated staff 16 Uniform (14 to 20) 
            Medical assistant 8 Uniform (6 to 9) 
      Annual costs of laboratory tests and physician office visits 
      per patient 
  DOC data; CMS [55] 
      Costs for laboratory tests, US$   
            Glycated hemoglobin   
                  DOC 47 Uniform (24 to 71) 
                  UC 38 Uniform (19 to 57) 
            Lipid panel   
                  DOC 53 Uniform (27 to 80) 
                  UC 41 Uniform (20 to 61) 
      Costs for physician office visits, US$   
            Primary care   
                  DOC 205 Triangular (118 to 371) 
                  UC 301 Triangular (170 to 536) 
            Specialty care   
                  DOC 1,035 Triangular (666 to 2,101) 
                  UC 1,149 Triangular (700 to 2,211) 
      One-time and annual costs of complications per patient   CDC Diabetes Cost-
Effectiveness Group [57]       One-time costs, US$   
            No complications 0 Not varied 
            Microvascular complications 2,165 Triangular (333 to 3,999) 
            Macrovascular complications 3,713 Log normal (0 to 37,924) 
                                
 
 
 
 
173 
            Microvascular and macrovascular complications 5,878 Log normal (333 to 41,923) 
      Annual costs, US$   
            No complications 0 Not varied 
            Microvascular complications 6,264 Triangular (3,133 to 9,397) 
            Macrovascular complications 1,518 Log normal (0 to 12,914) 
            Microvascular and macrovascular complications 7,783 Log normal (3,133 to 22,311) 
      One-time costs of death per patient   CDC Diabetes Cost-
Effectiveness Group [57]       Age<65 years, US$ 14,199 Not varied 
      Age=65-74 years, US$ 14,356 Not varied 
Direct nonmedical costs    
      Annual time costs per patient   DOC data; US Bureau of 
Labor Statistics [56]; 
Smith et al. [58] 
      Costs for physician office visits, US$   
            Primary care   
                  DOC 191 Not varied 
                  UC 276 Not varied 
            Specialty care   
                  DOC 1,085 Not varied 
                  UC 1,142 Not varied 
      Costs for GDC for the DOC and UC strategies, US$ 71 Not varied 
      Costs for DIGMA visit for the DOC strategy, US$ 89 Not varied 
      Annual monetary costs per patient   DOC data; US Bureau of 
Labor Statistics [56]; 
Smith et al. [58] 
      Costs for physician office visits, US$   
            Primary care   
                  DOC 10 Not varied 
                  UC 15 Not varied 
            Specialty care   
                  DOC 58 Not varied 
                  UC 61 Not varied 
      Costs for GDC for the DOC and UC strategies, US$ 15 Not varied 
      Costs for DIGMA visit for the DOC strategy, US$ 11 Not varied 
Abbreviations: DOC, Diabetes Outreach Clinic; GDC, Group Diabetes Class; DIGMA, Drop-In Group Medical Appointments; UC, usual care; CMS, Centers for 
Medicare and Medicaid Services. 
aUniform (a to b)=uniform distribution (minimum to maximum); Triangular (a to b)=triangular distribution (minimum to maximum); Log normal (a to b)=log 
normal distribution (95% CI). 
 
Table 8.2 (Continued) 
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Table 8.3 Parameters of health utilities and discount rates for the Markov decision model 
Parameter Value Reference 
 Base case 
analysis 
Probabilistic sensitivity 
analysis distributiona 
 
Health utilities   Coffey et al. [59] 
      Diabetes without complications 0.689 Normal (0.662 to 0.716) 
      Diabetes with microvascular complications 0.599 Uniform (0.519 to 0.678) 
      Diabetes with macrovascular complications 0.631 Uniform (0.617 to 0.645) 
      Diabetes with microvascular and macrovascular complications 0.599 Uniform (0.519 to 0.678) 
Discount rates    
      Discount rate applied to costs, % 3.00 (2.00 to 5.00)b Assumption 
      Discount rate applied to quality-adjusted life-expectancy, % 3.00 (2.00 to 5.00)b Assumption 
aNormal (a to b)=normal distribution (95% CI); Uniform (a to b)=uniform distribution (minimum to maximum). 
b(a to b)=(minimum to maximum). This parameter was not varied in the probabilistic sensitivity analysis. 
 
Table 8.4 Incremental cost-effectiveness of cost per quality-adjusted life-year by strategies from the base case analysis and three one-way 
sensitivity analyses over a 20-year time horizon of model 
Scenario Strategy Cost (US$) Incremental cost (US$) Effectiveness 
(QALYs) 
Incremental effectiveness 
(QALYs) 
ICER (Cost per 
QALY) 
Base case 
analysis 
UC $116,242 - 8.351 - - 
DOC $121,553 $5,311 8.467 0.117 $45,495 
Societal 
perspectivea 
UC $137,084   - 8.351  -  - 
DOC $141,993  $4,909 8.467 0.117 $42,051  
Mirror the 
DOC cohortb 
UC $152,647   - 7.236  -  - 
DOC $157,859  $5,212  7.321 0.085 $61,243  
Mirror the UC 
cohortc 
UC $153,333 - 7.214 - - 
DOC $158,552 $5,219 7.299 0.084 $61,813 
Abbreviations: DOC, Diabetes Outreach Clinic; UC, usual care; QALYs, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio. 
aThe ICER of cost per QALY was calculated from the societal perspective. 
bInitial proportions of patients in five heath states at the start of the model were changed to mirror the DOC cohort, and then the ICER of cost per 
QALY was calculated from the societal perspective. 
cInitial proportions of patients in five heath states at the start of the model were changed to mirror the UC cohort, and then the ICER of cost per 
QALY was calculated from the societal perspective. 
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8.8 FIGURES 
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Figure 8.1 Markov-state diagram for the basic model structure 
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Figure 8.2 One-way sensitivity analyses for the Diabetes Outreach Clinic (DOC) and usual care (UC) strategy 
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Figure 8.3 Probabilistic (second-order Monte Carlo) sensitivity analysis for the Diabetes Outreach Clinic (DOC) and usual 
care (UC) strategy 
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8.9 FIGURE LEGENDS 
 
Figure 8.1 Markov-state diagram for the basic model structure 
Ovals indicate health states. Subjects may remain within a health state (short curved arrow) or 
may move to a different health state (straight arrow or long curved arrow). 
 
Figure 8.2 One-way sensitivity analyses for the Diabetes Outreach Clinic (DOC) and usual 
care (UC) strategy 
One-way sensitivity analyses of parameters whose variations changed the base case incremental 
cost-effectiveness ratio (ICER; x-axis) by more than 20%. Horizontal bars depicted the range of 
incremental cost-effectiveness ratios corresponding to the values shown in each parameter. The 
vertical dotted line depicted the base case ICER. Variation of all other parameters not shown in 
the figure did not increase the ICER above $50,000 per quality-adjusted life-year (QALY). 
 
Figure 8.3 Probabilistic (second-order Monte Carlo) sensitivity analysis for the Diabetes 
Outreach Clinic (DOC) and usual care (UC) strategy 
The acceptability curve depicted the likelihood of the DOC or UC strategy being favored for a 
given cost-effectiveness acceptability threshold (willingness to pay). 
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8.10 SUPPLEMENTAL TABLES 
Table 8.5 Changes in demographic, clinical, and medical utilization characteristics by two intervention strategies in all 9,405 diabetic patients 
Characteristic DOC (n=1,171) UC (n=8,234) P value for 
baseline 
comparisonb 
Adjusted P value 
for follow-up 
comparisonc 
Baseline Follow-up Baseline Follow-up
Demographic characteristics
Mean age at study entry (SD), years 55.5 (9.2) --- 62.3 (14.3) --- <.001 --- 
Gender, n (%) .07 --- 
   Female 516 (44.1) --- 3,864 (46.9) --- 
   Male 655 (55.9) --- 4,370 (53.1) --- 
Race, n (%) .50 --- 
   White 370 (31.6) --- 1,399 (17.0) --- 
   Non-White 193 (16.5) --- 780 (9.5) --- 
   Missing 608 (51.9) --- 6,055 (73.5) --- 
Mean weight (SD), kg --- 94.5 (21.8) --- 88.4 (21.5) --- --- 
Mean height (SD), cm --- 169.9 (10.9) --- 169.1 (10.7) --- --- 
Mean BMI (SD), kg/m2 --- 32.6 (6.3) --- 30.9 (6.7) --- --- 
Insulin usage, n (%) .001 .07 
   Yes 293 (25.0) 394 (33.6) 1,625 (19.7) 2,324 (28.2) 
   No 874 (74.6) 774 (66.1) 6,124 (74.4) 5,667 (68.8) 
   Missing 4 (0.3) 3 (0.3) 485 (5.9) 243 (3.0) 
Clinical characteristics
Mean A1C (SD), % 7.8 (1.6) 7.2 (1.2) 7.0 (1.4) 7.0 (1.3) <.001 <.001
Mean SBP (SD), mmHg 129.8 (18.5) 131.4 (14.9) 126.6 (12.8) 132.7 (15.3) .18 <.001
Mean DBP (SD), mmHg 79.4 (10.1) 77.4 (8.9) 78.4 (9.1) 75.2 (8.4) .42 .41 
Mean total cholesterol (SD), mg/dL 176.0 (33.8) 164.4 (31.4) 170.1 (35.4) 165.7 (33.1) <.001 <.001
Mean HDLc (SD), mg/dL 48.9 (12.7) 47.9 (12.0) 49.7 (12.7) 49.5 (12.2) .08 .02
Mean LDLc (SD), mg/dL 94.1 (27.8) 87.6 (24.9) 89.0 (27.8) 86.4 (26.4) <.001 <.001
Diabetes complications, n (%) <.001 <.001 
   No complications 522 (44.6) 196 (16.7) 3,007 (36.5) 1,221 (14.8) 
Microvascular complications onlya 477 (40.7) 678 (57.9) 2,656 (32.3) 3,165 (38.4) 
Macrovascular complications onlya 46 (3.9) 27 (2.3) 656 (8.0) 302 (3.7) 
Micro- and macrovascular complicationsa 115 (9.8) 257 (21.9) 1,605 (19.5) 3,391 (41.2) 
   Missing 11 (0.9) 13 (1.1) 310 (3.8) 155 (1.9) 
Medical utilization characteristics
Mean yearly number of hospitalizations per patient (SD) 1.6 (1.2) 1.5 (1.0) 1.9 (1.7) 2.0 (1.6) <.001 .12 
Mean yearly number of primary care visits per patient (SD) 3.7 (2.9) 2.6 (2.5) 4.2 (3.9) 3.9 (4.2) <.001 <.001
Mean yearly number of specialty care visits per patient (SD) 10.5 (11.8) 11.9 (9.9) 14.2 (15.0) 15.0 (14.9) <.001 .06 
Mean yearly number of dispensed medications per prescription 
per patient (SD) 
2.8 (1.2) 2.6 (1.1) 2.3 (1.0) 2.3 (0.9) <.001 .09 
Mean yearly number of dispensed medications per patient (SD) 16.7 (8.5) 16.0 (7.2) 16.0 (9.1) 16.9 (8.5) .006 <.001
Mean yearly number of A1C tests per patient (SD) 2.4 (1.3) 2.6 (1.0) 2.1 (1.2) 1.9 (0.9) <.001 <.001
Mean yearly number of lipid panel tests per patient (SD) 2.0 (1.1) 2.1 (1.0) 1.7 (1.0) 1.5 (0.7) <.001 <.001
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Abbreviations: WHMC, Wilford Hall Medical Center; DOC, Diabetes Outreach Clinic; UC, usual care; SD, standard deviation; BMI, body mass index; A1C, glycated 
hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol. 
aMicrovascular complications included retinopathy, neuropathy, or nephropathy, while macrovascular complications included coronary heart disease (fatal or non-fatal myocardial 
infarction, sudden death, angina, ischemic heart disease, heart failure) or stroke (fatal or non-fatal stroke). 
bP value was derived from two-sample t test or chi-square test for comparing non-missing data in 2 study groups. 
cP value was derived from multiple linear or logistic regression analysis for comparing non-missing data in 2 study groups. Significant baseline demographic and clinical 
characteristics were adjusted in all analyses, while significant baseline medical utilization characteristics were only adjusted when analyzing each follow-up medical utilization 
characteristic. 
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Table 8.6 Changes in demographic, clinical, and medical utilization characteristics by two intervention strategies in the 1,417 diabetic patients surviving 
without diabetes complications at study end 
 
Characteristic DOC (n=196) UC (n=1,221) P value for 
baseline 
comparisona 
Adjusted P value 
for follow-up 
comparisonb 
 Baseline Follow-up Baseline Follow-up   
Demographic characteristics       
Mean age at study entry (SD), years 51.1 (10.1) --- 47.3 (14.2) --- <.001 --- 
Gender, n (%)     .01 --- 
   Female 96 (49.0) --- 715 (58.6) --- 
   Male 100 (51.0) --- 506 (41.4) --- 
Race, n (%)     .06 --- 
   White 70 (35.7) --- 322 (26.4) --- 
   Non-White 24 (12.2) --- 178 (14.6) --- 
   Missing 102 (52.0) --- 721 (59.0) --- 
Mean weight (SD), kg --- 90.0 (19.6) --- 88.6 (21.8) --- --- 
Mean height (SD), cm --- 169.1 (10.3) --- 167.7 (10.6) --- --- 
Mean BMI (SD), kg/m2 --- 31.4 (5.6) --- 31.4 (7.0) --- --- 
Insulin usage, n (%)     .21 .02 
   Yes 28 (14.3) 37 (18.9) 113 (9.3) 220 (18.0) 
   No 167 (85.2) 158 (80.6) 898 (73.6) 967 (79.2) 
   Missing 1 (0.5) 1 (0.5) 210 (17.2) 34 (2.8) 
Clinical characteristics       
Mean A1C (SD), % 7.8 (1.8) 7.2 (1.5) 6.8 (1.5) 7.0 (1.5) <.001 .004 
Mean SBP (SD), mmHg 121.8 (14.2) 130.3 (15.3) 126.1 (12.8) 129.2 (13.4) .11 .29 
Mean DBP (SD), mmHg 76.0 (9.5) 79.4 (9.5) 77.5 (8.7) 78.5 (7.7) .42 .58 
Mean total cholesterol (SD), mg/dL 183.9 (32.2) 172.8 (30.6) 183.5 (34.3) 184.3 (33.2) .92 .002 
Mean HDLc (SD), mg/dL 49.6 (13.3) 49.4 (12.6) 49.7 (11.6) 49.4 (11.6) .94 .27 
Mean LDLc (SD), mg/dL 100.7 (28.3) 93.2 (25.8) 102.1 (27.6) 102.3 (27.7) .61 .002 
Medical utilization characteristics       
Mean yearly number of hospitalizations per patient (SD) 1.5 (1.2) 1.3 (0.6) 1.5 (1.1) 1.3 (0.7) .99 .95 
Mean yearly number of primary care visits per patient (SD) 3.1 (2.0) 2.0 (1.4) 3.5 (2.8) 3.0 (2.1) .04 .004 
Mean yearly number of specialty care visits per patient (SD) 7.1 (9.1) 7.2 (4.8) 8.7 (11.1) 8.1 (9.0) .04 .51 
Mean yearly number of dispensed medications per prescription 
per patient (SD) 
2.6 (1.1) 2.6 (1.3) 2.1 (0.9) 2.2 (0.9) <.001 .38 
Mean yearly number of dispensed medications per patient (SD) 13.6 (6.3) 12.1 (5.1) 10.5 (7.2) 11.1 (6.2) <.001 .46 
Mean yearly number of A1C tests per patient (SD) 2.0 (1.1) 2.2 (0.9) 1.8 (1.1) 1.7 (0.8) .03 <.001 
Mean yearly number of lipid panel tests per patient (SD) 1.9 (1.0) 1.7 (0.8) 1.7 (0.9) 1.4 (0.6) .04 <.001 
Abbreviations: WHMC, Wilford Hall Medical Center; DOC, Diabetes Outreach Clinic; UC, usual care; SD, standard deviation; BMI, body mass index; A1C, glycated 
hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDLc, high-density lipoprotein cholesterol; LDLc, low-density lipoprotein cholesterol. 
aP value was derived from the two-sample t test or chi-square test for comparing non-missing data in 2 study groups. 
                                
182 
 
bP value was derived from multiple linear or logistic regression analysis for comparing non-missing data in 2 study groups. Significant baseline demographic and clinical 
characteristics were adjusted in all analyses, while significant baseline medical utilization characteristics were only adjusted when analyzing each follow-up medical utilization 
characteristic. 
 
 
Table 8.7 Annual transition probability of developing CHD, stroke, nephropathy, neuropathy, and retinopathy in diabetic patients without any 
complications 
 
Year Fatal CHD Nonfatal CHD Fatal stroke Nonfatal stroke Nephropathy Neuropathy Retinopathy 
DOC UC DOC UC DOC UC DOC UC DOC UC DOC UC DOC UC 
1 0.0013 0.0017 0.0029 0.0034 0.0001 0.0001 0.0009 0.0009 0.0135 0.0142 0.0350 0.0348 0.0555 0.0603 
2 0.0015 0.0019 0.0030 0.0036 0.0001 0.0001 0.0010 0.0010 0.0152 0.0160 0.0515 0.0512 0.0624 0.0678 
3 0.0017 0.0022 0.0031 0.0037 0.0001 0.0002 0.0011 0.0012 0.0163 0.0171 0.0601 0.0598 0.0668 0.0725 
4 0.0020 0.0025 0.0032 0.0038 0.0002 0.0002 0.0013 0.0013 0.0171 0.0179 0.0665 0.0661 0.0701 0.0761 
5 0.0023 0.0029 0.0033 0.0039 0.0002 0.0002 0.0015 0.0015 0.0177 0.0186 0.0715 0.0711 0.0727 0.0790 
6 0.0026 0.0033 0.0034 0.0040 0.0002 0.0002 0.0017 0.0018 0.0183 0.0192 0.0757 0.0752 0.0750 0.0814 
7 0.0029 0.0037 0.0035 0.0041 0.0002 0.0003 0.0019 0.0020 0.0188 0.0197 0.0793 0.0788 0.0769 0.0836 
8 0.0033 0.0042 0.0036 0.0042 0.0003 0.0003 0.0022 0.0023 0.0192 0.0202 0.0824 0.0819 0.0787 0.0854 
9 0.0038 0.0047 0.0037 0.0042 0.0003 0.0003 0.0025 0.0026 0.0196 0.0206 0.0852 0.0847 0.0802 0.0871 
10 0.0042 0.0053 0.0037 0.0043 0.0004 0.0004 0.0029 0.0030 0.0199 0.0210 0.0877 0.0871 0.0817 0.0887 
11 0.0048 0.0059 0.0038 0.0043 0.0004 0.0004 0.0033 0.0035 0.0203 0.0213 0.0899 0.0894 0.0830 0.0901 
12 0.0053 0.0066 0.0038 0.0044 0.0005 0.0005 0.0038 0.0040 0.0206 0.0216 0.0920 0.0914 0.0842 0.0914 
13 0.0060 0.0074 0.0038 0.0044 0.0005 0.0006 0.0043 0.0045 0.0208 0.0219 0.0938 0.0932 0.0853 0.0926 
14 0.0066 0.0082 0.0038 0.0044 0.0006 0.0007 0.0049 0.0052 0.0211 0.0222 0.0955 0.0949 0.0864 0.0938 
15 0.0074 0.0091 0.0038 0.0043 0.0007 0.0008 0.0056 0.0059 0.0214 0.0224 0.0970 0.0965 0.0874 0.0948 
16 0.0082 0.0101 0.0038 0.0043 0.0008 0.0009 0.0065 0.0068 0.0216 0.0227 0.0984 0.0979 0.0883 0.0959 
17 0.0090 0.0111 0.0038 0.0042 0.0009 0.0010 0.0074 0.0078 0.0218 0.0229 0.0998 0.0993 0.0892 0.0968 
18 0.0100 0.0122 0.0037 0.0042 0.0010 0.0011 0.0084 0.0089 0.0220 0.0231 0.1010 0.1005 0.0900 0.0977 
19 0.0110 0.0134 0.0037 0.0041 0.0011 0.0013 0.0096 0.0101 0.0222 0.0234 0.1021 0.1017 0.0909 0.0986 
20 0.0120 0.0146 0.0036 0.0040 0.0013 0.0014 0.0110 0.0116 0.0224 0.0236 0.1031 0.1028 0.0916 0.0994 
Abbreviations: CHD, coronary heart disease; DOC, Diabetes Outreach Clinic; UC, usual care. 
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Table 8.8 Annual transition probability of death and of developing macro- or microvascular complications in diabetic patients without any 
complications 
 
Year Death from any causea,b Development of macrovascular complications in 
patients staying livea 
Development of microvascular complications with 
or without macrovascular complicationsa 
DOC UC DOC UC DOC UC 
1 0.0022 0.0028 0.0038 0.0043 0.1010 0.1061 
2 0.0025 0.0032 0.0040 0.0046 0.1244 0.1300 
3 0.0029 0.0036 0.0042 0.0049 0.1375 0.1434 
4 0.0033 0.0042 0.0045 0.0052 0.1472 0.1533 
5 0.0038 0.0047 0.0048 0.0055 0.1549 0.1611 
6 0.0043 0.0054 0.0051 0.0058 0.1613 0.1678 
7 0.0049 0.0061 0.0055 0.0062 0.1669 0.1735 
8 0.0055 0.0069 0.0058 0.0065 0.1718 0.1785 
9 0.0063 0.0078 0.0062 0.0069 0.1762 0.1830 
10 0.0071 0.0088 0.0066 0.0074 0.1802 0.1871 
11 0.0079 0.0098 0.0071 0.0079 0.1838 0.1909 
12 0.0089 0.0110 0.0076 0.0084 0.1872 0.1944 
13 0.0100 0.0123 0.0082 0.0090 0.1903 0.1977 
14 0.0111 0.0137 0.0088 0.0097 0.1932 0.2007 
15 0.0124 0.0152 0.0096 0.0104 0.1959 0.2036 
16 0.0138 0.0168 0.0104 0.0112 0.1985 0.2064 
17 0.0152 0.0185 0.0113 0.0122 0.2010 0.2090 
18 0.0169 0.0204 0.0123 0.0133 0.2034 0.2115 
19 0.0186 0.0225 0.0135 0.0145 0.2056 0.2140 
20 0.0205 0.0247 0.0149 0.0159 0.2078 0.2164 
Abbreviations: DOC, Diabetes Outreach Clinic; UC, usual care. 
aMicrovascular complications included retinopathy, neuropathy, or nephropathy, while macrovascular complications included coronary heart disease or stroke. 
We assumed that (1) retinopathy, neuropathy, and nephropathy are independent but not mutually exclusive events, (2) coronary heart disease and stroke are 
independent but not mutually exclusive events, and (3) micro- and macrovascular complications are independent but not mutually exclusive events. 
bWe assumed that deaths from coronary heart disease or stroke account for 65% of all deaths in diabetes patients. 
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Table 8.9 Annual transition probability of disease progression in diabetic patients with microvascular complications only and those with macrovascular 
complications only 
 
Parameter Value Reference 
 Base case analysis Probabilistic sensitivity 
analysis distributiona 
 
Annual probability of disease progression in DOC and UC 
patients with microvascular complications only 
  Zoungas et al. [54] 
      Development of macrovascular complications 0.1271 Beta (0.0330 to 0.2720) 
Annual probability of disease progression in DOC and UC 
patients with macrovascular complications only 
  Zoungas et al. [54] 
      Development of microvascular complications 0.0649 Beta (0.0182 to 0.1389) 
Abbreviations: DOC, Diabetes Outreach Clinic; UC, usual care. 
aBeta (a to b)=beta distribution (95% CI). 
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Table 8.10 Annual death probability in diabetic patients with microvascular complications only, those with macrovascular complications only, and 
those with both complications 
 
Year Death from any cause in diabetes patients with microvascular complications only, those with macrovascular complications only, and 
those with both complicationsa 
DOC UC 
1 0.0202 0.0208 
2 0.0206 0.0212 
3 0.0209 0.0217 
4 0.0213 0.0222 
5 0.0218 0.0228 
6 0.0223 0.0234 
7 0.0229 0.0241 
8 0.0235 0.0249 
9 0.0242 0.0258 
10 0.0250 0.0267 
11 0.0259 0.0278 
12 0.0268 0.0289 
13 0.0279 0.0301 
14 0.0290 0.0315 
15 0.0303 0.0330 
16 0.0316 0.0346 
17 0.0331 0.0363 
18 0.0347 0.0382 
19 0.0364 0.0402 
20 0.0382 0.0423 
Abbreviations: DOC, Diabetes Outreach Clinic; UC, usual care. 
aThe death probability for diabetes patients with complications was an additive probability by adding the constant risk of death to the age- and strategy-specific 
risk of death for diabetes patients without complications. The constant risk of death was based on medical literature (Zoungas et al. [54]), while the age- and 
strategy-specific risk of death for diabetes patients without complications was calculated using the United Kingdom Prospective Diabetes Study risk equations 
[51-53; http://www.dtu.ox.ac.uk/riskengine/]. 
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Table 8.11 Medication costs of diabetes control, hypertension control, and cholesterol control for the Markov decision model 
 
Medication cost Diabetes control Hypertension control Cholesterol control Reference 
DOC UC DOC UC DOC UC 
Year 1 188.01 43.88 693.08 207.20 1602.24 1602.24 CDC Diabetes Cost-
Effectiveness Group [57] Year 2 226.41 78.36 734.94 255.72 1602.24 1602.24 
Year 3 260.21 126.21 770.70 269.23 1602.24 1602.24 
Year 4 304.72 178.98 780.95 275.46 1602.24 1602.24 
Year 5 352.12 243.40 785.76 288.32 1602.24 1602.24 
Year 6 398.10 298.25 796.34 291.57 1602.24 1602.24 
Year 7 421.18 341.62 815.28 353.06 1602.24 1602.24 
Year 8 462.17 387.32 810.50 353.06 1602.24 1602.24 
Year 9 486.83 415.46 833.91 428.45 1602.24 1602.24 
Year 10 509.89 452.13 833.91 428.45 1602.24 1602.24 
Year 11 533.44 538.77 833.91 428.45 1602.24 1602.24 
Year 12 556.84 564.80 833.91 428.45 1602.24 1602.24 
Year 13 558.78 577.45 833.91 428.45 1602.24 1602.24 
Year 14 560.72 577.45 833.91 428.45 1602.24 1602.24 
Year 15 and up 564.58 577.45 833.91 428.45 1602.24 1602.24 
Abbreviations: DOC, Diabetes Outreach Clinic; UC, usual care. 
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9.1 ABSTRACT 
 
Background:  While Internet-delivered lifestyle interventions are effective for weight control, 
there is limited research on their cost-effectiveness for diabetes prevention and risk reduction in 
primary care settings. 
Methods:  A Markov state-transition model was developed to estimate the cost-effectiveness of 
using an Online adaptation of the Diabetes Prevention Program lifestyle intervention (ODPP) 
compared to usual care to reduce metabolic risk in an overweight/obese cohort (mean age 53) 
over a 10-year time horizon.  Intervention costs and weight change outcomes were obtained from 
a prospective ODPP pilot study; other costs, disease progression data, and utilities were drawn 
from published reports.  In the model, diabetes risk was a function of weight change 
with/without the program. 
Results:  Compared to usual care, the base case incremental cost-effectiveness ratio (ICER) of 
the ODPP in our pilot study cohort (30% with diabetes) was $14,351 and $29,331 per quality-
adjusted life-year (QALY) gained from a health care system or societal perspective, respectively.  
In a hypothetical cohort without diabetes, the ICER was $7,777 and $18,263 per QALY gained, 
respectively.  Results were robust in sensitivity analyses, but enrolling cohorts with lower annual 
risk of developing diabetes (≤1.8%), enrolling fewer participants (≤15), or increasing the hourly 
cost (≥$91.2) or the annual per-participant time required (≥1.45 hours) for ODPP technical 
support could increase the ODPP to cost >$20,000 per QALY gained.  In probabilistic sensitivity 
analyses, the ODPP was cost-effective in 20-58% of model iterations using an acceptability 
threshold of $20,000, 73-92% at $50,000, and 95-99% at $100,000 per QALY gained. 
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Conclusions:  The ODPP delivered in primary care settings for weight management appears to 
be an economically reasonable intervention. 
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9.2 INTRODUCTION 
 
Overweight and obesity are common, serious, and costly.  These conditions are 
complicated, multifactorial diseases that develop from the interaction between genotype and 
the environment (1), and rank prominently among current major public health problems.  
Recent data from the Centers of Disease Control and Prevention show that approximately 69% 
of US adults aged 20 years and older were overweight or obese in 2009-2010, and 36% (over 
78 million) were obese (2,3).  Overweight and obesity are the major risk factors for morbidity 
from a wide range of medical conditions (e.g., type 2 diabetes, cardiovascular diseases, and 
certain types of cancer), social conditions (e.g., discrimination in employment and education 
settings), psychological conditions (e.g., depression), and impaired quality of life (1,4-9).  
Higher body weights are also associated with an increase in mortality from all causes (1).  A 
collaborative analysis of data from almost 900,000 adults in 57 prospective studies estimated 
that optimal survival is achieved at a body mass index (BMI) of 22.5-25 kg/m2 with reduction 
in life expectancy by about 2-4 and 8-10 years for individuals who would become obese (30-35 
kg/m2) and would become morbidly obese (40-50 kg/m2), respectively (10). 
Overweight and obesity are also costly.  It is estimated that medical costs associated 
with adult obesity in the US range from $147 billion to nearly $210 billion per year (11,12).  
People who are classified as obese spend $1,429 (42 percent) more on health care costs 
compared to those of normal-weight.  The additional costs attributable to obesity are almost 
entirely a result of costs generated from treating the diseases that obesity promotes (11,13). 
Development of effective weight loss programs that are widely accessible is a health 
care priority given that overweight and obesity are common.  Further, without intervention, 
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people that are already obese will steadily gain more weight over time.  Also, weight loss is 
recommended to reduce the health and economic impact of obesity (13-15).  Randomized 
controlled trials (RCTs) demonstrate that evidence-based lifestyle interventions leading to 
dietary and physical activity change can produce significant weight loss, reduce the incident 
type 2 diabetes, and improve cardiovascular disease risk factors (16,17).  Existing translational 
studies show that these RCT-based intensive lifestyle interventions can be translated to weight 
loss programs that can be effectively delivered in primary care and community-based settings, 
resulting in a greater weight loss in intervention subjects than in control subjects (18-20).  
Although the individual or group behavioral-based face-to-face programs involving clinic 
visits are the most effective treatment approach available for obesity, they are expensive and 
often inaccessible (21).  Also, most adults would prefer to lose weight without having to 
participate in a structure face-to-face treatment program (22).  To accommodate the needs of 
these individuals and to make the weight control treatment more accessible, an Internet-
delivered intervention allows individuals with barriers including geography, access to 
transportation, or time constraints to participate in these lifestyle interventions. 
Several reviews indicate that the Internet-based lifestyle intervention may be effective 
in facilitating weight control among overweight or obese individuals.  Although the evidence 
for effectiveness is modest due to mixed results, heterogeneity of designs, and limited 
generalizability of findings (23-29), a meta-analysis published by the Cochrane Collaboration 
indicated that online weight loss programs work almost as well as face-to-face interventions 
(30,31).  Moreover, the American Heart Association Scientific Statement suggests that the 
Internet is a vehicle through which lifestyle interventions can be delivered and could be a 
promising tool to promote weight loss (29).   
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One approach to successfully systematic implementation of Internet-based lifestyle 
weight loss programs into an existing health care system is to ensure that they are integrated 
with care delivery, cost-effective, and broadly supported (32,33).  Moreover, policy makers are 
increasingly asking not only whether an obesity intervention works, but also whether it offers 
value given costs (34).  Although current literature demonstrates that most lifestyle 
interventions delivered through a variety of approaches in different settings are among the 
intervention options usually regarded as cost-effective, evidence on the cost-effectiveness of an 
Internet-based lifestyle weight management intervention in coordination with primary care 
delivery is increasing but still relatively limited (17,34-38). 
The parent study (39) used for the current analysis hypothesized that an Online 
adaptation of the Diabetes Prevention Program (DPP) lifestyle intervention (ODPP) could 
facilitate the translation of an evidence-based lifestyle approach into ongoing clinical care in 
primary care practice.  In this analysis, the cost-effectiveness of the ODPP compared with 
usual care was assessed. 
 
9.3 METHODS 
 
Online Adaptation of the Diabetes Prevention Program Lifestyle Intervention (ODPP) at 
University of Pittsburgh Medical Center 
 
The implementation methods and pilot results of the ODPP have been previously 
described (39).  Briefly, the faculty at University of Pittsburgh and University of Pittsburgh 
Medical Center developed the ODPP by translating the DPP’s lifestyle curriculum (40,41) into 
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an online delivery format, which was integrated into primary clinical care.  As people with 
diabetes can also benefit from such a lifestyle curriculum with relatively low-fat, low-calorie diet 
and moderate physical activity recommendations, the curriculum was further adapted to be 
appropriate for this group, incorporating diabetes-related concerns such as the need for careful 
foot care when initiating physical activity and the possibility that weight loss may alter needs for 
antihyperglycemic agents. 
The ODPP comprised 16 weekly and 8 monthly lessons, incorporating behavioral tools 
such as e-mail prompts for online self-monitoring of diet, physical activity, and weight; 
automated weekly progress reports; and links to community resources.  Participants received 
regular, brief, individualized counseling via electronic messaging as the further support.  
Referring physicians were notified of their patients’ progress and were contacted by the health 
coaches whenever health-relevant issues arose. 
At 12 months of follow-up, on average, 50 patients who were enrolled in the ODPP pilot 
study lost 4.94 kg (95% CI: 2.48 to 7.39), had reduced systolic blood pressure by 6.56 mmHg 
(95% CI: 3.39 to 9.73), and had minimally changed diastolic blood pressure (+0.28 mm Hg; 95% 
CI: -2.25 to +2.81) (39).  Outcomes of weight change in the pilot study provided the foundation 
for this cost-effectiveness analysis to compare the ODPP with usual care (without ODPP). 
 
The Framework of a Markov Decision Model 
 
Using TreeAge Pro Suite 2009 (TreeAge Software, Williamstown, MA) decision analysis 
software, a Markov decision model (42) was modified to estimate the incremental cost-
effectiveness of the ODPP.  The model directly incorporated intervention costs and effectiveness 
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from ODPP pilot study (39) to estimate life expectancy, quality-adjusted life-expectancy 
(expressed as quality-adjusted life-years, or QALYs), clinical outcomes, as well as direct 
medical and nonmedical costs associated with the ODPP.  Our base case model examined the 
cohort of 53-year-old adults who participated in the ODPP pilot study at yearly intervals for 10 
years from a health care system perspective.  The incremental cost-effectiveness ratio (ICER) 
was defined as the additional cost of applying the ODPP compared with usual care, divided by 
the additional clinical effectiveness of applying the ODPP compared with usual care.  In the light 
of the reference case recommendations of the Panel on Cost-Effectiveness in Health and 
Medicine (43), future costs and benefits were discounted at 3% annually.  The US Consumer 
Price Index (44) was used to convert all monetary costs to 2010 US dollars. 
 
Basic Model Structure 
 
A four-state Markov decision model was used to analyze the cost-effectiveness of the 
ODPP (Figure 9.1).  The target population included ODPP pilot study participants with a body 
mass index ≥25 kg/m2 and history of at least one weight-related cardiovascular risk factor (e.g., 
hypertension, dyslipidemia, diabetes, or impaired fasting glucose).  At the start of the base case 
model, the proportions of subjects in four health states were set to mirror the cohort in the ODPP 
pilot study.  Over time, subjects could progress to have diabetes without complications (stable 
diabetes), diabetes with complications (complicated diabetes), or die.  In subjects who developed 
diabetes, the transition to complicated diabetes was preceded by a stable diabetes stage.  
Complications from diabetes included retinopathy, nephropathy, neuropathy, coronary heart 
disease, or stroke, and they were assumed to be irreversible.  To be conservative, the ODPP and 
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usual care were assumed to have identical effects on the progression of disease in patients who 
already had stable diabetes, thus implying that the model only examined differences between 
strategies in delaying or preventing the development of stable diabetes.  In the model, subjects in 
all health states can die; rates of death are based on age- and sex-specific US mortality (which 
accounts for baseline mortality) and the relative risks of death for overweight/obesity, stable 
diabetes, and complicated diabetes (45-48). 
Clinical outcomes and progress related to stable and complicated diabetes for both the 
ODPP and usual care were derived from published literature (Table 9.1).  The intervention 
effectiveness of the ODPP on weight change was obtained from the ODPP pilot study (39).  The 
weight change status through usual care was derived from the WiLLoW (Weight Loss through 
Living Well) study (49).  Comparable with the ODPP pilot study, the WiLLoW study was 
conducted by the same research team at the same medical practice setting within the overlapped 
time period, using similar inclusion and exclusion criteria to examine weight change in the 
referral primary care patients who were or were not enrolled to the WiLLoW program.  The 
WiLLoW program was an in-person, group-based version of DPP-based lifestyle curriculum 
which is the same intervention used in the ODPP.  Hence, the non-enrolled group in the 
WiLLoW study could be considered as a usual care group of primary care patients who were 
from the main general internal practice represented in the ODPP pilot study and were referred for 
the DPP-based lifestyle management. 
In the model, the incidence of diabetes as a function of baseline BMI and the odds ratios 
for diabetes risk as a function of weight change were derived from the published reports of 
studying a nationally representative sample of US adults (50,51).  These odds ratios for diabetes 
risk were adjusted for age, baseline BMI, sex, race, education, systolic blood pressure, skinfold 
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ratio and reported change in physical activity (50).  These outcomes and effectiveness data are 
shown in Table 9.1. 
According to patient demographic characteristics, cardiovascular risk factors and 
macrovascular complications, the annual direct medical costs related to stable and complicated 
diabetes were estimated using published data (42,52).  Indirect costs were not included, assuming 
their capture in the assessment of QALYs, per the recommendation of the Panel on Cost-
Effectiveness in Health and Medicine (43).  Patient demographics and ODPP-related intervention 
costs were derived from the ODPP pilot study (39), being shown in Tables 9.1-9.3.  
To account for changes in life expectancy and quality of life for diabetes-related health 
states, we used QALYs which adjust for quality based on a utility weight (or preference) for the 
health state, ranging from 0 (death) to 1 (perfect health).  This utility weight for each health state 
is multiplied by time in that state.  As an individual’s health changes over time, these products 
are summed to represent the total number of QALYs (43). 
 
Sensitivity Analyses   
 
Many new intervention strategies or programs are more costly but also more effective.  In 
such cases, the new strategies may be considered cost-effective if the ICER is below some 
threshold value such that the decision makers deem the added expense is worth the added 
benefits.  However, different decision makers may value benefits differently.  Hence, extensive 
sensitivity analyses were conducted to assess the effect of varying original assumptions made for 
the base case model on the ICERs. 
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First, the base case ICER was estimated using three other clinical effectiveness 
measurements, including incidence of stable diabetes, complicated diabetes, and deaths due to 
stable or complicated diabetes.  Second, the cost-utility was assessed from a societal perspective 
by including the direct nonmedical costs of the ODPP intervention (i.e., costs of participant time 
to partake in the ODPP).  Third, the original assumption that the study cohort was set to mirror 
the ODPP pilot study cohort at the start of the model was tested by starting the model with a 
hypothetical cohort without diabetes and then recalculating the ICER.  Fourth, one-way 
sensitivity analyses were performed for model input parameters (Tables 9.1-9.3) to assess the 
effect of varying parameter estimates within clinically plausible ranges and identify parameters 
whose variation changed the base case ICER ≥20%.  Fifth, the effect of lower and higher overall 
Website-related costs of the ODPP on cost-effectiveness was evaluated.  Sixth, the effect of 
variation in the number of participants enrolled in the ODPP was assessed.  Seventh, a two-way 
sensitivity analysis was performed to evaluate the effect of variation in both overall Website-
related costs of the ODPP and the number of participants enrolled in the ODPP. 
Probabilistic sensitivity analyses were performed from a health care system and a societal 
perspective, where model parameters were simultaneously varied over distributions (Tables 9.1-
9.3).  Distributions for parameters were chosen to reflect the level of certainty and the 
characteristics of the parameter range: Prevalence, incidence, and probability parameters were 
varied over beta distributions; odds ratios and relative risks were varied over normal or log-
normal distributions; utility and cost data were varied over uniform or triangular distributions; 
and cost multipliers were varied over normal distributions.  A value from each parameter’s 
probability distribution was randomly selected during each of 10,000 Monte Carlo iterations, and 
then these values were used to compute the cost-effectiveness among strategies of being studied 
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for each iteration.  The cost-effectiveness acceptability curve (59) was used to summarize results, 
showing the likelihood that a given strategy would be favored for a given acceptability threshold, 
which is defined as the maximum amount that society is willing to pay for an incremental gain in 
health (60). 
 
9.4 RESULTS 
 
Base Case Analysis 
 
The simulated incremental cost-effectiveness analysis results under base case 
assumptions are summarized in Table 9.4.  Over 10 years, the ODPP cost $591 more than usual 
care and produced 0.0412 more QALYs, resulting in an ICER of $14,351 per QALY gained 
from the health care system perspective.  When using the incidence of stable diabetes, 
complicated diabetes, and deaths due to stable or complicated diabetes as the effectiveness 
measurement, the ODPP cost $13,977, $47,889, and $177,109 per case or death averted, 
respectively. 
 
Sensitivity Analyses 
  
When a societal perspective was adopted and the direct nonmedical cost was included, 
the cost of the ODPP increased by $617 and the ICER increased to $29,331 per QALY gained.  
If starting the model with a hypothetical cohort without diabetes, the ODPP cost $7,777 and 
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$18,263 per QALY gained from a health care system and a societal perspective, respectively 
(Table 9.4). 
Table 9.5 and Figure 9.2 show the results of one-way sensitivity analyses, where nine 
parameters whose variations changed the base case ICER ≥20% were identified.  Results were 
robust in one-way sensitivity analyses, but enrolling the cohort with lower annual risk of 
developing diabetes (≤1.8%), enrolling fewer participants (≤15), or increasing the hourly cost 
(≥$91.2) or the annual per-participant time required (≥1.45 hours) for ODPP technical support 
could increase the ODPP to cost >$20,000 per QALY gained.  Variation of all other model 
parameters did not increase the ODPP to cost $20,000 or more per QALY gained.  
Two components (i.e., hourly cost billed for providing and participant time for requiring 
technical support of the ODPP) of the Website-related costs for the ODPP and the number of 
participants enrolled in the ODPP were amongst the most influential variables in the base case 
analysis and were the parameters that we could modify (Table 9.5 and Figure 9.2).  Therefore, 
two separate one-way sensitivity analyses and a two-way sensitivity analysis were performed to 
examine the effect of their variations on the base case ICER.  If the overall Website-related costs 
for the ODPP were set at low-range estimates, the ODPP relative to usual care could be cost-
saving.  When these Website-related costs for the ODPP were even doubled, the ODPP was still 
favored, costing less than $55,000 per QALY gained (Table 9.6a and Figure 9.3a).  Furthermore, 
enrolling more participants in the ODPP would reduce the costs of the ODPP, resulting in more 
favored ICERs.  If the ODPP is implemented in a group of 16 participants or greater, the ODPP 
relative to usual care would cost less than $20,000 per QALY gained (Table 9.6b and Figure 
9.3b).  Results of the two-way sensitivity analysis on the overall Website-related costs of the 
ODPP and the number of participants enrolled in the ODPP are shown in Table 9.6c.  When the 
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ODPP enrolled 100 participants or more, the ODPP was favored at a willingness-to-pay 
threshold of $20,000, $50,000, and $53,000 per QALY if the overall Website-related costs were 
≤19%, 91%, and 100% higher than the base case costs, respectively. 
A probabilistic sensitivity analysis of base case results is presented as a cost-effectiveness 
acceptability curve (Figure 9.4), showing the proportion of cost-effectiveness calculations that 
would be considered acceptable from a health care system and a societal perspective for various 
willingness-to-pay (or acceptability) thresholds.  The ODPP was more likely to be favored with 
an acceptability threshold ≥$17,500 and $35,000 per QALY gained from a health care system 
and a societal perspective, respectively.  At a threshold of $20,000, $50,000, and $100,000 per 
QALY gained, the ODPP was favored in 20-58%, 73-92%, and 95-99% of model iterations from 
a health care system and a societal perspective, respectively. 
 
9.5 DISCUSSION 
 
 As the prevalence of obesity continues to rise, the need for practical, easily disseminated 
and effective weight control programs for overweight or obese people is increasingly important.  
Internet-based interventions may serve as an efficient and cost-effective approach to meet this 
growing public health need (31).  Although start-up and sustainability costs may be high and 
require consideration in relation to a program’s effectiveness, Internet-based interventions may 
be more economical in the long term (61).  Our analysis showed that, from the perspective of a 
health care system and a society over 10 years, the ODPP delivered in the primary care setting 
compared with usual care was quite cost-effective, costing approximately $14,400 and $29,300 
per QALY gained, respectively. 
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Among those nine sensitive parameters shown in Table 9.5, four of them are worth 
mention.  First, the number of participants enrolled in the ODPP is one of the important 
considerations for keeping the ODPP cost-effective.  Enrollment of 50 participants in the ODPP 
pilot study was very low.  It is expected that as the program becomes more widely available in a 
routine practice clinic or community, the Website-related costs will be spread over a greater 
number of participants and thus total costs of the ODPP will reduce, which is most likely to 
produce a much more favored level of cost-effectiveness.  Second, results were sensitive to the 
participant time required for technical support of the ODPP.  If the online settings and functions 
of the ODPP were problematic frequently and substantially, it may become less cost-effective 
because of higher costs for technical support and potential for reduced intervention benefits.  
Hence, ensuring a stable and reliable online platform is quite important.  Third, some well-
organized orientation and training session(s) to enhance health coaches’ ability to deliver 
counseling in a brief and efficient manner may further assure the cost-effectiveness of the ODPP.  
Lastly, an increasing number of weight management initiatives focus on employing coaches with 
minimal clinical training as a way to cut costs; however, the ODPP was effective for weight 
control using coaches with more clinical knowledge and was still be highly cost-effective despite 
high wages. 
While the participant time spent in the in-person orientation session and the online 
sessions activities were considered, the ODPP still cost less than $30,000 per QALY gained.  
Time investment is necessary for behavior change (i.e., self-monitoring is one of the most 
effective tools to support behavior change, and sustained counseling is one of the best predictors 
of sustained weight loss), and thus it likely cannot be eliminated or even significantly minimized.  
Also, our model could not capture variations in the quality of participation time.  For example, 
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with an online intervention, people can do their lifestyle counseling and behavioral support 
activities at the time/location that is convenient for them (vs. the original DPP where they had to 
make an appointment and travel to have a face-to-face meeting with a counselor), or people may 
feel more active and motivated (vs. the usual care without a lifestyle promotion plan), which 
could bias the analysis against the ODPP.  
Cost per QALY gained and per disability-adjusted life-year (DALY) averted are the two 
most widely used measures in economic evaluations for combining morbidity and mortality into 
one common unit, allowing comparisons across studies.  Four of the published reports (31,61-72) 
used these two measures to evaluate the cost-effectiveness of an Internet-based lifestyle weight 
management intervention and thus were selected for facilitating comparison with our findings.  
These studies suggested that the Internet-based intervention compared with usual care cost (in 
2010 US$) $950-$2,000 (68), $30,400 (64), and $159,500 (70) per QALY gained, or $2,650-
$8,830 per DALY averted (67).  Our estimates of ODPP cost-effectiveness ranged from $7,777 
to $29,331 per QALY gained, confirming most of these studies’ observations that the Internet-
based intervention is at a moderate to high level of cost-effectiveness. 
Most new strategies in diabetes prevention or control are more effective but also costly, 
requiring more incremental resources per QALY gained (52,73).  There are no absolute criteria 
for cost-effectiveness, and the long-cited benchmark of $50,000 per QALY gained is 
unsupported (74,75).  However, in general, interventions costing less than $20,000 per QALY 
gained may be considered as having strong evidence for adoption; interventions costing $20,000 
to $100,000 per QALY gained have moderate evidence; and those costing more than $100,000 
per QALY gained have weaker evidence for adoption (75,76).  In this regard, this study found 
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that the ODPP had strong evidence for implementation in the primary care setting, especially for 
a cohort of participants without diabetes. 
Several limitations should be considered when interpreting these findings.  First, 
interpretations of study results are contingent on data quality and model assumptions.  Second, 
subjects in this analysis were representative of a primary care population in an academic general 
internal medicine practice, and may not be fully generalizable to other populations or health care 
settings.  Third, a ten-year time frame was used to model the cost-effectiveness of the ODPP due 
to uncertainty in the empirical data for long-term effectiveness of weight change on diabetes risk 
(50,51).  However, delaying or preventing type 2 diabetes will delay or prevent incurring the 
direct medical costs of diabetes, including the costs of diabetes education and nutritional 
counseling, glucose monitoring, treatment, surveillance for complications, and treatment of 
complications.  Hence, adopting a ten-year time horizon may overestimate treatment costs and 
underestimate the benefits of the ODPP intervention. 
Several conservative practice and assumptions were used and expected to negatively bias 
our findings.  First, assuming an identical risk of disease progression to have diabetes-related 
complications for subjects with stable diabetes who achieved different magnitude of weight 
gain/loss was a conservative strategy.  This is because our studies showed that the ODPP resulted 
in more participants with larger weight losses, and according to the Look AHEAD (Action for 
Health in Diabetes) study (77), the overweight/obese patients with type 2 diabetes with larger 
weight losses were associated with greater improvements in cardiovascular disease risk factors, 
which may reduce diabetes-related complications.  Thus, this assumption potentially biases the 
model against the ODPP effect.  Second, because there is no empirical utility or mortality data 
from the ODPP intervention, application of the same literature-based utility weights and the 
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same mortality risks to the four health states in the cohorts who achieved different magnitude of 
weight gain/loss may again underestimate the ODPP’s potential to improve quality of life (78-
80) and length of life (1,10).  Third, the health- and cost-generating obesity-related conditions 
used in the current model were only limited to diabetes.  Many other conditions known to be 
obesity-related, as illustrated by increased health and economic burden (4,81), were not 
considered, making our model conservative and biasing against the ODPP effect. 
 An Internet-based lifestyle intervention for weight management may offer a significant 
opportunity to reach individuals who may experience barriers to access interventions for 
addressing overweight or obesity and reducing chronic disease risk factors.  Compared with 
usual care, the ODPP integrated into primary care practice provides greater health benefits at an 
attractive cost and, from the perspective of a financially prudent policy maker, it represents an 
intervention of choice. 
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9.7 TABLES AND TABLE LEGENDS 
 
Table 9.1 Parameters of cohort characteristics, probabilities, odds ratios, relative risks, utilities, costs and multipliers, and 
discount rates for the decision model: Base case values and ranges examined in sensitivity analyses 
 
Parameter Base case value Range examined (PSA 
distribution) 
Source 
Cohort characteristics    
     Starting age, years 53 27–79 (Uniform) ODPP pilot 
study (39) 
 
     Female, % 76.0 7.2–100.0 (Beta) 
     African American, % 8.0 2.1–17.0 (Beta) 
     Angina, % 3.2 0.9–7.0 (Beta) (58) 
     Hypertension, treated, % 64.0 9.2–99.3 (Beta) ODPP pilot 
study (39) 
 
     History of cardiac arrest or MI, % 10.0 2.7–21.6 (Beta) 
     History of stroke, % 2.0 0.5–4.4 (Beta) 
     Peripheral vascular disease, % 0.0 Not varied 
Probabilities and incidence rates     
     Probability of weight change status between baseline and the 12-month 
     follow-up, % 
Usual 
care 
ODPPa   
          Weight loss ≥2.0 kg 24.39 58.00 Not varied 
 
ODPP pilot 
study (39); 
WiLLoW 
study (49) 
          Weight loss 1.5–<2.0 kg 3.66 4.00 
          Weight loss 1.0–<1.5 kg 4.88 0.00 
          Weight loss 0.5–<1.0 kg 1.22 10.00 
          Weight loss 0.1–<0.5 kg 3.66 0.00 
          Weight remained relatively stable (loss or gain <0.1 kg) 20.73 6.00 
          Weight gain 0.1–<0.5 kg 4.88 0.00 
          Weight gain 0.5–<1.0 kg 3.66 6.00 
          Weight gain 1.0–<1.5 kg 4.88 2.00 
          Weight gain 1.5–<2.0 kg 6.10 0.00 
          Weight gain ≥2.0 kg 21.95 14.00 
     Annual probability of developing diabetes in participants whose weight 
     remained relatively stable, %   
2.336 0.620–5.072 (Beta) (50, 51) 
     Annual probability of progressing to complicated diabetes, % 7.500 1.931–16.661 (Beta) (42, 52-54) 
Odds ratios of developing diabetes    
     Weight loss ≥2.0 kg 0.45 0.34–0.60 (Normal) (50) 
      Weight loss 1.5–<2.0 kg 0.55 0.44–0.68 (Normal) 
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     Weight loss 1.0–<1.5 kg 0.67 0.58–0.78 (Normal) 
     Weight loss 0.5–<1.0 kg 0.82 0.76–0.88 (Normal) 
     Weight loss 0.1–<0.5 kg 0.96 0.95–0.97 (Normal) 
     Weight remained relatively stable (loss or gain <0.1 kg) 1.00 Not varied 
     Weight gain 0.1–<0.5 kg 1.04 1.03–1.06 (Normal) 
     Weight gain 0.5–<1.0 kg 1.22 1.13–1.31 (Normal) 
     Weight gain 1.0–<1.5 kg 1.49 1.29–1.73 (Normal) 
     Weight gain 1.5–<2.0 kg 1.82 1.46–2.27 (Normal) 
     Weight gain ≥2.0 kg 2.22 1.66–2.98 (Normal) 
Relative risks of death    
     No diabetes 1.26 1.14–1.39 (Log-normal) (46) 
     Stable diabetes 2.00 1.81–2.21 (Log-normal) (42, 47) 
     Complicated diabetes 2.40 2.18–2.65 (Log-normal) (42, 48) 
Utilities    
     No diabetes 0.880 0.840–0.920 (Uniform) (42, 55) 
     Stable diabetes 0.689 0.662–0.716 (Uniform) (42, 52, 56, 
57)      Complicated diabetes 0.593 0.505–0.681 (Uniform) 
Costs (in 2010 US$) and multipliers    
     No diabetes (annual), $ 780 Not varied (42) 
     Base diabetes cost (annual), $ 2,132 Not varied (42, 52) 
          Multiplier for female 1.25 1.11–1.39 (Normal) 
          Multiplier for African American 0.82 0.69–0.96 (Normal) 
     Base complicated diabetes cost (annual), $ 2,132 Not varied 
          Multiplier for female 1.25 1.11–1.39 (Normal) 
          Multiplier for African American 0.82 0.69–0.96 (Normal) 
          Multiplier for angina 1.73 1.32–2.14 (Normal) 
          Multiplier for hypertension, treated 1.24 1.09–1.40 (Normal) 
          Multiplier for history of cardiac arrest or MI 1.90 1.66–2.16 (Normal) 
          Multiplier for history of stroke 1.30 1.11–1.52 (Normal) 
          Multiplier for peripheral vascular disease 1.31 1.15–1.48 (Normal) 
Discount rates    
     Discount rate applied to cost and effectiveness, % 3.00 2.00–5.00b Assumed 
Abbreviations: MI, myocardial infarction; ODPP, Online adaptation of the Diabetes Prevention Program; PSA, probabilistic sensitivity analysis; WiLLoW, 
Weight Loss through Living Well. 
aThe probability was the number of participants who had complete weight data at any follow-up assessments in each of weight change categories divided by the 
total number of participants who had complete weight data at the baseline assessment. Data were obtained using a last observation carried forward approach. 
bThe parameter was not varied in the probabilistic sensitivity analysis. 
Table 9.1 (Continued) 
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Table 9.2 Direct cost of the one-year ODPP intervention for the decision model: Base case values and ranges examined in 
sensitivity analyses 
 
Type of cost Base case valuea Range examined 
(PSA distribution) 
Source 
Amount, 
US$ 
Time, 
hour 
1) Orientation and training sessions for 2 health coaches   Not varied ODPP 
pilot study 
(39) 
 
     Manuals (300 pages; $0.05 a page) 0.60 - 
2) Orientation session for the participants   
     The dietary book detailing fat and calorie content of various foods 4.70 - 
     Pedometer 3.76 - 
3) Greeting cards 2.10 - 
4) Posters/flyers 0.26 - 
5) Postage ($0.43 an USPS Forever stamp) 2.58 - 
6) Photocopies and printings ($0.05 a page) 0.50 - 
     Total direct Web-unrelated costs of the ODPP intervention per 
     participant 
14.5 - 7.25–21.75 
(Triangular)  
7) Website licensing, maintenance, and technical supportb    
     Total cost of hosting and 
     maintaining the ODPP (annual) 
First year 3,000 - 0–6,000 (Triangular) 
Second year and afterward 300 - 0–600 (Triangular) 
     Time required for technical support (annual) - 1.0 0.5–1.5 (Triangular) 
     Hourly cost of providing technical support (annual) 63 - 0–126 (Triangular) 
Abbreviations: ODPP, Online adaptation of the Diabetes Prevention Program; PSA, probabilistic sensitivity analysis. 
aThese base case values were per-participant values, except that the total annual costs of hosting and maintaining ODPP was for 50 participants 
enrolled in the ODPP pilot study. In sensitivity analyses, the number of participants enrolled in the ODPP was assumed to range from 5 to 500 
with a Log-normal distribution. 
bIn base case analysis, the costs for “Website licensing, and maintenance, and technical support” were considered as a license purchase fee to 
distribute ODPP in a clinic or community and thus was included in the model, while in sensitivity analysis, the costs for “Website licensing, and 
maintenance, and technical support” were evaluated from 0 to the double of their base case values. 
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Table 9.3 Time cost of providing or partaking in the one-year ODPP intervention for the decision model: Base case values and ranges 
examined in sensitivity analyses 
 
Activity of providing or partaking in the one-year ODPP intervention Base case value Range examined (PSA 
distribution) 
Source 
Amount, 
US$ 
Time, 
hourf 
Health coach    ODPP 
pilot 
study 
(39) 
1) Attend staff orientation and training session(s) - 0.32 Not varied 
2) Conduct patient orientation session(s) by health coaches - 0.16 
3) Review each patient’s progress regularly (including, lesson completion, self-monitoring, 
and workbook entries) 
- 6.80 
4) Write coaching notes to offer support and suggestions and send them to patients via secure 
emails (weekly during the core 16 lessons, and biweekly thereafter) 
5) Consult with a nutrition specialist as needed 
6) Consult with physician(s) as needed 
7) Consult with other professional(s) as needed 
8) Respond to and provide coaching advice to any patients’ questions or concerns as needed 
via secure emails 
- 0.68 
9) Conduct chat room sessions and answer patients’ questions (1-2 chats/week)a - 0.00 
10) Personalize the quarterly patient progress reports for primary care providers - 0.10 
11) Notify and communicate with primary care providers if patients’ health concerns arise - 0.03 
12) Provide the reminder message to the potential inactive patient by making phone calls - 0.19 
     Total health coach time per participant for the one-year ODPP intervention - 8.28 4.14–12.42 (Triangular) 
     Hourly wage rate for the health coachb 29.83 - 14.91–44.74 (Triangular) 
Health coach assistant    
     Total health coach assistant time per participant for the one-year ODPP interventionc - 1.128 0.564–1.692 (Triangular) 
     Hourly wage rate of the health coach assistantd 22.47 - 11.23–33.70 (Triangular) 
Participant    
     Total time that the participant spent participating in the in-person orientation session 
     and the online sessions activities related to the one-year ODPP 
- 33.675 16.837–50.512 
(Triangular) 
     Hourly wage rate for the participante 18.33 - 9.165–27.495 (Triangular) (44) 
Abbreviations: ODPP, Online adaptation of the Diabetes Prevention Program; PSA, probabilistic sensitivity analysis. 
aEach chat lasted 45 minutes, but hardly anyone ever attended. 
bThe health coaches were paid at approximately the midpoint ($29.83 per hour in 2010 US$) for a Health Professional II job, not including benefits 
(http://www2.hr.pitt.edu/comp). 
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cFirst-line technical support, copying materials, and scheduling for participation for those sessions (when orientation sessions are happening) would be 
appropriate for a “coach helper”, but this was no more than 1-2 hours per active week. On average, these were 37.6 active weeks over a year for 50 participants 
enrolled in the ODPP pilot study. 
dThe health coach assistant was paid at approximately the midpoint ($22.47 per hour in 2010 US$) for a Research IV job, not including benefits 
(http://www2.hr.pitt.edu/comp). 
eHourly wage rate for the participant was based on the average hourly wage of a US nonfarm production worker, i.e. $18.33 in 2010 US$. 
fThese base case values were per-participant time. 
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Table 9.4 Cost-effectiveness analysis results 
 
Scenario Strategy 
Cost, 
US$ 
Increment 
cost (US$) 
Effectiveness 
Incremental 
effectiveness 
ICER 
Base case 
(health care 
system 
perspective) 
Using QALY as the effectiveness 
measurement 
Usual care $12,007  - 6.5610 QALYs - - 
ODPP $12,599  $591  6.6022 QALYs 0.0412 QALYs 
$14,351 per 
QALY gained 
Using incidence of stable diabetes as the 
effectiveness measurement 
Usual care $12,007  - 15.77% - - 
ODPP $12,599  $591  11.54% -4.23% 
$13,977 per 
case averted 
Using incidence of complicated diabetes 
as the effectiveness measurement 
Usual care $12,007  - 15.70% - - 
ODPP $12,599  $591  14.47% -1.23% 
$47,889 per 
case averted 
Using deaths due to stable or complicated 
diabetes as effectiveness measurement 
Usual care $12,007  - 5.5506% - - 
ODPP $12,599  $591  5.2168% -0.3339% 
$177,109 per 
death averted 
Societal perspectivea 
Usual care $12,007  - 6.5610 QALYs - - 
ODPP $13,216  $1,209  6.6022 QALYs 0.0412 QALYs 
$29,331 per 
QALY gained 
Start of the 
model with a 
hypothetical 
cohort 
without 
diabetesb 
Health care system perspective 
Usual care $8,173  - 7.1305 QALYs - - 
ODPP $8,631  $458  7.1894 QALYs 0.0589 QALYs 
$7,777 per 
QALY gained 
Societal perspectivea 
Usual care $8,173  - 7.1305 QALYs - - 
ODPP $9,248  $1,075  7.1894 QALYs 0.0589 QALYs 
$18,263 per 
QALY gained 
Abbreviations: ICER, incremental cost-effectiveness ratio; ODPP, Online adaptation of the Diabetes Prevention Program; QALY(s), quality-adjusted life-year(s). 
aIn addition to direct medical costs, the cost of time that the participant spent participating in the in-person orientation session and the online sessions activities 
related to ODPP was included to assess the cost-effectiveness from a societal perspective. 
bThe study cohort was assumed to have no stable or complicated diabetes at the start of the model. 
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Table 9.5 One-way sensitivity analyses: Nine parameters whose variations changed the base case incremental cost-effectiveness ratio by 
20% or greater 
 
 Base 
case 
value 
Range of base case values 
(low range value / high 
range value) 
ICER (ODPP vs. Usual care), $ per 
QALY gained (ICER at low range 
value / ICER at high range value) 
Base case analysis   14,351 
Annual probability of developing stable diabetes in our 
overweight/obese study cohort whose weight remained 
relatively stable after the ODPP intervention, % 
2.336 0.620 / 5.072 67,201 / 4,263 
Hourly cost of providing technical support for the ODPP 
(annual), $ 
63 0 / 126 1,703 / 26,999 
Number of participants enrolled in the ODPP, persons 50 5 / 500 37,206 / 12,065 
Time required for technical support of the ODPP (annual, 
per participant), hour 
1.0 0.5 / 1.5 8,027 / 20,675 
Odds ratio of developing stable diabetes for individuals 
with annual weight loss ≥2.0 kg 
0.45 0.34 / 0.60 11,989 / 18,557 
Hourly wage rate of the health coach, $ 29.83 14.91 / 44.74 11,353 / 17,347 
Health coach time of providing the ODPP intervention 
(per participant), hour 
8.28 4.14 / 12.42 11,354 / 17,348 
Odds ratio of developing stable diabetes for individuals 
with annual weight gain ≥2.0 kg 
2.22 1.66 / 2.98 17,222 / 11,601 
Utility of overweight/obese individuals without diabetes 0.88 0.84 / 0.92 17,552 / 12,137 
Abbreviations: ICER, incremental cost-effectiveness ratio; ODPP, Online adaptation of the Diabetes Prevention Program; QALY, quality-adjusted 
life-year. 
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Table 9.6a One-way sensitivity analysis on the costs for Website licensing, maintenance, and technical support 
 
Multiplier for 
Website-
related costsa 
Annual total cost of hosting and maintaining 
ODPP, $ 
Per-participant time 
required for technical 
support (annual), hour 
Hourly cost of 
providing technical 
support (annual), $ 
ICER (ODPP vs. 
Usual care), $ per 
QALY gained First year Second year and afterward 
0.00 0 0 0 0 Cost-saving 
0.17 510 51 0.17 10.71 Cost-saving 
0.18 540 54 0.18 11.34 30 
0.50 1,500 150 0.50 31.50 3,595 
1.00 (base case 
value) 
3,000 300 1.00 63.00 14,351 
1.18 3,540 354 1.18 74.34 19,771 
1.19 3,570 357 1.19 74.97 20,096 
1.90 5,700 570 1.90 119.70 49,648 
1.91 5,730 573 1.91 120.33 50,155 
2.00 6,000 600 2.00 126.00 54,835 
Abbreviations: ICER, incremental cost-effectiveness ratio; ODPP, Online adaptation of the Diabetes Prevention Program; QALY, quality-adjusted 
life-year. 
aThe Website-related costs included (1) annual total costs of hosting and maintaining ODPP, (2) annual per-participant time required for technical 
support, and (3) annual hourly cost of providing technical support. The multiplier for Website-related costs was assumed to range from 0 to be 
double. 
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Table 9.6b One-way sensitivity analysis on the number of participants enrolled in the ODPP 
 
Number of participants 
enrolled in the ODPP, persons 
ICER (ODPP vs. Usual care), $ per QALY gained 
5 37,206 
10 24,509 
20 18,160 
30 16,044 
40 14,986 
50 (base case value) 14,351 
100 13,081 
200 12,446 
300 12,235 
400 12,129 
500 12,065 
Abbreviations: ICER, incremental cost-effectiveness ratio; ODPP, Online adaptation of the Diabetes 
Prevention Program; QALY, quality-adjusted life-year. 
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Table 9.6c Two-way sensitivity analysis on the overall costs for Website licensing, maintenance, and technical support and the number of 
participants enrolled in the ODPPa 
 
ICER (ODPP vs. 
Usual care), $ per 
QALY gained 
Number of participants enrolled in the ODPP, persons 
5 10 20 30 40 50 (base 
case value) 
100 200 300 400 500 
M
ul
tip
lie
r f
or
 W
eb
si
te
-r
el
at
ed
 c
os
ts
b  
 
0.00 Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-saving Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
0.17 3,846 1,687 608 248 68 Cost-saving Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
0.18 4,144 1,858 716 335 144 30 Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
Cost-
saving 
0.50 15,023 8,674 5,499 4,441 3,912 3,595 2,960 2,643 2,537 2,484 2,452 
1.00 (base 
case value) 
37,206 24,509 18,160 16,044 14,986 14,351 13,081 12,446 12,235 12,129 12,065 
1.18 46,740 31,757 24,266 21,769 20,520 19,771 18,273 17,524 17,274 17,149 17,074 
1.19 47,294 32,184 24,629 22,111 20,852 20,096 18,585 17,830 17,578 17,452 17,376 
1.90 93,073 68,948 56,886  52,865 50,854 49,648 47,236 46,029 45,627 45,426 45,306 
1.91 93,809 69,557 57,431 53,389 51,368 50,155 47,730 46,518 46,113 45,911 45,790 
2.00 100,546 75,151 62,453 58,221 56,105 54,835 52,295 51,026 50,602 50,391 50,264 
Abbreviations: ICER, incremental cost-effectiveness ratio; ODPP, Online adaptation of the Diabetes Prevention Program; QALY, quality-adjusted 
life-year. 
aCompared with usual care, green-highlighted cells indicated that the ODPP was cost-saving; blue-highlighted cells indicated that the ODPP cost 
less than $20,000 per QALY gained; yellow-highlighted cells indicated that the ODPP cost less than $50,000 per QALY gained; orange-
highlighted cells indicated that the ODPP cost less than $100,000 per QALY gained; and pink-highlighted cells indicated that the ODPP cost 
higher than $100,000 per QALY gained. 
bThe Website-related costs for each multiplier were detailed in Table 9.6a. 
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9.8 FIGURES 
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Figure 9.1 Markov-state diagram for the basic model structure
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Figure 9.2 Tornado diagram from one-way sensitivity analyses for the ODPP compared with usual care  
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Figure 9.3a One-way sensitivity analysis on the multiplier for Website-related costs 
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Figure 9.3b One-way sensitivity analysis on the number of participants enrolled in the 
ODPP 
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Figure 9.4 Probabilistic sensitivity analysis for the ODPP compared with usual care 
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9.9 FIGURE LEGENDS 
 
Figure 9.1 Markov-state diagram for the basic model structure 
Ovals indicate health states. Subjects may remain within a health state (short curved arrow) or 
may move to a different health state (straight arrow or long curved arrow) during each model 
cycle. 
 
Figure 9.2 Tornado diagram from one-way sensitivity analyses for the ODPP compared 
with usual care 
One-way sensitivity analyses included the model parameters whose variations changed the base 
case incremental cost-effectiveness ratio (ICER) (x axis) by 20% or greater. Horizontal bars 
depicted the range of ICERs corresponding to the values shown in each parameter. The vertical 
solid line depicted the base case ICER of $14,351 per quality-adjusted life-year (QALY) gained, 
the vertical dash line depicted the ICER of $20,000 per QALY gained, and the vertical long dash 
line depicted the ICER of $50,000 per QALY gained. Variation of all other model parameters 
not shown in the figure did not increase the ICER to be $20,000 per QALY gained or greater. 
 
Figure 9.3a One-way sensitivity analysis on the multiplier for Website-related costs 
The Website-related costs included (1) annual total cost of hosting and maintaining ODPP, (2) 
annual per-participant time required for technical support, and (3) annual hourly cost of 
providing technical support. Results were shown as the incremental cost-effectiveness ratio of 
comparing the ODPP with usual care by the multiplier for considering the Website-related costs 
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as a whole. ODPP indicated Online adaptation of the Diabetes Prevention Program; QALY, 
quality-adjusted life-year. 
 
Figure 9.3b One-way sensitivity analysis on the number of participants enrolled in the 
ODPP 
Results were shown as the incremental cost-effectiveness ratio (ICER) of comparing the ODPP 
with usual care by the number of participants enrolled in the ODPP. When 20 or more 
participants were enrolled in the ODPP, the model revealed the ICER of less than $20,000 per 
QALY gained under the base case assumptions and values for all other model parameters. ODPP 
indicated Online adaptation of the Diabetes Prevention Program; QALY, quality-adjusted life-
year. 
 
Figure 9.4 Probabilistic sensitivity analysis for the ODPP compared with usual care 
Results were shown as a cost-effectiveness acceptability curve the ODPP. The y-axis showed the 
likelihood that strategies would be considered cost-effective for a given cost-effectiveness 
willingness to pay (or acceptability) threshold in the x-axis. ODPP indicated Online adaptation of 
the Diabetes Prevention Program; QALY, quality-adjusted life-year. 
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10.0 DISCUSSION 
 
10.1 SUMMARY OF STUDY FINDINGS 
 
This dissertation assessed long-term cost-effectiveness of implementing interventions to control 
and prevent diabetes in the community and military settings.  Three specific aims of this 
dissertation were to: 1) evaluate cost-effectiveness of implementing the Chronic Care Model 
(CCM) intervention for diabetes control relative to a provider continuing medical education 
(PROV) intervention and to usual care (UC) in an underserved community population in 
Pittsburgh, PA; 2) estimate cost-effectiveness of implementing the CCM intervention through the 
Diabetes Outreach Clinic (DOC) for diabetes control relative to UC in a military population in 
San Antonio, TX; and 3) examine cost-effectiveness of implementing an Online adaptation of the 
Diabetes Prevention Program lifestyle intervention (ODPP) compared with UC (or do nothing) to 
reduce metabolic risk in the primary care patients with high cardiovascular risk in Pittsburgh, 
PA. 
For the first aim, analyses showed that compared with the PROV and UC strategies over 
a 3-year period, the CCM strategy reduced the incidence of diabetes with either microvascular or 
macrovascular complications by an absolute 41.3 (from 86.2% to 44.9%) and 3.9 (from 48.7% to 
44.9%) percentage points, respectively.  From a health care system perspective, the costs over 3 
years for the CCM strategy compared with the UC strategy were $70,317 per QALY gained and 
$29,573 per diabetes complication averted; the CCM strategy dominated the PROV strategy in 
both analyses.  Over 10 years, the costs per QALY gained from a health care system and a 
societal perspective for the CCM strategy compared with the UC strategy were $42,179 and 
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$113,280, respectively.  In the probabilistic sensitivity analysis, the PROV was unlikely to be 
favored over CCM or UC; using a willingness-to-pay threshold of $50,000/QALY, the CCM was 
favored in 45% of model iterations (compared with 50% for UC and 5% for PROV); with a 
threshold of $100,000/QALY, the CCM was favored in 51%.  This study suggested that 
application of the comprehensive six-element CCM for diabetes care in an underserved 
community is a sound and cost-saving investment compared with the provider continuing 
medical education intervention, and is economically reasonable relative to usual care. 
For the second aim, analyses showed that from a health care system perspective, the DOC 
compared with UC cost $45,495 per QALY gained; from a societal perspective, the DOC 
compared with UC cost $42,051 per QALY gained (when the model started with the 
uncomplicated diabetes cohort), $61,243 per QALY gained (when the model started with the 
DOC cohort), or $61,813 per QALY gained (when the model started with the UC cohort).  In 
one-way sensitivity analyses, results were most sensitive to the yearly costs for specialty care 
visits.  In the probabilistic sensitivity analysis, the DOC was favored in 51% of model iterations 
using an acceptability threshold of $50,000/QALY and in 72% at a threshold of 
$100,000/QALY.  This study suggested that the DOC strategy for diabetes care, performed with 
the CCM methodology in a military population, appears to be economically reasonable 
compared with UC. 
For the third aim, analyses showed that compared to UC, the ODPP performed in the 
pilot study cohort (30% with diabetes) cost $14,351 and $29,331 per QALY gained from a health 
care system and a societal perspective, respectively.  In a hypothetical cohort without diabetes, 
the ODPP cost $7,777 and $18,263 per QALY gained, respectively.  Results were robust in 
sensitivity analyses, but enrolling cohorts with lower annual risk of developing diabetes (≤1.8%), 
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enrolling fewer participants (≤15), or increasing the hourly cost (≥$91.2) or the annual per-
participant time required (≥1.45 hours) for ODPP technical support could increase the ODPP to 
cost >$20,000 per QALY gained.  In the probabilistic sensitivity analysis, the ODPP was cost-
effective in 20-58% of model iterations using an acceptability threshold of $20,000/QALY, 73-
92% at $50,000/QALY, and 95-99% at $100,000/QALY.  This study suggested that the ODPP 
delivered in the primary care settings for weight management appears to be an economically 
reasonable intervention. 
 
10.2 CONTRIBUTION TO THE LITERATURE 
 
The findings of this dissertation are significant and help fill the gap in the literature by providing 
evidence of revealing the economic value in the effective interventions for diabetes control and 
prevention.  Full economic evaluation (i.e., cost-effectiveness analysis, cost-utility analysis, or 
cost-benefit analysis) is quite limited in the CCM for diabetes care and in the Internet-based 
lifestyle intervention for diabetes prevention and risk reduction.  The first study that is 
incorporated into this dissertation provides supporting evidence that performing the full six-
element CCM as a secondary and tertiary prevention strategy for diabetes care (i.e., treating 
diabetes to prevent complications or death) in an underserved community-based population is 
cost-effective compared with the PROV or UC strategy.  To our knowledge, our study provides 
the first comprehensive attempt to determine the cost-effectiveness of implementing the full 
CCM for diabetes care in an underserved community-based population.  Also, our study 
confirms Huang et al.’s study (314) that was the only published, full economic evaluation of 
comparing the costs of implementing the partial CCM to the benefits of improved health 
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outcomes in people with diabetes in US Federally Qualified Health Centers, and found that CCM 
reduced lifetime risk of blindness, ESRD, and coronary artery disease, resulting in an increase in 
health benefits at a cost of $33,386 per QALY gained.  Despite discrepancies in study 
population/design and model setups/assumptions, both of these studies suggest that community-
based efforts to implement the CCM are economically reasonable. 
 The second study that is incorporated into this dissertation provides the finding that 
implementing the CCM through the DOC for secondary and tertiary prevention of diabetes care 
in a military population is cost-effective compared with the UC strategy.  We believe that this is 
the first study to evaluate the cost-effectiveness of implementing the CCM in a military 
population.  Although there are differences in study population/design and model 
setups/assumptions, the first two studies of this dissertation and the study published by Huang et 
al. (314) indicate that implementation of the CCM compared with UC is economically 
reasonable in the community and military settings. 
 The third study that is incorporated into this dissertation provides positive results that 
compared with UC, the Internet-based weight management intervention delivered as a primary 
prevention strategy for the primary care population at a high risk of diabetes is at a high level of 
cost-effectiveness.  Research on the cost-effectiveness of this intervention modality is relatively 
sparse.  Among the published reports, four studies that were viewed as a full economic 
evaluation with a cost-effectiveness outcome of either cost per QALY gained or cost per 
disability-adjusted life-year (DALY) averted were selected for facilitating comparison with our 
findings.  These studies suggested that the Internet-based weight management intervention 
compared with UC cost $950-$2,000 (315), $30,400 (316), and $159,500 (317) per QALY 
gained, or $2,650-$8,830 per DALY averted (318).  Although there is a difference in study 
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population and design between this third study and the published reports, our estimates of ODPP 
cost-effectiveness ranged from $7,777 to $29,331 per QALY gained, confirming most of these 
four published studies’ observations that the Internet-based weight management intervention is at 
a moderate to high level of cost-effectiveness. 
 
10.3 STUDY LIMITATIONS 
 
Like all modeling efforts (319), the computational models developed here have several 
limitations.  First, interpretations of study results are contingent on data quality and model 
assumptions.  The source data that were selected and used in all analyses of this dissertation were 
based on empirical data, pivotal studies, commonly cited references, or the published studies at a 
nationally representative level, which would ensure the quality of input data.  Second, subjects in 
three studies incorporated into this dissertation are representative of different populations and 
settings, and thus extrapolation to other populations or health care settings requires caution. 
In the first study, we restricted our long-term simulations about costs, quality of life, and 
clinical outcomes to 3 and 10 years because we employed the empirically observed data on 
complications directly from Piatt et al.’s clinical trial with 12-month follow-up data.  Indeed, to 
have longer length of simulated follow-up and more robust predicted rates of complications, we 
would consider using one of the publicly available epidemiological models of diabetes 
complications which would allow accounting for improvements in intermediate risk factors 
attributable to the CCM.  In addition, because of the short-term follow-up period of Piatt et al.’s 
clinical trial, we conservatively assumed identical mortality and incidence of ESRD for all three 
intervention strategies, perhaps biasing the model against the CCM.  Lastly, due to lack of utility 
                                
238 
 
data, we applied the same literature-based utility weights to all three intervention strategies, and 
again, this is a conservative response that may underestimate the CCM’s potential to improve 
quality of life. 
In the second study, the effectiveness data were not from a randomized controlled trial, 
resulting in differences in baseline characteristics; hence, the analyses adjusted for significant 
differences in demographics and clinical characteristics at baseline.  In addition, assuming an 
identical risk of disease progression for DOC and UC patients who have had diabetes 
complications is a conservative strategy that potentially biases the model against the CCM effect.  
Lastly, because there is no empirical utility data, we applied the same literature-based utility 
weights to both strategies, which again may underestimate the CCM’s potential to improve 
quality of life. 
In the third study, a ten-year time frame was used to simulate the cost-effectiveness of the 
ODPP due to uncertainty in the empirical data for long-term effectiveness of weight change on 
diabetes risk (113,299).  However, delaying or preventing type 2 diabetes will delay or prevent 
incurring the direct medical costs of diabetes, including the costs of diabetes education and 
nutritional counseling, glucose monitoring, treatment, surveillance for complications, and 
treatment of complications.  Hence, adopting a ten-year time horizon may overestimate treatment 
costs and underestimate the benefits of the ODPP intervention.  In addition, assuming an 
identical risk of developing diabetes-related complications for participants with stable diabetes 
who achieved different magnitude of weight gain or loss is a conservative strategy.  This is 
because according to the Look AHEAD (Action for Health in Diabetes) study (320), the 
overweight/obese patients with type 2 diabetes with larger weight losses were associated with 
greater improvements in cardiovascular disease risk factors, which may reduce diabetes-related 
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complications.  Thus, this assumption potentially biases the model against the ODPP effect.  
Furthermore, because there is no empirical utility or mortality data from the ODPP intervention, 
application of the same literature-based utility weights and the same mortality risks to the four 
health states in the cohorts who achieved different magnitude of weight gain or loss may again 
underestimate the ODPP’s potential to improve quality of life and length of life.  Lastly, the 
health- and cost-generating obesity-related conditions used in the current model were only 
limited to diabetes.  Many other conditions known to be obesity-related, as illustrated by 
increased health and economic burden, were not considered, making our model conservative and 
biasing against the ODPP effect. 
 
10.4 PUBLIC HEALTH SIGNIFICANCE 
 
Diabetes is common, serious, and costly, representing not only a major clinical care concern but 
also an immense and growing public health challenge.  In 2010, diabetes affected 25.8 million 
Americans – 8.3 percent of the US population – including 18.8 million people with diagnosed 
diabetes and 7.0 million people with undiagnosed diabetes (268).  Another seventy-nine million 
(35%) American adults aged 20 years or older with prediabetes were at high risk of developing 
the disease over the next decade (268).  One in three American children born in 2000 is likely to 
develop diabetes over their lifetimes (32).  The percentage of the population with diagnosed 
diabetes continues to rise, with one study projecting that as many as one in three US adults could 
have diabetes by 2050 if current trends continue (269). 
 Diabetes is the leading cause of kidney failure, non-traumatic lower-limb amputations, 
and new cases of blindness among adults; a major cause of heart disease and stroke; and the 
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seventh leading cause of death in the US (268).  Financially, diabetes imposes a substantial 
burden on the US economy in terms of increased direct medical costs and indirect costs from 
work-related absenteeism, reduced productivity at work and at home, reduced labor force 
participation from chronic disability, and premature mortality.  Additionally, diabetes imposes 
high intangible costs on society in terms of reduced quality of life as well as pain and suffering 
of individuals with diabetes, their families, and friends (231).  The total estimated cost of 
diagnosed diabetes in 2012 reached $245 billion (including $176 billion in direct medical costs 
and $69 billion in reduced productivity), a 41% increase from the previous estimate of $174 
billion in 2007 (231). 
Overweight and obesity also rank prominently among current major clinical care and 
public health problems since they are common, serious, and costly as well as the major 
predisposing factor for insulin resistance and type 2 diabetes.  Approximately 69% of US adults 
aged 20 years or older were overweight or obese in 2009-2010, and 36% (over 78 million) were 
obese (321,322).  Overweight and obesity are the major risk factors for morbidity from a wide 
range of medical conditions, social conditions, psychological conditions, and impaired quality of 
life (323).  Higher body weights are also associated with an increase in mortality from all causes 
(323).  Financially, medical costs associated with adult obesity in the US are estimated to range 
from $147 billion to nearly $210 billion per year (324,325).  People who are classified as obese 
spend $1,429 (42 percent) more on health care costs compared to those of normal-weight.  The 
additional costs attributable to obesity are almost entirely a result of costs generated from 
treating the diseases that obesity promotes (324,326). 
Considering the increasing prevalence of diabetes and the burgeoning cost of managing 
patients with this disease, improving the efficiency of diabetes management is an important goal.  
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Many interventions can reduce the health and financial burden of diabetes and 
overweight/obesity; however, health care resources are limited.  Hence, interventions for 
diabetes prevention and control should be prioritized (260).  Indeed, the rapid rate of growth in 
health care expenditures in the US raises both public and private decision makers’ great concerns 
about the financial sustainability of the US health care system.  Now, an increasing number of 
people believe that, in deciding whether to cover a particular treatment or prevention strategy, 
employer or other health care payers are justified in asking whether the net benefits of the 
strategy are worth its costs (261).  Costs are already a consideration in establishment of public 
health priorities or recommendations for clinical practices in much of the world (261); in other 
words, efforts to control expenditures should focus on seeking the value of health care 
interventions, reflecting health benefits that justify their costs (271).  This dissertation report 
compared the effectiveness and costs of various interventions in order to identify those that are 
the most effective for a lower cost.  The cost-effectiveness analysis conducted in the three studies 
presented demonstrates that this is a useful tool for this purpose.  Such analyses consist of 
compiling the incremental cost-effectiveness ratio (e.g., cost per QALY gained), which is 
calculated as a ratio of the difference in costs to the difference in effectiveness between the 
intervention of interest and the comparison intervention, and can provide a key measure of the 
value of a health care intervention (260,271). 
There are no absolute criteria for cost-effectiveness; however, in general, interventions 
costing less than $20,000 per QALY gained may be considered as having strong evidence for 
adoption; interventions costing $20,000 to $100,000 per QALY gained have moderate evidence; 
and those costing more than $100,000 per QALY gained have weaker evidence for adoption 
(312,327).  Hence, the findings of the three studies in this dissertation (see Section 10.1) suggest 
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that compared with usual care, the CCM intervention (delivered in either an underserved 
community population or a military population) appears to be a good-value secondary and 
tertiary prevention strategy for diabetes, and likewise, the ODPP intervention (delivered in a 
primary care population with high cardiovascular risk) for primary diabetes prevention provides 
both health benefits and good use of health care resources.  Policy makers should consider giving 
these interventions a higher priority. 
Epidemiology (or clinical epidemiology) is an integral part of a cost-effectiveness 
analysis.  This is because epidemiology is a set of methods and techniques that are used to create 
and interpret scientific observations in medicine and public health problems.  These methods and 
techniques are used to study the natural history and prognosis of disease, and evaluate the role of 
both existing and newly developed preventive and therapeutic measures and modes of health 
care delivery as determinants of health-related states or events (328,329).  Specifically, 
epidemiology can be used to measure and value the impact of health care interventions either 
under ideal conditions (efficacy) or in real-life situation (effectiveness), which is one of crucial 
elements in a cost-effectiveness analysis. 
The findings in this dissertation using the economic evaluation (i.e., cost-effectiveness 
analysis) of interventions for diabetes prevention and control are of public health significance.  
The rationale for economic evaluation is simple: Resources are always limited; not everything 
worth doing can be done, and not everything that can be done is worth doing (330).  Economic 
evaluation is an increasingly used tool which aims to provide a formal, explicit and transparent 
framework for informing decisions about allocating public funds in the health care sector (331).  
By utilizing economic evaluation in the fields of clinical care and public health, questions about 
the efficiency of allocating resources to fund interventions aimed at improving clinical care and 
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public health can be addressed.  In other words, the basic economic principle of establishing the 
opportunity cost of devoting resources to a particular intervention, i.e. whether the benefits of 
devoting resources to a particular intervention exceed the benefits that could have been achieved 
with an alternative use of those resources, can be used to ensure that public funds are directed to 
the most valuable interventions (331).    
Public health is the art and science of preventing disease, prolonging life, and promoting 
health through organized community efforts.  It is made up of systematic efforts to identify 
health needs and to organize comprehensive health services within a well-defined population 
base.  Thus, planning of and prioritizing clinical services are integral parts of public health (330).  
An important area where economic evaluation seems to play a major role is in insurance 
coverage decisions, especially those concerning pharmaceutical coverage (330).  For example, in 
the UK, the National Institute for Health and Clinical Excellence (NICE) assumed responsibility 
for the development of indicators for the pay-for-performance program to ensure that cost-
effectiveness is taken into account and to increase transparency and independence (332).  To 
encourage use of good-value services or treatments, in the USA, the insurers commonly reduce 
cost sharing (user charges) when patients use preferred providers (e.g., those offering higher 
quality care) or cost-effective prescription drugs and preventive services.  Through the work of 
NICE and the planned introduction of value-based pricing for drugs in 2014 in England, 
initiatives already exist to encourage cost-effective prescribing (332).  In addition, economic 
evaluation could help identify the interventions which may potentially reduce the overall costs of 
health care, which is one of the major public health concerns and one of the goals contained in 
the Patient Protection and Affordable Care Act in the US (332). 
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Indeed, to achieve state and national objectives for improved clinical care and public 
health, more widespread adoption of evidence-based strategies has been recommended.  It has 
been argued that increased focus on evidence-based medicine and public health practice has 
numerous direct and indirect benefits, including access to more and higher-quality information 
on what works, a higher likelihood of successful programs and policies being implemented, 
greater workforce productivity, and more efficient use of public and private resources (333).  
Economic evaluation is one of the critical analytic tools which can be useful in accelerating the 
uptake of evidence-based medicine and public health practice, and it can provide information to 
help assess the relative value of alternative expenditures on public health programs/policies and 
has become an increasingly important tool for researchers, practitioners, and policy makers 
(333).  Also, it has been argued that both clinical epidemiology and public health share the view 
that efficacy, effectiveness, and cost-effectiveness are all important in defining the impact of 
clinical and public health care strategies on health disparities (329). 
 
10.5 FUTURE RESEARCH 
 
When facing increasing demand for limited resources from the growing number of new effective 
interventions available, translational research with full economic evaluations is vital to inform 
changes in the health care delivery systems that would improve diabetes management, and even 
to guide enhanced public health efforts and community-based programs for diabetes prevention. 
 Indeed, evidence on the cost-effectiveness of the chronic care model (CCM) for diabetes 
care is still very limited, and more research is needed to understand the costs and benefits to 
practices, payers, and patients.  Furthermore, there is no published available comparative 
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effectiveness research with full economic analysis among different effective quality 
improvement strategies on diabetes management, e.g. CCM, team changes, and case 
management.  Since several of these strategies may be marginally beneficial relative to other 
strategies and the resource intensity of the different strategies varied significantly (253), further 
exploration of the relative cost-effectiveness of these quality improvement strategies is needed.  
Public or private policy decision makers might also consider how they value the expected 
benefits before widely implementing such quality improvement strategies.  Moreover, among 
different modalities of quality improvement strategies for delivering secondary and tertiary 
diabetes prevention, further research is warranted to identify which interventions and 
combination of quality improvement strategies will optimally improve important outcomes in 
patients with diabetes at an acceptable cost to aid health-system planning. 
In addition, there is a paucity of full economic evaluations for a successful Internet-
delivered weight management program in comparison with the in-person delivery of a 
comparable program.  Such a comparison would inform policy decisions about the cost-
effectiveness of different modalities of disseminating effective weight management as the 
primary diabetes prevention strategies to a large population of overweight and obese individuals. 
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